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ABSTRACT	 	Lung	 cancer	 is	 the	 leading	 cause	 of	 cancer-related	 deaths	 worldwide	 and	 cigarette	smoking	is	related	to	90%	of	all	deaths	due	to	lung	cancer.	Tobacco	smoke	contains	many	classes	of	carcinogens	and,	although	nicotine,	the	addictive	and	 most	 active	 component	 of	 tobacco	 smoke,	 is	 unable	 to	 initiate	 tumourigenesis	 in	humans	 and	 rodents,	 it	 promotes	 tumour	 growth	 and	metastasis	 by	 inducing	 cell-cycle	progression,	 cell	 migration,	 angiogenesis	 and	 the	 evasion	 of	 apoptosis	 in	 a	 variety	 of	systems.	Nicotine	 and	 its	 metabolites	 are	 highly	 lipophilic	 compounds	 that	 bind	 and	 activate	 a	family	 of	 ligand-gated	 cation	 channels	 (the	 neuronal	 nicotinic	 acetylcholine	 receptors,	nAChRs)	that	are	widely	expressed	in	the	central	and	peripheral	nervous	systems.		Over	 the	 last	 few	 decades,	 the	 extra-neuronal	 localisation	 of	 nAChRs	 has	 been	demonstrated	 in	 a	 large	 number	 of	 cell	 types	 including	 endothelial	 cells,	 glia,	 immune	cells,	 lung	tissue	and	cancer	cells,	 indicating	that	they	might	have	functions	well	beyond	simple	neurotransmission.	Recent	 studies	 have	 shown	 that	 most	 of	 the	 tumour-promoting	 effects	 of	 nicotine	 are	primarily	 due	 to	 the	 binding	 and	 the	 activation	 of	 nAChRs,	 which	 lead	 to	 downstream	intracellular	signalling	cascades.	However,	identifying	the	receptor	subtypes	expressed	in	lung	tumour	cells	and	their	signalling	pathways	is	still	in	its	early	stage.	For	these	reasons,	we	investigated	the	pathophysiological	role	of	nAChRs	in	lung	cancer	cells.		We	 found	 that	 different	 non-small	 cell	 lung	 cancer	 (NSCLC)	 cells	 express	 distinctive	nicotinic	 receptor	 subtypes	 and	 that	 this	 variety	 affects	 nicotine-induced	 proliferation	and	migration.	 In	the	A549	adenocarcinoma	cell	 line,	nAChRs	containing	the	α7,	α9	and	
α5	 subunits	 regulate	 not	 only	 the	 nicotine-induced	 cell	 proliferation	 and	migration	 but	also	 the	 activation	 of	 anti-apoptotic	 and	 proliferative	 pathways.	 Blocking	 nAChRs	containing	the	α7	or	α9	or	α5	subunits	with	specific	toxins	or	silencing	their	expression	by	 means	 of	 subunit-specific	 siRNAs	 abolishes	 the	 nicotine-induced	 proliferation,	migration	and	signalling.	Prompted	 by	 these	 results,	 we	 also	 studied	 oxystylbene	 compounds	 previously	characterised	by	our	group	and	started	to	syntehesise	some	new	oxystylbene/resveratrol	derivatives	with	specific	modifications.	 	We	found	that	these	4-oxystilbene	derivates	act	
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on	both	α7	and	α9-containing	receptors	and	block	NSCLC	cell	proliferation	and	viability	in	a	dose-dependent	manner.		These	 results	 highlight	 the	 pathophysiological	 role	 of	 specific	 nAChR	 subtypes	 in	promoting	NSCLC	cell	growth	and	migration	and	raise	the	possibility	of	targeting	them	in	order	to	treat	tobacco	related	cancer.																															
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RIASSUNTO			Il	cancro	al	polmone	è	la	principale	causa	di	decessi	correlati	al	cancro	in	tutto	il	mondo	e	il	90%	è	legato	al	fumo	di	sigaretta.	Il	 fumo	di	 tabacco	contiene	molte	classi	di	 sostanze	cancerogene	e	anche	se	 la	nicotina,	l’elemento	 principale	 e	 più	 attivo	 del	 fumo	 di	 tabacco,	 non	 è	 in	 grado	 di	 avviare	tumorigenesi	 nell'uomo	 e	 nei	 roditori,	 essa	 è	 però	 in	 grado	 di	 promuovere	 la	 crescita	tumorale,	 indurre	 la	 progressione	 del	 ciclo	 cellulare,	 la	 migrazione,	 l'angiogenesi	 e	l’evasione	dall'apoptosi	in	una	varietà	di	sistemi.	La	nicotina	e	i	suoi	metaboliti	sono	composti	lipofili	che	legano	e	attivano	una	famiglia	di	canali	cationici	ligando-dipendenti	(i	recettori	neuronali	nicotinici,	nAChRs)	ampiamente	espressi	nel	sistema	nervoso	centrale	e	periferico.	Nel	 corso	 degli	 ultimi	 decenni,	 la	 localizzazione	 extra-neuronale	 dei	 nAChRs	 è	 stata	dimostrata	in	un	gran	numero	di	tipi	cellulari,	comprese	le	cellule	endoteliali,	gliali,	cellule	del	 sistema	 immunitario,	 il	 tessuto	 polmonare	 e	 le	 cellule	 tumorali,	 indicando	 che	 essi	potrebbero	svolgere	funzioni	diverse,	oltre	la	semplice	neurotrasmissione.	Recenti	studi	hanno	dimostrato	che	la	maggior	parte	degli	effetti	pro-tumorigenici	indotti	dalla	 nicotina	 sono	 principalmente	 dovuti	 al	 legame	 e	 alla	 conseguente	 attivazione	 dei	nAChRs,	 che	 stimolano	 diversi	 signalling	 intracellulari.	 Tuttavia,	 l'identificazione	 dei	sottotipi	recettoriali	nicotinici	espressi	nelle	cellule	tumorali	del	polmone	e	le	loro	vie	di	segnalazione	sono	ancora	in	una	fase	di	studio	primordiale.	Per	queste	ragioni,	abbiamo	studiato	il	ruolo	fisiopatologico	dei	nAChRs	in	linee	cellulari	di	tumore	al	polmone.	Abbiamo	 scoperto	 che	 diverse	 linee	 di	 carcinoma	 polmonare	 non	 a	 piccole	 cellule	(NSCLC)	esprimono	distinti	sottotipi	recettoriali	nicotinici	e	che	questa	varietà	influenza	la	proliferazione	 e	 la	migrazione	 cellulare	 indotta	dalla	nicotina.	Nella	 linea	 cellulare	di	adenocarcinoma	 A549	 sono	 espresse	 le	 subunità	 nicotiniche	 α7,	 α9	e	 α5,	 che	 regolano	non	solo	la	crescita	cellulare	e	la	migrazione	indotte	dalla	nicotina,	ma	anche	l'attivazione	di	 vie	 intracellulari	 anti-apoptotiche	 e	 proliferative.	 Bloccando	 i	 nAChRs	 contenenti	 tali	subunità	con	tossine	specifiche	o	silenziandone	l’espressione	mediante	siRNA	specifici	è	possibile	inibire	gli	effetti	proliferazione,	migrazione	e	attivazione	di	cascate	intracellulari	indotte	dalla	nicotina.	Spinti	da	questi	risultati,	abbiamo	anche	studiato	i	composti	oxy-stilbenici,	in	precedenza	caratterizzati	nel	nostro	gruppo,	 e	 abbiamo	 iniziato	 a	 sintetizzare	 alcuni	nuovi	derivati	
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oxy-stilbenici	 o	 ricavati	 dal	 resveratrolo	 apportando	 modifiche	 specifiche.	 Abbiamo	osservato	che	questi	derivati	4-oxystilbenici	agiscono	sia	sui	recettori	α7	sia	α9	espressi	in	cellule	di	NSCLC	e	sono	 in	grado	di	bloccare	 la	proliferazione	cellulare	e	 la	vitalità	 in	maniera	concentrazione-dipendente.	Questi	 risultati	 evidenziano	 il	 ruolo	 fisiopatologico	 di	 specifici	 sottotipi	 di	 nAChRs	 nel	promuovere	 la	 crescita	 e	 la	 migrazione	 di	 cellule	 tumorali	 polmonari	 e	 forniscono	 la	possibilità	di	poter	migliorare	 la	caratterizzazione	di	specifici	composti	al	 fine	di	poterli	utilizzare	per	i	casi	di	cancro	legati	al	tabacco.				
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ABBREVIATIONS	
α-Bgtx-	α-Bungarotoxin	Abs-	antibodies	AKT-	serine/threonine	protein	kinase	AKT	ALK-	anaplastic	lymphoma	kinase	A549-	human	alveolar	adenocarcinoma	cell	line	
β−AR-	β−arrestin	BAD-	Bcl-2-associated	death	promoter	BAX-	Bcl-2-associated	X	protein	CDK-	cyclin-dependent	kinase	CNS-	central	nervous	system	CREB-	cAMP	response	element-binding	protein	DA-	dopamine	ECM-	extracellular	matrix	E-cig-	e-cigarette	EGF-	epidermal	growth	factor		ERK-	extracellular	signal-regulated	protein	kinase	1	and	2	FBS-	fetal	bovine	serum	GABA-	gamma-Aminobutyric	acid	(γ-Aminobutyric	acid)	GWAS-	genome-wide	association	studies		ID1-	DNA-binding	protein	inhibitor	H1975-	human	adenocarcinoma	cell	line	JAK-	Janus	kinase	LTP-	long-term	potentiation	MAPK-	mitogen	activated	protein	kinase	MLA-	methyllycaconitine	NA-	noradrenaline		NAc-	nucleus	accumbens	nAChR-	nicotinic	acethylcoline	receptor	NAM-	negative	allosteric	modulators	NNK-	4-(methylnitrosamino)-1-(3-pyridyl)1-butanone	NNN-	N-nitrosonornicotine		NSCLC-	non-small	cell	lung	cancer	PAM-	positive	allosteric	modulators	PFC-	prefrontal	cortex		PI3K-	phosphatidylinositol-4,5-bisphosphate	3-kinase	PKC-	protein	kinase	C	
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PNEC-	pulmonary	neuroendocrine	cells		PSN-	peripheral	nervous	system	RAF-	proto-oncogene	serine/threonine-protein	kinase	ROS-reactive	oxigen	species		RT-	room	temperature	SCLC-	small	cell	lung	cancer	siRNA-	small	interfering	RNA	SNP-	single	nucleotide	polymorphism	SRC-	tyrosine-protein	kinase	Src	STAT-	signal	Transducer	and	Activator	of	Transcription	VTA-	ventral	tegmental	area	WHO-	world	health	organisation	XIAP-	X-linked	inhibitor	of	apoptosis	protein	
	
	
	
	
	
	
	
	
	
	
	
	 10	
INTRODUCTION	
Foreword	Tobacco	smoke	 is	a	complex	and	reactive	mixture	of	about	5000	molecules;	a	 toxic	and	carcinogenic	combination	that	represents	one	of	the	most	significant	causes	of	dangerous	chemical	 exposure	and	 chemically	mediated	diseases	 in	humans	 (Fowles	 J	 et	 al.,	 2003).	The	World	Health	Organisation	(WHO)	has	stated	that	5.4	million	of	preventable	deaths	a	year	are	due	to	tobacco	smoking	worldwide	(WHO,	2008)	and	it	has	been	estimated	that	this	number	double	in	2025	(Hatsukami	et	al.,	2008).		ISS/Doxa	data	showed	that	in	Italy	11.5	million	people	are	smokers	(6.9	million	men	and	4.6	million	women)	with	the	highest	prevalence	occurring	among	those	aged	25-44	years	of	both	sexes	(24.1%	of	women	and	31.9%	of	men).	The	prevalence	of	male	smokers	is	in	the	 Central	 regions	 of	 Italy	 (30.4%)	 while	 the	 prevalence	 of	 female	 smokers	 is	 in	 the	North	(19.9%).		Every	smoker	smokes	about	6.5	kg	of	tobacco	per	year	with	an	average	consumption	of	1600	 cigarettes.	These	numbers	 are	 increasing	not	 only	 in	 the	 industrialised	world	but	also	in	the	third	world	where,	since	1970,	the	consumption	of	tobacco	increased	by	67%.	Given	 these	 data,	 it	 is	 clear	 how	 smoking	 is	 a	 health	 and	 social	 problem	 that	must	 be	confirmed	by	public	health	agencies	throughout	the	world.	Many	smokers	have	recently	switched	 to	e-cigarettes	 (E-cigs)	as	an	alternative	mean	of	nicotine	 delivery.	 E-cigs	 are	 devices	 that	 produce	 an	 aerosol	 by	 heating	 a	 liquid	 that	contains	 a	 solvent	 (vegetable	 glycerine,	 propylene	 glycol,	 or	 a	mixture	 of	 both),	 one	 or	more	flavourings	and	nicotine.	The	inhalation	of	this	aerosol	leads	to	peak	serum	nicotine	concentrations	within	five	minutes.	This	rapidity	of	systemic	delivery,	and	the	fact	that	E-cigs	 look,	 feel	 and	 taste	 like	 traditional	 cigarettes,	 but	 do	 not	 contain	 toxic	 combustion	products,	had	led	them	being	increasingly	used.	 	Dawkins	et	al.	(2012;	2013)	found	that	smokers	 using	 E-cigs	 had	 less	 desire	 to	 smoke,	 fewer	 symptoms	 associated	 with	abstinence	 from	 tobacco,	 improved	 prospective	 and	 working	memory.	 Furthermore	 E-cigs,	as	are	less	harmful	product,	are	increasingly	used	as	a	mean	of	reducing	or	stopping	smoking	 despite	 the	 contrary	 recommendation	 of	 WHO	 (World	 Health	 Organization,	2008).	 However,	 as	 reported	 by	 the	 Food	 and	 Drug	 Administration	 (USFAD),	 many	studies	 have	 shown	 the	 harmfulness	 of	 E-cigs,	 which	 contain	 carcinogens	 and	 toxic	compounds	 leading	to	the	 idea	that	more	scientific	studies	are	necessary	to	define	their	safety	and	their	real	benefits.	
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Statistical	analyses	have	shown	that	in	Italy	the	E-cig	consumption	is	variable	among	the	population	being	from	4%	in	the	2014,	1,1%	in	2015	and	increasing	in	this	year	(3,9%	in	2016).		The	harmful	effects	of	tobacco	do	not	end	with	smoking	because	every	year	thousands	of	non-smokers	 die	 from	 heart	 disease	 and	 lung	 cancer	 and	 many	 children	 suffer	 from	respiratory	 infections	 caused	 by	 the	 exposure	 to	 second-hand	 smoke	 (Rockville,	 MD,	Public	Health	Service,	Office	of	Surgeon	General,	2010).		Tobacco	 is	 responsible	 for	 the	 onset	 of	 the	 25%	 of	 cardiovascular	 diseases	 (including	hypertension,	 stroke,	 coronary	 aortic	 aneurysms),	 80%	 of	 chronic	 respiratory	 disease	(bronchitis	and	emphysema)	and	90%	of	lung	cancers.		Moreover,	 it	 is	 also	 associated	 with	 reproductive	 disorders,	 increased	 likelihood	 of	developing	cataracts	and	in	women	it	contributes	to	decrease	the	bone	density	that	leads	to	an	increase	in	the	percentage	of	fractures	(HHS,	2004).			We	can	conclude	that	there	is	no	risk-free	level	of	exposure	to	tobacco	smoke,	and	there	is	no	safe	tobacco	product.		
1. The	addiction	to	smoke	Tobacco	addiction	represents	one	of	the	most	social	and	medical	problem	worldwide.	The	percentage	of	people	that	try	smoking	and	then	becomes	smoker	is	very	high,	as	is	high	the	difficulty	to	quit	smoking	and	the	facility	to	relapse.		The	 age	 of	 smoking	 onset	 and	 the	 cigarette	 consumption	 are	 two	 important	 elements,	which	can	lead	to	smoke	addiction.		The	 long-term	 exposure	 to	 nicotine	 produces	 biological	 adaptations,	 which	 can	 be	translated	in	tolerance	and	need	of	higher	nicotine	doses	to	feel	the	same	effects.	
1.1	Tobacco	components		Tobacco	 smoke	 is	 a	 complex	 and	 dynamic	 chemical	 mixture,	 composed	 by	 gas	 and	particulate	portions.	Tobacco	is	so	dangerous	for	human	health	because	it	is	composed	by	several	toxic	components,	which	can	lead	to	different	toxic	effects,	as	seen	before.		Tobacco	components	 include	different	classes	of	chemicals,	gas	and	particulate	portions	responsible	for	tobacco	harmfulness.	Carbon	monoxide,	an	odourless	and	tasteless	gas,	has	chemical	affinity	 for	haemoglobin	over	 200	 times	 greater	 than	 oxygen.	 It	 binds	 the	 haemoglobin	 reducing	 the	 amount	 of	oxygenated	 blood	 circulating	 in	 the	 body	 organs	 possible	 leading	 to	 coronary	 heart	disease.	
	 12	
Cigarette	smoke	contains	also	relatively	high	levels	of	nitrogen	oxide:	this	gas	is	known	to	cause	lung	damages	in	experimental	animals	similar	to	that	found	in	smokers,	and	may	be	responsible	for	initiating	lung	damage	leading	to	emphysema.	Moreover,	there	are	many	compounds	that	affect	the	cilia	present	in	the	respiratory	tract	(that	 filter	 out	 dust	 and	 other	 particles	 that	 enter	 to	 the	 nose	 with	 the	 breathed	 air),	among	which	hydrogen	cyanide,	acrolein,	ammonia,	nitrogen	dioxide	and	formaldehyde.	In	particular	hydrogen	cyanide	has	a	direct	 interfering	effect	with	the	“cleaning”	system	that	results	in	an	accumulation	of	toxic	agents	in	the	lungs	that	increases	the	likelihood	of	developing	diseases.	Tobacco	smoke	contains	also	more	than	thirty	metals	including	cadmium,	nickel,	arsenic,	chromium,	which	are	associated	with	human	cancers.		
1.1.2	Nicotine	and	its	derivatives			Nicotine,	 the	 addictive	 and	most	 active	 component	 of	 tobacco	 smoke,	was	 first	 isolated	from	 the	 tobacco	 plant	 Nicotiana	 tabacum	 (Solanaceae)	 in	 1828	 by	 German	 chemists	Posselt	and	Riemann.		Nicotine	is	a	tertiary	amine	consisting	of	a	pyridine	and	a	pyrrolidine	ring	(3-(-1methyl-2-pyrrolidnyl)	 pyridine);	 in	 tobacco	 is	 largely	 present	 the	 levorotary	 (S)-isomer	 and	 only	0.1	to	0.6%	of	total	nicotine	content	is	(R)-nicotine	(Figure	1).			It	 is	a	volatile	and	lipophilic	molecule	with	an	absorption	and	renal	secretion	highly	pH	dependent.	Alkaline	environment	increases	its	absorption	in	the	non-ionized	state,	which	crosses	more	rapidly	the	lipid	membranes	(Benowitz	N.	1999).							 Figure	1.	Nicotine	structure		Tobacco	 smoking	 releases	 nicotine,	 which	 rapidly	 enters	 into	 the	 lungs,	 in	 the	 large	surface	 area	 of	 the	 alveoli	 and	 small	 airways	 and	 undergoes	 dissolution	 in	 pulmonary	fluid.	It	is	then	transported	to	the	heart	and	immediately	passes	into	the	brain	reaching	a	brain	concentration	of	100–500	nM,	a	concentration	comparable	to	that	found	in	animals	that	self-administer	nicotine.		
	 13	
About	the	70-80%	of	human	nicotine	is	converted	by	the	liver	enzyme	CYP26	in	cotinine,	an	important	metabolite	used	as	marker	of	tobacco	consumption.	The	half-life	of	nicotine	is	about	two	hours	whereas	that	of	cotinine’s	is	much	longer	(Hukkanen	et	al.,	2005).		Animal	 studies	 have	 demonstrated	 that	 cotinine	 is	 a	 psychoactive	 and	 behaviourally	active	(Hatsukami	et	al.,	1997)	compound	whereas	human	clinical	studies	have	shown	the	opposite	effects,	indicating	that	cotinine	has	an	antagonist	effect	(Keenan	et	al.,	1994).	The	 polycyclic	 aromatic	 nitrosamines	 N-Nitrosonornicotine	 (NNN)	 and	 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone	 (NNK)	 are	 two	 nicotine	 combustion	derivatives	 very	 harmful	 and	 dangerous	 for	 human	 health.	 NNN	 and	 NNK	 are	 able	 to	directly	 bind	 the	 DNA	 and	 induce	 modifications,	 which	 can	 lead	 to	 mutations	 and	genotoxic	effects.	In	the	brain	nicotine	stimulates	different	cerebral	areas	involved	in	nicotine	addiction	and	reward	 through	 the	 activation	 of	 neuronal	 nicotinic	 cholinergic	 receptors	(nAChRs)(Hatsukami	 et	 al.,	 2008).	 Brain	 imaging	 studies	 demonstrate	 that	 nicotine	increases	activity	in	the	prefrontal	cortex,	thalamus	and	visual	system	consistent	with	the	activation	of	corticobasal	ganglia-thalamic	brain	circuits	(Brody,	2006).	The	 nicotine-induced	 psychoactive	 effects,	 both	 positive	 effects,	 such	 as	 pleasure,	decrease	 in	 stress,	 improvement	 in	 concentration	 and	 negative	 such	 as	 addiction,	withdrawal,	 increase	 in	 irritability,	 depression,	 insomnia	 and	 anxiety	 are	 due	 to	 the	nicotine	modulation	of	 the	 release	of	 the	neurotransmitters	 in	 the	different	brain	areas		(Hughes,	2006).		
2. Neuronal	nicotinic	acetylcholine	receptors		The	 cholinergic	 pathways	 in	 the	 central	 nervous	 system	 (CNS)	 of	 animals	 and	 humans	have	always	been	considered	highly	relevant	to	cognitive	and	behavioural	functions.	Until	a	 few	years	ago	the	key	molecules	transducing	the	cholinergic	message	were	thought	to	be	 the	 muscarinic	 receptors,	 the	 role	 of	 neuronal	 nicotinic	 receptors	 (nAChRs)	 has	recently	been	re-evaluated.	nAChRs	 are	 a	 heterogeneous	 family	 of	 ion	 channels	 involved	 in	 a	 wide	 range	 of	physiological	 functions	 both	 in	 the	 central	 nervous	 system	 (CNS)	 and	 in	 the	 peripheral	nervous	system	(PNS).	nAChRs	 are	 widespread	 distributed	 in	 the	 brain	 with	 a	 preferential	 localisation	 at	 the	presynaptic	 and/or	 preterminal	 sites,	 where	 they	 regulate	 the	 release	 of	 several	neurotransmitters,	 either	 excitatory	 or	 inhibitory	 (Gotti	 et	 al.,	 2006).	As	 a	 consequence	
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they	 can	 have	 opposite	 modulatory	 effects	 on	 the	 same	 circuit,	 depending	 on	 the	inhibitory	or	excitatory	nature	of	stimulated	neurons.	nAChRs		are	expressed	also	at	the	somatodendritic	 postsynaptic	 terminals,	 where	 they	 regulate	 neuron	 depolarisation,	firing	and	long-term	potentiation	(LTP)	(Hurst	et	al.,	2013).	Moreover	these	receptors	are	also	involved	in	proliferation,	differentiation	and	migration	of	neural	progenitors	(Liu	et	al.,	2007;	Campbell	et	al.,	2010).	Much	of	our	knowledge	has	been	obtained	by	studying	genetically	modified	mice	in	which	nAChR	 subunit	 genes	 have	 been	 knock	 out	 (KO)	 or	modified	 (knock-in).	 These	 studies	have	 provided	 important	 knowledge	 on	 the	 physiological	 role	 of	 different	 nAChR	subtypes.	nAChRs	 contribute	 to	 cognitive	 function,	 and	 their	decline	or	dysfunction	has	been	 observed	 in	 neurodegenerative	 diseases	 and	 mental	 illness.	 In	 addition	 genetic	studies	have	linked	nAChRs	to	epilepsy	and	schizophrenia,	and	studies	of	KO	or	knock-in	mice	 have	 shown	 that	 they	 are	 involved	 in	 pain	 mechanisms,	 anxiety	 and	 depression	(Gotti	et	al.,	2004).	nAChRs	 are	 particularly	 important	 in	 two	 critical	 periods	 of	 brain	 life:	 early	 pre-	 and	post-natal	 circuit	 formation,	 and	 age-related	 cell	 degeneration.	 They	 are	 involved	 in	neuronal	 survival,	 as	 it	 has	 been	 shown	 that	 nicotinic	 agonists	 are	 neuroprotective	 in	both	in	vivo	and	in	vitro	models	(Quik	et	al.,	2015;	Kalappa	et	al.,	2013).	Furthermore,	it	is	becoming	 evident	 that	 the	 perturbation	 of	 cholinergic	 nicotinic	 neurotransmission	 can	lead	 to	 various	 diseases	 during	 development,	 adulthood	 and	 aging	 (Changeux	 and	Edelstein,	2001).	
2.1	Structure	of	the	nAChRs	nAChRs	belong	 to	 the	superfamily	of	homologous	receptors	called	Cys-loop	 ion	channel	receptors,	which	include	muscle-type	nAChR,		GABAA,	GABAC,	glycine	and	serotonin	5HT3	receptors	(Gotti	et	al.,	2009).	nAChRs	 are	 a	 family	 of	 ligand-gated	 ion	 channels	 permeable	 to	 mono-	 and	 divalent	cations.	 They	 are	 expressed	 in	 the	 CNS	 and	 PNS	 and	 share	 a	 common	 basic	 structure	consisting	of	 five	 subunits	distributed	around	a	 central	pore,	permeable	 to	 cations.	The	nine	α	 (α2–α10)	and	 three	β	 (β2–β4)	 subunits	 identified	 so	 far	 can	assemble	 in	 a	high	variety	 of	 combinations,	 conferring	 specific	 functional	 and	 pharmacological	 features	 to	receptor	subtypes.	nAChRs	 are	 formed	 by	 the	 pentameric	 assembly	 of	 identical	 (homomeric	 receptors)	 or	homologous	subunits	(heteromeric	receptors).	Two	main	classes	have	been	identified:	the	
α-Bungarotoxin	 (α−Bgtx)-sensitive	 receptors,	 which	 are	 made	 up	 of	 the	 α7,	 α8,	 α9	
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and/or	α10	 subunits	 and	 can	 form	 homomeric	 or	 heteromeric	 receptors,	 and	α−Bgtx-insensitive	 receptors,	 which	 are	 heteromeric	 receptors	 that	 consist	 of	 α2-6	 and	 β2-4	subunits,	which	bind	nicotine	and	many	other	nicotinic	agonists	with	high	affinity,	but	not	
α−Bgtx.	All	 the	 different	 subunits	 have	 a	 common	 architecture	 consisting	 of	 a	 large	N-terminal	extracellular	 domain	 followed	 by	 four	 transmembrane	 (TM)	 domains	 and	 a	 large	cytoplasmic	 loop	 between	 TM3	 and	 TM4	 followed	 by	 a	 short	 extracellular	 carboxyl	domain	(C-domain)	(Zoli	et	al.,	2015)	(Figure	2).	The	 M1–M4	 transmembrane	 domains	 are	 arranged	 in	 concentric	 layers	 around	 the	central	 aqueous	 pore:	 the	M2	domain	 lines	 the	 pore	membrane,	M1	 and	M3	 shield	M2	from	the	surrounding	lipid	bilayer,	and	M4	is	in	contact	with	lipids.	The	 subunits	 are	 arranged	 around	 a	 central	 pore	 and	 site-directed	 mutagenesis	experiments	have	identified	in	the	transmembrane	M2	domain	the	important	residues	for	the	ion	selectivity,	permeability	and	channel	gating	of	the	receptors.	The	intracellular	loop	contributes	 most	 of	 the	 cytoplasmic	 domain	 of	 these	 receptors	 and	 includes	 multiple	interaction	 sites	 for	 putative	 trafficking	 and	 postsynaptic	 scaffold	 proteins	 as	 well	 as	phosphorylation	 sites	 for	 diverse	 serine/threonine	 and	 tyrosine	 kinases	 (Changeux,	2010).	The	α-subunits	present	adjacent	cysteines	(192	and	193)	 involved	 in	the	agonist	binding	 specificity,	 whereas	 β	 subunits	 do	 not	 have	 such	 cysteines	 (Changeux	 and	Edelstein,	1998).																																																																																																																																				Figure	2.	nAChR	protein	structure	(Modified	from	Karlin,	2002)		Upon	agonist	binding	to	pentameric	nAChRs,	the	domains	of	each	subunit	rearrange	and	open	the	central	pore	to	allow	ion	flux	through	the	channel	for	a	few	milliseconds,	after	which	 the	 receptor	 closes	 to	 a	 non-conducting	 state.	 All	 the	 subunits	 participate	 to	channel	 kinetics,	 ion	 conductance	 and	 selectivity	 (Albuquerque	 et	 al.,	 2009)	 and	 their	composition	 determines	 the	 specific	 functional	 and	 pharmacological	 features	 of	 the	receptor.	
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Chronic	 exposure	 to	 a	 low	nicotine	 concentration	 (such	 as	 that	 present	 in	 the	 blood	 of	smokers)	 leads	 to	consistent	receptor	desensitisation,	which	stabilises	 the	receptor	 in	a	closed	state	that	is	unresponsive	to	agonist	(Gotti	et	al.,	2009).	
2.1.1	nAChR	subtypes	Earlier	studies	designed	to	characterise	the	nAChRs	in	different	brain	areas	were	based	on	binding	assays	using	nicotinic	radioligands,	which	demonstrated	that	the	nervous	system	contains	at	least	two	classes	of	putative	nAChRs:	one	class	that	binds	nicotineand	nicotinic	agonists	 with	 high	 affinity	 but	 not	α−Bungarotoxin	 (α−Bgtx),	 and	 the	 other	 that	 binds	nicotine	and	nicotinic	agonists	with	µM	affinity	and	α−Bgtx	with	nM	affinity	(Lindstrom,	1997;	Gotti,	et	al.,	1997;	Hogg,	et	al.,	2003).		The	pharmacological	heterogeneity	of	nAChRs	revealed	by	these	ligand	studies	was	later	confirmed	and	extended	by	means	of	the	molecular	cloning	of	a	family	of	genes	encoding	twelve	subunits	and	by	studies	their	expression	in	heterologous	systems.	The	 class	 of	 α−Bgtx	 receptors	 is	 composed	 by	 homo-	 and	 hetero-meric	 subtypes	(α7, α8, α9, α7−α8, α9−α10), whereas	 the	 class	 of	 high	 affinity	 receptors	 is	 composed	only	by	heteromeric	receptors	made	of	α2−α6; β2−β4 subunits	(Gotti	et	al.,	2004).	In	the	case	 of	 heteromeric	 high	 affinity	 receptors	 the	 heterogeneity	 is	 very	 elevated	 with	nAChRs	made	up	of	four	different	subunits.	The	 homomeric	 receptors	 are	 composed	 by	 five	 identical	 α−subunits	 with	 five	(orthosteric)	 binding	 sites	 per	 receptor	molecule	 (Figure	 3A)	whereas	 the	 heteromeric	receptors	are	composed	by	different	nicotinic	subunits	and	have	two	orthosteric	binding	sites	(Figure	3B)	at	the	interface	between	α and	β subunits. 			 							Figure	3.	Representation	of	the	structure	in	the	homome	ric	α7	(A)	and	heteromeric	α4β2	(B)	subtypes	and	localisation	of	the	ACh	binding	site	(Modified	from	Gotti	et	al.,	2004)		
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2.1.1.2	The	α7	subunit	variant	CHRFAM7A		The	α7	subunit	is	encoded	by	the	10-exon	CHRNA7	gene	located	on	chromosome	15q14,	which	gives	rise	to	a	transcript	that	is	translated	into	a	protein	of	approximately	57	kDa.	The	 neuronal	 α7	 nicotinic	 receptor	 subunit	 gene	 (CHRNA7)	 is	 partially	 duplicated		(α7dup)	 in	 the	 human	 genome	 and	 forms	 a	 hybrid	 gene	 with	 the	 novel	 FAM7A	 gene	(CHRFAM7A,	 α7dup)	 whose	 transcript	 codes	 for	 a	 α7dup	 protein	 that	 has	 a	molecular	weight	of	46.2	kDa	and	is	unique	to	humans	(Gault	et	al.,	1998)	(Figure	4	A	and	B).		The	resulting	subunit	lacks	the	signal	peptide	and	the	ligand-binding	domain	for	ACh.		The	CHRFAM7A	mRNA	is	expressed	in	the	human	brain	at	low	level,	while	is	abundant	in	peripheral	lymphocyte	cells	and	other	tissues	(Araud	et	al.,	2011).	Several	mutations	have	been	mapped	specifically	on	CHRFAM7A	gene	including	a	deletion	of	 2bp	 in	 exon	 6	 (CHRFAM7AΔ2bp)	 (Figure	 4C),	 which	 seems	 to	 be	 associated	 with	schizophrenia	 (Sinkus	 et	 al.,	 2009).	 This	 particular	 mutation	 is	 more	 common	 in	Caucasian	populations	than	those	of	American	and	African.	Recent	studies	have	shown	that	the	CHRFAM7A	cDNA	injected	in	Xenopus	laevis	oocytes	acts	 as	 a	 dominant	 regulator	 of	α7	 nAChR	 (de	 Lucas-Cerrillo	 et	 al.,	 2011;	 Araud	 et	 al.,	2011).	In	oocytes,	the	co-expression	of	CHRFAM7A	and	α7	cDNAs	reduces	the	ACh-evoked	current	 by	 53%	 and	 oocytes	 expressing	 the	 CHRFAM7AΔ2bp	 form	 have	 a	 further	decrease	of	10%	of	the	ACh-evoked	current		(Araud	et	al.,	2011).		Pharmacological	 binding	 studies	 using	 the	 selective	 α7	 ligand	 α−Bgtx	 in	 oocyte-expressing	 α7	 subunit	 alone	 or	 α7	 together	 with	 α7dup	 show	 a	 lower	 expression	 of	surface	binding	sites,	suggesting	that	the	presence	of	the	α7	dup	might	alter	the	level	of	the	receptors	inserted	in	the	plasma	membrane	(Araud	et	al.,	2011).	In	 the	 same	year	another	group	have	shown	 that	GH4CI	 cells	 transfected	both	with	 the	
α7-	 and	 α7	 dup	 cDNAs	 have	 comparable	 protein	 expression	 level	 but	 a	 different	localisation:	 α7	 is	 primarily	 located	 at	 the	 plasma	 membrane	 while	 α7	 dup	 in	 the	endoplasmic	reticulum	(ER)	(de	Lucas-Cerrillo	et	al.,	2011).		More	 recently,	 by	 using	 the	 Forster	 resonance	 energy	 transfer	 (FRET)	 technique	 it	 has	been	 confirmed	 that	 the	 α7dup	 subunits	 are	 assembled	 and	 transported	 to	 the	 cell	membrane	 together	 with	 full-length	 α7	 subunits	 and	 these	 α7-α7dup	 receptors	 show	altered	receptor	function	(Wang	et	al.,	2014).	Until	 now	 it	 is	 not	 clear	 how	α7dup	works	 and	 it	 has	 been	 hypothesised	 that	 it	 could	interfere	with	the	correct	assembly	of	α7	receptors,	 leading	to	a	decrease	in	the	plasma	
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membrane	 insertion	 of	 them	 and/or	 the	 α7-α7dup	 receptors	 present	 in	 the	 plasma	membrane	 have	 pharmacological	 properties	 different	 from	 that	 of	 the	 homomeric	 α7	receptors.																																							 Figure	4.	Structure	of	CHRNA7,	CHRFAM7A	and	CHRFAM7AΔ2	bp	gene	products:	(A)	normal	α7	subunit;	(B)	duplicated	 form	(dupα7)	and	(C)	CHRFAM7A	 gene	with	a	deletion	of	2bp	 in	exon	6	 (dupΔα7);	 (D)	Pentameric	structure	of	the	normal	α7nAChR	(on	the	left)	and	a	pentamer	containing	the	peptide	of	the	duplicated	subunit	(on	the	right)	(Modified	from	Sinkus	et	al.,	2015)		
2.2	nAChR	transition	states	The	difficulty	in	studying	nAChR	pharmacology	is	that	in	addition	to	structurally	distinct	subtypes,	 the	 nervous	 system	 has	 functionally	 distinct	 transition	 states	 for	 individual	nAChRs.		Functionally,	 nAChRs	 can	 exist	 in	 three	 conformations:	 closed,	 open,	 and	 desensitised	closed	channel	state	(D	or	I).	The	agonists,	by	binding	to	the	orthosteric	site,	determine	a	rapid	transition	of	the	receptor	from	the	closed	to	the	open	state	and	stabilise	the	open	state	 whereas	 the	 antagonists	 (competitive	 and	 non-competitive)	 stabilise	 the	 closed	state.	 The	 competitive	 antagonists	 prevent	 the	 binding	 of	 agonists	 at	 the	 orthosteric	binding	 site,	 whereas	 non-competitive	 antagonists	 interact	 at	 sites	 distinct	 from	 the	orthosteric	site	(Hurst	et	al.,	2013).	nAChRs	have	a	transition	from	the	agonist-bound	open	conformation,	to	a	non-conducting	desensitised	state	(D),	either	by	dissociation	of	the	agonist	 from	the	receptor,	known	as	deactivation,	or	by	an	agonist	bound	conformational	change	to	a	high	affinity	(pM	-	nM),	non-conducting	state,	called	desensitisation.	When	this	desensitisation	state	goes	on	for	a	long	time	the	receptor	enters	in	the	inactive	state	(I)	(Gotti	et	al.,	2004).	Deactivation	 is	 the	 transition	 from	 the	 open	 state	 to	 the	 resting	 state	 associated	 with	dissociation	of	the	agonist	from	the	ligand-binding	domain.	The	binding	of	 ligands	to	the	receptors	at	the	neurotransmitter-binding	site	or	in	any	of	
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the	 allosteric	 sites	 can	 modify	 the	 equilibrium	 between	 the	 different	 conformational	states	of	the	receptors.	The	kinetics	of	 the	 transition	 states	depend	on	 the	different	 subtypes	 and	 the	 chemical	nature	of	the	agonist,	which	binds	to	the	ligand-binding	domain	(Hurst	et	al.,	2013),	but	is	also	regulated	by	 the	activity	of	kinases	and	phosphatases	and/or	allosteric	modulators	(Changeux	and	Edelstein,	1998;	Quick	and	Lester,	2002).		
2.3	Ligand-binding	sites	
2.3.1	The	orthosteric	achetylcholine	binding	site	Crystal	 structural	 studies	 of	 ACh	 binding	 proteins	 from	 the	 fresh	water	 snail	 Lymnaea	
stagnalis,	have	given	a	significant	contribution	to	the	identification	of	the	ligand	binding	site	 in	nAChRs,	allowed	us	 to	understand	the	molecular	details	of	 the	nicotinic	receptor	binding	 site	 (Gotti	 et	 al.,	 2006).	 Snail	 glial	 cells	 produce	 this	 homopentameric	 soluble	protein,	which	has	an	affinity	spectrum	resembling	that	of	homomeric	α7	or	α9	receptors.	Structural	 data	 concerning	 the	 crystallised	 ACh	 binding	 protein	 have	 revealed	 that	 the	topology	of	the	binding	sites	is	very	similar	to	that	predicted	by	mutations	and	computer	modelling.	The	binding	sites	for	the	nAChR	agonists	are	located	in	hydrophobic	pockets	that	lie	at	the	interface	 between	 two	 adjacent	 subunits.	 One	 subunit	 provides	 the	 main	 binding	component,	consisting	of	short	non-contiguous	sequences	that	form	loops	A,	B	and	C	and	the	other	participate	with	the	complementary	component	formed	by	loops	D,	E	and	F.	In	the	case	of	homomeric	receptors	the	same	subunit	contributes	to	both	the	principal	and	complementary	 component	 (Figure	 5A).	 In	 the	 heteromeric	 nAChRs	 the	 principal	component	is	carried	by	the	α2,	α3,	α4	and	α6	subunits	while	the	complementary	site	by	the	β2	or	β4	subunits	(Figure	5B).		In	order	to	fully	activate	homomeric	nAChR,	ACh	needs	to	bind	three	binding	sites	at	non-consecutive	subunit	interfaces	whereas	in	the	heteromeric	receptors	it	binds	two	binding	sites	(Rayes	et	al.	2009).						
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			 							Figure	5.	Localisation	of	the	orthosteric	binding	sites	in	homomeric	(A)	and	heteromeric	(B)	nicotinic	receptors	(Modified	from	Zoli	et	al.,	2015)	
 The	conformational	changes	that	take	place	after	ACh	binding	to	nicotinic	receptors	have	not	yet	been	fully	defined,	but	the	binding	site	located	in	the	extracellular	portion	of	the	α	subunit	is	closely	connected	to	the	adjacent	subunit.	It	is	believed	that	the	binding	of	the	quaternary	ammonium	cationic	head	of	ACh	to	a	subsite	present	in	loops	A,	B,	C	and	D	and	the	simultaneous	attraction	of	negatively	charged	amino	acids	by	quaternary	ammonium	residues	of	the	adjacent	subunits,	close	the	two	sites,	and	create	a	movement	between	the	subunits	that	leads	to	the	channel	opening	(Taly	et	al.,	2009).	Interestingly,	the	α10 subunit,	even	if	it	is	considered	an	α subunit,	cannot	act	as	principal	component	 of	 the	ACh	binding	 site	 and	 operates	 only	with	 the	α9 subunit (Sgard	 et	 al.,	2002).	Notwithstanding	their	initial	classification	in	the	α	and	β	subunit	list,	α5	and	β3	subunits	carry	neither	the	principal	nor	the	complementary	component	of	the	ACh	binding	site	but	both	 form	 functional	 channels	 in	 the	 Xenopus	 expression	 system	 only	 when	 they	 are	expressed	with	a	 ligand	binding	and	a	complementary	subunit;	 for	 this	 reason	 they	are	known	as	non-ligand-binding	(accessory)	subunits	(Lindstrom,	2000).	The	 accessory	 subunit	 α5 in	 the	 α4β2	 receptors	 changes	 their	 pharmacological	 and	biophysical	 properties	 with	 higher	 sensitivity	 to	 the	 allosteric	 modulator	 galantamine	(Kuryatov	et	al.,	2008).		It	 has	 been	 demonstrated	 that	 α5 is	 able	 to	 modulate	 ACh	 sensitivity	 in	 receptors	composed	by	different	subunits	and	in	particular	it	increases	the	response	of	ACh	in	the	
α3β2 subtype	but	not	 if	β2	is	replaced	with	β4	in	the	α3β4	subtype,	 indicating	a	specific	and	selective	activity	of	the	α5	accessory	subunit	(Wang	et	al.,	1996).	
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β3 seems	 to	be	 important	 in	 the	 formation	of	α6β2*	or	α4α6β2*	 receptors,	 and	 its	 loss	causes	defects	in	nAChR	assembly,	degradation	and/or	trafficking	(Gotti	et	al.,	2006).		In	 conclusion	 the	 accessory	 subunits	 modulate	 and	 influence	 the	 pharmacological	 and	functional	 properties	 of	 the	 receptors	 such	 as	 sensitivity	 to	 agonists,	 channel	 kinetics,	permeability	to	calcium,	correct	assembly	and	membrane	localization	(Hurst	et	al.,	2013;	Taly	et	al.,	2009).	
2.3.2	Allosteric	binding	site	Allosteric	binding	 sites	 are	 evolutionary	 less	 conserved	and	exhibit	 a	 greater	 structural	diversity	 than	 ortostheric	 sites.	 Therefore,	 allosteric	 sites	 are	 more	 likely	 to	 allow	selective	targeting	by	synthetic	compounds	than	the	orthosteric	ones	(Yang	et	al.,	2012).		Allosteric	modulators	are	a	pharmacological	group	of	molecules	that	bind	to	the	receptor	at	 distinct	 allosteric	 ligand-binding	 site	 changing	 the	 free	 energy	 associated	 with	transitions	between	functional	states	(Young	et	al.,	2008).	These	molecules	have	mainly	low	intrinsic	activity	and	act	as	enhancer	or	inhibitor	in	the	physiological	activity	of	the	nAChR	in	the	presence	of	agonist.	They	are	not	able	to	induce	the	activation	of	the	channel	per	se	but	co-operate	with	the	agonist	favouring	or	limiting	the	opening	and	the	entry	of	ions.	The	positive	allosteric	modulators	(PAM)	are	molecules	able	to	reduce	the	energy	barrier	from	 resting	 to	 activation	 state,	 increase	 the	 receptor	 affinity,	 the	 slope	 of	 the	 dose-response	 curve	 and	 the	 maximal	 effect	 of	 the	 responses.	 They	 can	 reduce	 the	 agonist	concentration	 required	 to	 achieve	 channel	 opening	 and	 enhance	 the	 channel	 opening.	When	they	are	administered	alone,	they	do	not	activate	nicotinic	receptors	but	they	can	increase	 the	 activation	 of	 endogenous	 nicotinic	 agonist,	 like	 choline	 or	 acetylcholine	(Bertrand	 et	 al.,	 2007).	 On	 the	 contrary,	 the	 negative	 allosteric	modulators	 (NAM)	 are	compounds	 that	 increase	 the	energy	barrier	between	the	resting	and	open	states	of	 the	channel,	 increasing	 the	concentration	of	agonist	 required	 for	 its	activation	 (Hurst	et	 al.,	2013).		For	 the	 α7	 nAChRs	 Daniel	 Bertrand	 and	 Murali	 Gopalakrishnan	 (2007)	 show	 the	existence	of	 two	 classes	of	positive	 allosteric	modulators:	 called	 type	 I	 and	 type	 II.	 The	first	(i.e.	NS-1738)	predominantly	affects	the	peak	current	response,	whereas	the	second	(i.e.	PNU-120596)	affects	both	peak	current	responses	and	the	kinetics	of	agonist-evoked	response.			
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2.4	Receptor	stoichiometry	A	further	complexity	in	studying	nAChR	subtypes	is	due	to	the	fact	that	in	addition	to	the	high	level	of	subunit	heterogeneity,	nAChR	subtypes,	made	by	one	type	of		α	and	1	type	of	
β subunit,	 can	 also	 show	 the	 same	 subunit	 composition	 but	 with	 different	 subunit	stoichiometry.	The	 α4β2	and	α3β4	subtypes	 can	 exist	 in	 two	 stoichiometries, made	 of	 either	 two	 or	three	 copies	 of	 the	 α	 subunit	 in	 the	 channel	 pentamer.	 The	 two	 stoichiometries	 of	the	α4β2	 subtype	 can	 be	 distinguished	 because	 the	 subtype	 with	 two	 α4	 subunits	((α4)2(β2)3)	is	activated	at	much	lower	ACh	concentrations	and	is	more	sensitive	to	other	agonists	 than	 the	 subtype	with	 three	α4	 subunits	 ((α4)3(β2)2)	 (Moroni,	 2006).	The	 two	stoichiometries	 also	 have	 different	 Ca2+	 permeability	 with	 the	 (α4)3(β2)2	stoichiometry	having	a	higher	Ca2*	permeability	than	the	(α4)2(β2)3	(Tapia	et	al.,	2007).	Studies	of	transfected	cells	have	shown	that	chronic	exposure	to	nicotine	up-regulates	the	expression	 of	 (α4)2(β2)3	 stoichiometry	 and	 normalises	 the	 intracellular	 subunit	stoichiometry	 of	 nAChRs	 carrying	 mutations	 linked	 to	 autosomal	 dominant	 nocturnal	frontal	lobe	epilepsy	(Son	et	al.,	2009).	In	 the	 case	of	 the	α3β4	 stoichiometries	 the	EC50	 for	ACh	 is	not	 significant	different,	but	they	differ	for	the	conductance	and	the	single	channel	kinetic	(Krashia	et	al.,	2010).		Moreover	 only	 the	 (α3)2(β4)3	 subtype	 is	 susceptible	 to	 enhancement	 by	 low	 zinc	concentrations.		
2.5	Biosynthetic	and	secretory	pathways	of	nAChRs	The	assembly	of	nAChRs	channels	is	a	slow	and	inefficient	process.		nAChR	 subunits	 cannot	 exit	 the	 ER	 until	 they	 have	 achieved	 their	 correctly	 folded	conformation	and	the	ER	apparatus	have	evolved	several	mechanisms	to	regulate	protein	quality	control.	This	quality	control	machinery	prevents	that	dysfunctional	subunits	reach	to	the	membrane	and	retro-translocated	misfolded	or	unassembled	proteins	 from	ER	to	the	cytoplasm	for	proteasomal	degradation	(Colombo	et	al.,	2013).	Vertebrate	neuronal	nAChRs	can	assemble	 in	many	different	combinations	but	 it	 seems	that	native	nAChRs	have	a	restricted	number	of	possible	subunit	combination	(Millar	and	Gotti,	 2009).	 For	 example	 in	 neurons	 the	 assembly	 depends	 mainly	 on	 the	 cell-type	specificity	and	localisation.		
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Many	 chaperones	 proteins	 play	 a	 critical	 role	 in	 the	 folding,	 assembly	 and	 retention	 of	immature	nAChR	subunits	 in	 the	ER.	This	 class	of	proteins	are	not	only	 responsible	 for	helping	 nascent	 polypeptides	 folding	 but	 they	 are	 also	 important	 in	 retaining	 the	immature	 polypeptides	within	 the	 ER.	 This	 retention	 increases	 the	 probability	 that	 the	immature	polypeptide	will	be	correctly	folded	and	that	it	does	not	prematurely	enter	to	the	 secretory	 pathway.	 At	 the	 end,	 the	 prolonged	 retention	 of	 the	 misfolded	 or	incompletely	assembled	polypeptide	leads	to	its	degradation.	In	the	case	of	nAChRs	several	chaperone	proteins	have	been	identified	among	which	RIC-3,	UBXD4	and	VILIP-1.	RIC-3	(Resistance	to	Inhibitors	of	Cholinesterase)	protein	interacts	with	a	number	of	nAChR	subtypes	and	enhances	their	functional	response	depending	on	the	 subtype	or	 the	host	 system	 (Millar,	 2008).	RIC3	 increases	 the	 expression	of	 certain	nAChR	subtype	in	particular	the	α7 subtype and	in	certain	host	cell	types,	in	the	absence	of	RIC-3	no	functional	receptors	are	expressed	on	the	plasma	membrane.	RIC-3	probably	associates	 with	 unassembled	 receptor	 subunits	 in	 the	 ER	 facilitating	 their	 receptor	folding	and	assembly.	In	two	hybrid	screening	studies	the	calcium	sensor	protein	VILIP-1		(visinin-like	protein)	(Lin,	2002)	and	UBXD4	(Rezvani	et	al.,	2010)	were	found	to	interact	with	the	intracellular	loop	 between	 trasmembrane	 domains	 3-4	 of	α3 and α4 subunits	 and	 these	 interactions	significantly	 increase	 the	 α4 subunits	 steady-state	 levels.	 The	 greater	 availability	 of	
α4 subunit	 increases	 the	 formation	 of	 the	 α4β2 subtype	 and	 the	 surface	 expression	
α4β2 receptors.	UBXD4	 is	 expressed	 both	 in	 neuronal	 and	 non-neuronal	 cells	 where	 it	 increases	 the	amount	of	α3-containing	receptors	at	the	plasma	membrane,	possibly	by	preventing	the	ubiquitination	and	degradation	of	this	subunit	(Rezvani	et	al.,	2010).							 	Figure	 6.	 Schematic representation of the 
biosynthetic and trafficking pathways of 
nAChRs	(Modified	from	Colombo	et	al.,	2013)		
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	The	 exit	 from	 the	 ER	 is	 the	 limiting	 step	within	 the	 secretory	 pathway,	 pointing	 to	 an	accumulation	of	receptors	in	the	ER,	as	demonstrated	for	neuronal	α4β2	AChRs	(Sallette	et	al.,	2005)	(Figure	6).	 In	 the	ER	nAChRs	that	pass	quality	control	are	exported	 in	coat	protein	 complex	 II	 vesicles	 from	 the	ER	 to	Golgi,	 presumably	 after	masking	 specific	 ER	retention	 signals	 (Keller	 et	 al.,	 2001;	Wang	 et	 al.,	 2002)	 and	 recognition	 of	 ER	 export	motifs	 in	properly	 folded	and	oligomerized	nAChR	subunits.	After	passing	 the	Golgi	 the	receptors	are	transported	to	the	plasma	membrane	where	depending	on	their	localisation	they	carry	specific	functions:	if	they	are	expressed	in	the	soma	they	influence	the	resting	potential,	whereas	if	they	have	a	presynaptic	localisation	they	can	regulate	the	release	of	many	neurotransmitters.		
2.6	Native	nAChR	subtypes:	localisation	and	composition	The	nAChRs	expression	in	the	SNC	is	highly	heterogeneous	and	their	subunit	composition	is	cell	-	and	region-specific	(Figure	7).		The	 identification	 of	 the	 nAChR	 subtypes	 expressed	 in	 different	 brain	 areas	 have	 been	obtained	 using	 different	 techniques,	 which	 include	 in	 situ	 hybridisation,	 PCR,	immunoprecipitation,	receptor	binding	studies	and	autoradiography	as	well	as	functional	assays	(Zoli	et	al.,	2015)	using	brain	tissues	from	WT	and	KO	mice.	The	large	majority	of	nAChRs	in	the	nervous	system	contain	one	type	of	α and	one	type	of	
β subunit.	α4β2	 receptors	accounts	 for	 the	90%	of	 the	high	affinity	neuronal	nAChRs	 in	mammalian	brain	while	the	α3β4	subtype	is	expressed	in	the	autonomic	ganglia,	adrenal	medulla	and	in	a	subset	of	CNS	neurons	 located	in	the	medial	habenula,	dorsal	medulla,	pineal	gland	and	retina	(Gotti	and	Clementi,	2004).	Both	 the	α4β2	 and	α3β4	 subtypes	may	 also	 contain	 the	α5 subunit,	whose	 presence	 is	believed	 to	 increase	 the	 rate	 of	 channel	 desensitisation	 and	 calcium	permeability and/or	modify	receptor	localisation	(Lindstrom,	2000).	mRNA	 distribution	 of	 the	 α3,	 α6,	 β3	 and	 β4	 subunits	 in	 brain	 shows	 that	 receptors	containing	these	subunits	have	a	more	restricted	localisation,	with	the	α6	and	β3	subunits	expressed	in	the	dopaminergic	cells	of	the	mesocorticolimbic	and	visual	pathways	and	the	
α3β4	subunits	in	the	habeno-interpeduncular	pathway.	Biochemical	 and	 functional	 assays	 have	 characterised	 two	 principal	 nAChR	 subtypes	(α6β2β3	and	α6α4β2β3) in	rodent	striatum	and	retina	containing	the	α6	subunit.	
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The	 distribution	 of	 sensitive	 α-Bgtx	 receptors	 was	 studied	 mostly	 by	 pharmacological	binding	experiments.	These	studies	showed	a	high	level	of	α7	in	the	cortex,	hippocampus,	subcortical	 limbic	regions,	while	they	are	expressed	at	 low	level	 in	the	thalamic	regions	and	in	the	basal	ganglia	(Gotti	et	al.,	2006;	Jones	and	Wonnacott,	2004).		Recent	studies	have	identified	a	new	α7-containing	subtype	containing	the	α7β2 subunits,	which	 has	 been	 biochemically	 purified	 from	mice	 and	 human	 basal	 forebrain,	 but	 not	from	human	cerebellum	(Moretti	et	al.,	2014).	The	receptors	α9	and	α10	are	not	present	in	the	brain	and	they	are	only	expressed	in	the	cochlea	and	in	certain	ganglia	where	the	α9	subunit	forms	homomeric	channels,	while	the	
α10	subunit	forms	functional	channels	only	when	co-expressed	with	the	α9	subunit.	
α8	 subunit	 is	 not	 expressed	 in	 mammals,	 but	 only	 in	 the	 chickens	 CNS	 where	 form	homomeric	and	heteromeric	α7- α8	receptors.	The α2−containing	 nAChR	 has	 a	 very	 restricted	 localisation	 in	 rodent	 brain	 (in	 the	interpeduncolar	 nucleus)	while	 in	 primates	 (human	 and	monkey)	 this	 subtype	 is	much	more	widely	expressed	(Han	et	al.,	2000).	The	 physiological	 functions	 of	 nAChR	 subtype	 depend	 on	 their	 location	 on	 the	 plasma	membrane:	 in	 pre-	 or	 postsynaptic	 domains,	 in	 the	 active	 zones	 of	 the	 synapse	 or	extrasinaptic	domains.	
		 Figure	7.	Regional	distribution	and	subunit	organization	of	the	nicotinic	acetylcholine	receptors	in	rodents	(Modified	from	Gotti	C	et	al.,	2006)			
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2.7	Regulation	of	native	subtypes	by	chronic	nicotine	exposure	Nicotine	 induces	 psycho-stimulation,	 reward	 and	 reduces	 stress	 and	 anxiety.	 Nicotine,	once	in	the	bloodstream,	rapidly	crosses	the	blood	brain	barrier	and	accumulates	in	the	brain	 where	 it	 exerts	 its	 pharmacological	 effects	 by	 binding	 the	 nAChRs	 (Changeux,	2010).		Chronic	 nicotine	 exposure	 induces	 neural	 adaptations	 that	 change	 cell	 physiology	 and	behaviour	 and	 these	 effects	 are	mainly	 due	 to	 the	 activation	 and/or	 desensitisation	 of	nAChRs.	 Studies	 on	 animals	 and	 smoker	 brains,	 chronically	 exposed	 to	 nicotine,	 have	shown	 an	 increase	 in	 the	 number	 of	 nAChRs	 (called	 up-regulation).	 The	 molecular	mechanisms	 underlying	 the	 increased	 expression	 of	 cell	 surface	 nAChRs	 have	 been	investigated	in	vitro	and	in	vivo.	It	 has	 been	 found	 that	 in	 brains	 of	 mice	 treated	 chronically	 with	 nicotine	 there	 is	 an	increase	 in	 3H-agonist	 labelled	 nAChRs,	 with	 no	 change	 in	 α2, α3, α4, α5 or β2	 mRNA	levels,	 indicating	 a	 post-transcriptional	 effect	 induced	 by	 nicotine.	 Autoradiography,	immunoprecipitation	and	Western	blotting	experiments	have	shown	that	the	α4β2	is	the	most	 up-regulated	 subtype,	 but	 the	 presence	 of	 the	 accessory	 subunit	
α5,  in	the α4β2α5  subtype,	leads	to	the	in	vivo	 resistance	to	nicotine	up-regulation	(Mao	et	al.,	2008).		The	homomeric	α7 	 receptor	 is	 less	up-regulated	 in	vivo	 probably	because	 this	 subtype	needs	 very	 high	 concentration	 of	 nicotine	 that	 is	 not	 normally	 reached	 in	 the	 brain	 of	smokers	or	animals	treated	with	nicotine.	In	vivo	chronic	nicotine	exposure	decreases	the	number	of	α6∗ receptors	expressed	in	midbrain	dopaminergic	neurons	(Lai	et	al.,	2005). The	decrease	of	α6∗ is	correlated	with	a	decrease	in	β3-containing	receptor,	according	to	the	fact	that	70%	of	α6*-receptors	contain	the	β3subunit	(Gotti	et	al.,	2010).	In	conclusion	 the	 in	vivo	effects	of	nicotine	are	very	complex	and	depend	on	 the	nAChR	subtype	 and	 the	 identity	 of	 the	 neuron	 expressing	 it.	 Moreover,	 the	 fact	 that	 several	subtypes	might	co-exist	in	the	same	neuron	suggests	that	the	functional	effect	of	nicotine	depends	on	the	neuronal	circuit	in	which	the	nAChRs	are	expressed.	
2.7.1	Molecular	mechanisms	for	the	up-regulation	Nicotine	up-regulates	nAChRs	with	post-transcriptional	mechanisms:	these	processes	are	independent	 from	 the	 cell	 type	 and	 interfere	 with	 key	 steps	 of	 nAChRs	 (assembly,	trafficking	and	cell	surface	expression).		Nicotine,	by	acting	 intracellular	at	 the	early	 stages	of	 receptor	biogenesis,	 increases	 the	number	of	receptor	subunits	in	the	ER	(Sallette	et	al.,	2005)	and	induces	a	5-fold	increase	
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of	 the	 lifetime	 of	 AChRs	 on	 the	 cell	membrane	 surface.	Moreover	Rezvani	 et	 al.	 (2007)	have	 shown	 that	 nicotine	 reduce	 proteasomal	 degradation	 of	 the	 subunits	 and	 slowly	stabilise	the	α4β2	receptor	in	a	high-affinity	state	for	nicotine	(Vallejo	et	al.,	2005).	Nicotine	 also	 alter	 the	 subunit	 stoichiometry	 of	 nAChRs,	 in	 particular	 it	 shifts	 the	
α4β2	receptor	 to	 the	 high	 affinity	 stoichiometry	 (α4)2(β2)3	 stoichiometry	 and	 these	receptors	are	more	efficiently	transported	to	the	plasma	membrane			Chronic	nicotine	also	affects	the	stoichiometry	of	the	α3β4	subtype	towards	the	formation	of	the	(α3)2(β4)3	stoichiometry		(Mazzo	et	al.,	2013).	Receptors	with	this	stoichiometry	are	less	 prone	 to	 proteasomal	 degradation	 and	more	 efficiently	 transported	 to	 the	 plasma	membrane.			
3.	Nicotine	effects	on	the	CNS		The	pharmacological	effects	of	nicotine,	 the	major	reinforcing	component	of	tobacco,	on	the	CNS	are	due	to	its	binding	to	presynaptic	nAChRs	expressed	in	different	brain	areas,	where	 it	 stimulates	 the	 release	 of	 different	 neurotransmitters.	 Within	 a	 certain	concentration	 range,	 nicotine	 binding	 activates	 nAChRs,	 but	 at	 the	 concentrations	observed	 in	the	blood	of	regular	smokers,	 it	desensitises	most	heteromeric	nAChRs	and	induces	a	long-term	increase	in	receptor	numbers	known	as	up-regulation.		Recent	studies	suggest	that	the	mesocorticolimbic	system	is	responsible	for	the	pleasant	aspects	of	smoking	that	support	the	onset	of	nicotine	dependence	and	is	also	responsible	for	 the	 physical	 and	 physiological	 symptoms	 occurring	 during	 nicotine	 withdrawal	(Livingstone	and	Wannacott,	2009;	Picciotto	and	Kenny,	2013).		The	 mesocorticolimbic	 system	 is	 the	 central	 mediator	 of	 nicotine	 reward	 and	reinforcement,	 and	 this	 neural	 pathway	 connects	 the	 neurons	 present	 in	 the	 ventral	tegmental	area	(VTA)	with	two	principal	targets:	the	nucleus	accumbens	(NAc))	and	the	prefrontal	 cortex	 (PFC).	 Dopamine	 (DA)	 neurons	 that	 project	 to	 the	 NAc	 receive	 both	excitatory	afferents	(glutamatergic	and	cholinergic),	which	mediate	nicotine	reward	and	inhibitory	afferents	(GABAergic),	which	mediate	aversion	(Lammel	et	al.,	2011).		In	the	mesocorticolimbic	pathway	the	reinforcing	effects	of	nicotine	are	principally	due	to	the	activity	of	VTA	DA	neurons	and	nicotine	exposure	increases	the	release	of	dopamine	(DA)	in	the	NAc,	which	is	critical	for	the	nicotine-induced	reward.	In	the	VTA	DA	neurons	are	modulated	 by	 other	 neurotransmitters,	whose	 release	 is	modulated	 by	 the	 nAChRs	expressed	 in	 cholinergic,	 glutamatergic	 and	 GABAergic	 terminals.	 Chronic	 nicotine	
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treatment	activates	the	α7 	receptors		expressed	on	glutamatergic	terminals,	increases	the	release	 of	 glutamate	 that	 facilitates	 the	 burst	 firing	 of	 VTA	 DA	 neurons,	 increases	 the	NMDA	receptors	activity	and	induces	long-term	potentiation	(Zhao-Shea	et	al.,	2011).	In	the	mean	time	chronic	nicotine	induces	the	desensitisation	of	α4β2	receptors	localised	on	GABAergic	 input,	 leading	 to	a	reduced	GABA	release	and	a	 lower	DA	neurons	 inhibition	(Mansvelder	 et	 al.,	 2002).	 Finally	 nicotine	 directly	 activates	 the	 nAChRs	 present	 on	DA	terminals	in	the	NAc	and	increases	DA	release.			
4.The	non-neuronal	cholinergic	system		The	presence	of	ACh	in	primitive	organisms,	such	as	bacteria,	protozoa	and	algae	that	do	not	 have	 a	 real	 CNS	 and	 PNS,	 underlines	 the	 fact	 of	 considering	 ACh	 not	 only	 as	 a	neurotransmitter.	 Free	 ACh	 is	 found	 in	 almost	 all	 mammalian	 non-neuronal	 cells	 and	tissues	where	it	acts	in	autocrine	and	paracrine	manner	with	different	biological	activity	depending	on	cell	type	(Grando,	2014).	Non-neuronal	 ACh	 is	 released	 from	 living	 cells	 and	 binds	 nAChRs	 expressed	 in	 non-neuronal	 cells	 such	 as	 epithelial	 cells	 (skin,	 digestive	 and	 respiratory	 tracts,	 kidneys,	placenta)	endothelial	cells,	immune	cells,	astrocytes,	and	mesenchymal	cells	(Wessler	and	Kirkpatrick,	2008).		Activation	 of	 the	 nAChRs	 can	 lead	 to	 cell	 proliferation	 or	 inhibition	 and	 this	 balance	 is	crucial	to	maintain	physiological	functions.	However,	there	are	many	pathophysiological	diseases	correlated	with	an	aberrant	expression	of	nAChRs	in	malignant	cells	stimulated	by	ACh	and	above	all	nicotine,	which	might	contribute	to	health	problems	such	as	cancer.	
4.1.Connection	of	nicotine	to	cancer	Most	tumors	are	formed	as	a	consequence	of	genetic	alterations	of	cellular	genes,	which	may	 be	 inherited	 or	 arise	 spontaneously	 as	 a	 result	 of	 DNA	 damage	 induced	 by	environmental	 carcinogens	 or	 mutations	 arising	 from	 replication	 errors.	 These	alterations	 confer	 a	 selective	 advantage	 to	 the	 cells	 that	 together	 with	 changes	 in	 the	microenvironment	promote	tumor	growth,	progression	and	spreading.	The	 list	 of	 cancers	 connected	with	 nicotine	 includes	 small-cell	 and	 non-small	 cell	 lung	carcinomas,	 head	 and	 neck,	 gastric,	 pancreatic,	 gallbladder,	 liver,	 colon,	 breast,	 cervical	and	kidney	 cancers	 (Grando,	 2014).	Data	present	 in	 literature	 show	 the	mutagenic	 and	tumour-promoting	 activity	 of	 nicotine:	 it	 can	 damage	 the	 DNA,	 disturb	 cell	 metabolic	processes	 and	 facilitate	 growth	 and	 spreading	 of	mutated	 cells.	Nicotine	 also	 alters	 the	
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physiology	 of	 different	 organs	 such	 as	 the	 lung	 or	 mammary	 glands	 by	 inducing	 the	release	 of	 different	 factors,	 which	 lead	 to	 tumour	 growth	 and	 metastasis	 (Schall	 and	Chellappan,	2014).	Nicotine	 and	 its	 derivatives	 can	 both	 promote	 (nicotine	 itself)	 and	 initiate	 (NNN	 and	NNK)	smoking-induced	carcinogenesis	and	their	effects	are	mainly	due	to	their	binding	to	nAChRs.		
4.1.2	Nicotinic	acetylcholine	receptors	in	cancer	nAChRs	 are	 expressed	 in	 the	 plasma	 membrane	 of	 many	 mammalian	 cells,	 including	endothelial	 cells,	 gastrointestinal	 tissue,	 glia,	 immune	 cells	 keratinocytes,	 respiratory	tract	 and	 also	 cancer	 cells.	 They	 regulate	 the	 release	 of	 growth,	 angiogenic	 and	neurogenic	factors	that	stimulate	signal	transduction	in	normal	and	malignant	cells.	nAChRs	are	usually	overexpressed	in	malignant	cells	where	chronic	exposure	to	nicotine	or	nicotine-derived	nitrosamines	(NNK	and	NNN)	up-regulate	cancer-stimulatory	nAChRs	(i.e. α7 nAChRs)	 and	desensitise	 cancer-inhibitory	nAChRs	 (i.e.	α4β2	 nAChRs)	 (Schuller,	2009).		Both	nAChR	types	are	up-regulated	when	exposed	to	chronic	nitrosamine	or	nicotine	but	the	 α4β2	 nAChRs	 desensitise	 very	 quickly	 at	 low	 agonist	 concentration,	 whereas	 the	tumor-promoting	 α7	 nAChRs	 remains	 active	 for	 longer	 time,	 might	 inducing	 cancer	development	and	progression.	 	
α7 receptor	can	activate	 the	release	of	DA,	which	stimulates	 the	proliferation	of	at	 least	prostate	 and	 mammary	 cancers,	 regulates	 the	 release	 of	 glutamate,	 serotonin,	noradrenaline	 and	 adrenaline	 as	 well	 as	 the	 neuropeptide	 mammalian	 bombesin,	 an	autocrine	growth	factor	involved	in	lung	cancer	(Olincy	et	al.,	1999).	On	the	contrary	the	heteromeric	α4β2 nAChRs	are	the	major	 inhibitors	of	malignancies:	they	 induce	 the	 release	 of	 GABA,	which	 acts	 as	 a	 tumour	 suppressor	 in	 lung,	 pancreas,	breast	and	colon	cancers	and	block	the	production	of	cyclic	AMP	that	controls	the	release	of	endothelial	and	epidermal	growth	 factors	(Figure	8).	The	unbalance	between	the	up-regulated	α7 receptor	and	the	desensitised	α4β2 receptor	may	be	the	driving	force	to	the	most	common	human	cancers.		 					
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																		Figure	8.	The	α7	and	α4β2		nAChRs	opposite	role	in	cancer	cells.	Their	activation	stimulates	different	neuro	and	 not	 neuro	 -neurotrasmitters	 release	 involved	 in	 the	 balance	 between	 cancer	 development	 and	inhibition	(Modified	from	Schuller,	2009)	 	
4.2.	nAChR	in	lung	cancer		It	 is	well	known	that	tobacco	 is	one	of	 the	most	harmful	and	preventable	risk	 factor	 for	cancer,	particularly	lung	cancer.	Indeed,	it	is	responsible	for	the	80-90%	of	all	lung	cancer	cases	(Beasley	et	al.,	2005).		
4.2.1.	Lung	cancers		Lung	cancer	is	one	of	the	most	common	types	of	cancer,	causing	many	people	death	every	year	 worldwide.	 According	 to	 histological	 features,	 lung	 cancers	 are	 traditionally	classified	 into	 two	groups:	 small	 cell	 lung	 cancer	 (SCLC)	and	non-small	 cell	 lung	 cancer	(NSCLC).	SCLC	is	the	most	aggressive	tumour	with	a	very	high	level	of	mortality.	It	originates	from	pulmonary	neuroendocrine	cells	(PNEC)	localised	in	the	lungs,	in	the	airways	or	grouped	in	 small	 groups	 of	 neuroepithelial	 bodies.	 The	 PNEC	 cells	 synthesise	 neurotransmitters	and	neuropeptides,	which	 show	an	autocrine	and	paracrine	action	as	 trophic	 factors	or	chemo-	and	mechano-receptors	(Sunday	et	al.,	1996).	
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NSCLC	 represents	 80%	 of	 all	 lung	 cancers	 and	 is	 divided	 into	 three	 main	 subtypes:	adenocarcinoma,	 squamous	 cell	 carcinoma,	 and	 large	 cell	 carcinoma.	 Adenocarcinoma	arises	from	epithelial	cells	of	the	small	airways	and	alveolar	type	II	cells,	while	squamous	cell	 carcinoma	 develops	 from	 epithelial	 cells	 of	 the	 large	 lung	 airways	 (Improgo	 et	 al.,	2011).	Tobacco	use	is	a	clear	risk	factor	in	the	onset	of	cancer	and	in	particular	is	associated	with	90%	of	cases	of	SCLC	and	with	60%	of	NSCLC	tumours	(Egleton	et	al.,	2008).	
4.2.2.	nAChR	expression	and	function		Using	RT-PCR,	qRT-PCR,	and	in	situ	hybridization,	nAChR	subunit	 transcripts	have	been	detected	in	the	lung	and	airways	of	normal	and	malignant	cells	(Maus	et	al.,	1998).	In	SCLC	cells	there	is	an	altered	expression	of	the	α3, α5, α7, β2 and β4	nAChRs	subunits	(Zhang	et	al.,	2010),	whereas	 the	expression	of	nAChR	 in	NSCLC	cells	are	 less	clear	and	depends	on	the	smoking	history	of	the	subject	(Ambrosi	and	Becchetti,	2013).		The	 most	 convincing	 identification	 of	 nAChRs	 in	 lung	 cells	 has	 derived	 from	pharmacological	 analysis	 using	 subunit-specific	 antagonists	 (Wu	 et	 al.,	 2011)	 and	 RNA	interfering	approaches.	Maouche	et	al.	(2009)	demonstrated	that	α7	nAChR,	by	restricting	cell	growth,	promotes	basal	cells	differentiation	toward	a	mucociliary	epithelium	and	α7	nAChRs	are	essential	for	 the	plasticity	of	 the	 epithelium	as	α7	KO	mice	 showed	alteration	 in	basal	 cell	 layer,	hyperplasia	 and	 uncontrolled	 growth.	 This	 group	 also	 observed	 that	 the	 chronic	inactivation	of	α7	nAChRs	by	the	antagonist	α−Bgtx	prevents	the	in	vitro	differentiation	of	the	 normal	 human	 epithelium	 while	 in	 mice	 the	 absence	 of	 α7	 nAChR	 induces	modifications	 of	 the	 epithelium	 phenotype	 and	 an	 altered	 epithelial	 regeneration	 after	wound	healing.	On	 the	 contrary,	 in	 cancer	 cell	 lines	 it	 was	 found	 that	 α7-containing	 receptors,	 by	activating	 different	 signalling	 pathways,	 mediate	 the	 proliferative	 effects	 of	 nicotine	(Schaal	 and	 Chellappan,	 2014).	 These	 results	 indicate	 that	 the	 regulation	 of	 cell	proliferation	by	α7	nAChR	 is	 different	 in	 the	normal	 airway	 epithelium	and	 in	primary	cultures	of	normal	lung	cells	from	that	in	lung	cancer	tissue	and	cell	lines. Additionally	 it	 has	 been	 demonstrated	 that	 α7	 nAChRs	 are	 expressed	 also	 on	 the	mitochondrial	membrane	 of	 non	 neuronal	 cells	 and	 nicotine,	 by	 permeating	 cells,	 may	activate	mitochondrial	α7	nAChRs	coupled	to	inhibition	of	the	mitochondrial	permeability	transition	pore	opening,	thus	preventing	cell	apoptosis	(Mucchietto	et	al.,	2016).	Finally	 genome-wide	 association	 studies	 (GWAS)	 identified	 polymorphisms	 and	 a	 lung	
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cancer	susceptibility	locus	on	chromosome	15q24-25	which	are	correlated	with	increased	risk	of	nicotine	dependence	and	lung	cancer	development.	
4.2.2.1	 CHRNA5,	 CHRNA3	 and	 CHRNB4	 subunit	 genes	 and	 genetic	
variants	Genome-wide	 association	 studies	 have	 identified	 sequence	 variants	 in	 the	 region	encoding	 nAChR	 α3, β4 and	 α5 subunits	 that	 increase	 risk	 of	 nicotine	 dependence,	development	of	 lung	cancer	and	chronic	obstructive	pulmonary	disease	(Kuryatov	et	al.,	2011)	(Figure	9).							Figure	9.	The	human	nAChR	α3/α5/β4 gene	clusters.	Horizontal	arrows	indicate	the	transcription	direction	(Modified	from	Improgo	et	al.,	2010)		Hung	et	al.	(2008)	have	conducted	a	GWAS	of	DNA	by	analysing	317,139	single-nucleotide	polymorphisms	 in	1,989	 lung	cancer	cases	and	2,625	controls	 from	six	different	central	European	countries.	They	found	a	locus	in	the	15q25	chromosome	region	that	is	strongly	associated	 with	 lung	 cancer.	 This	 region	 contains	 several	 genes	 including	 the	 genes	coding	for	the	α5−α3−β4 subunits	that	are	predominantly	expressed	in	neurons	but	also	in	alveolar	epithelial	cells,	pulmonary	neuroendocrine	cells,	and	in	lung	cancer	cell	lines.	Two	of	the	clustered	nAChR	genes	coding	for	the	α3−β4 subunits	 are	significantly	over-expressed	 in	 SCLC	 cells	 (Improgo	 et	 al.,	 2010)	 and	 silencing	 them	 decreases	 cell	proliferation	(Improgo	et	al.,	2013).	These	findings	and	the	recent	demonstration	that	the	surface	expression	of	α3β4 receptors	increases	more	than	5-fold	with	low	concentration	of	 nicotine	 (Mazzo	 et	 al.,	 2013),	 suggest	 that	 nicotine	 can	 increase	 the	 proliferative	capacity	of	cancer	cells	expressing	α3β4	receptors.			Genetic	studies	have	shown	that	the	SNP	rs1051730	found	in	the	non-coding	region	of	the	
CHRNA3	gene,	and	rs578776	found	in	CHRNA3	gene	un-translated	region	(Saccone	et	al.,	2007)	 are	 correlated	with	 nicotine	 dependence	 risk.	 These	 SNPs	 influence	 the	 onset	 of	smoking,	 the	 daily	 intake	 in	 cigarettes	 and	 are	 associated	 with	 more	 severe	 nicotine	dependence	 in	 adults	 (Weiss	 et	 al.,	 2008).	Moreover,	 SNP	 rs1051730	 is	 also	 associated	
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with	increased	risk	for	 lung	cancer	and	with	a	 larger	tumour	size,	especially	 in	smokers	(Shen	et	al.,	2012).	Other	 studies	 have	 shown	 that	 the	 non-synonymous	 single	 nucleotide	 polymorphism	(SNP)	 rs16969968	 in	 the	 CHRNA5	 gene,	 leading	 to	 an	 aspartic	 acid	 to	 asparagine	substitution	 (D398N)	 is	 also	 associated	with	 lung	 cancer	 (Improgo	 et	 al.,	 2010).	 In	 the	latter	case,	the	disease	appears	not	to	be	the	consequence	of	smoking,	but	may	be	a	direct	consequence	 of	 altered	 functional	 properties	 of	 the	 variant	 receptor,	 as	 non-smokers	bearing	this	polymorphism	are	also	at	increased	risk	of	lung	cancer.		Subjects	who	had	one	copy	of	the	risk	variant	have	a	1.3	fold	increase	in	risk	to	develop	nicotine	dependence	once	exposed	to	smoking,	and	those	with	two	copies	have	two-fold	increase	(Saccone	et	al.,	2009).	There	was	evidence	for	a	recessive	mode	of	inheritance	for	this	SNP	and	the	risk	due	to	genotype	was	higher	for	males	than	females	(Saccone	et	al.,	2007).		The	 quantitative	 messenger	 RNA	 expression	 analyses	 investigated	 the	 association	 of	15q25	locus	genes	with	 lung	cancer,	demonstrating	that	CHRNA5	mRNA	is	up-regulated	30-fold	in	lung	adenocarcinoma	compared	to	normal	lung	tissue	(Falvella	et	al.,	2009).	Falvella	et	al.	(2010)	found	three	variants	 in	the	5’	promoter	region	and	three	in	the	3’-untraslated	 region	 of	 CHRNA5.	 The	 three	 promoter	 variants	 were	 associated	 with	statistically	 significant	 CHRNA5	 expression,	 but	 those	 in	 the	 3’	 region	 were	 not.	 These	polymorphisms	 can	 modify	 the	 binding	 site	 for	 the	 transcription	 factors	 that	 alter	
CHRNA5	expression	levels	and	the	risk	of	lung	cancer.	The	same	group	(2013)	have	also	found	 five	mRNA	 isoforms	 that	 can	encode	 for	 full-length	or	 truncated	proteins.	All	 the	isoforms	 are	present	 both	 in	normal	 and	malignant	 lung	 tissue:	 in	 particular	 isoform	1	(corresponding	to	the	full-length	transcript)	 is	more	abundant	in	normal	samples,	while	the	others	(corresponding	to	truncated	proteins)	in	cancer	tissues.	In	the	case	of	the	CHRNA5	gene,	there	are	at	least	two	distinct	mechanisms	underlying	the	risk	of	dependence	and	lung	cancer:	altered	receptor	function	caused	by	the	D398N	amino	acid	variant	in	CHRNA5	and	variability	in	CHRNA5	mRNA	expression.	
4.2.2.2	CHRNA7	subunit	gene	and	genetic	variants	The	α7−nAChR	is	highly	and	selectively	expressed	 in	the	CNS	where	 functions	as	 ligand	gated	ion	channel	permeable	to	Na+	and	K+	and	Ca2+.	This	receptor	is	characterised	by	a	fast	activation	and	desensitisation	and	is	involved	in	the	release	of	neurotransmitters.		
α7−nAChR	 is	expressed	widely	 in	both	normal	and	malignant	non-neuronal	 tissues	and	cells	 where	 it	 may	 act	 or	 not	 as	 an	 ion-channel	 (Chernyavsky	 et	 al.,	 2015).	 The	 ion	
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channel-independent	events	include	activation	of	intracellular	pathways	through	protein	kinases,	second	messengers	and	transcription	factors.	Different	studies	have	shown	the	expression	of	α7	nAChRs,	as	mRNA	and	protein,	in	many	different	lung	cancer	cells	obtained	from	human	SCLC	and	NSCLC	tumours.	One	 important	 characteristic	 of	α7	 is	 its	 ability	 to	 activate,	 after	 agonist	 (i.e.	 nicotine)	binding,	 different	 downstream	 pathways,	which	 in	 turn	 stimulate	 the	 proliferation	 and	migration	of	NSCLC	cells.	An	important	variant	of	α7	gene	is	CHRFAM7A		(see	page	16).	
4.2.2.3.	CHRNA9	subunit	gene	and	genetic	variants	The	α9	nAChRs	are	homomeric	receptors	characterised	by	high	affinity	to	the	antagonist	
α−Bgtx	and	a	very	high	Ca2+	permeability.	Lee	et	al.	(2010)	has	recently	shown	that	α9	nAChRs	are	ubiquitously	expressed	in	many	epithelial,	 lungs,	 and	 breast	 cancer	 cell	 lines,	 and	 most	 of	 the	 same	 cell	 lines	 also	expressed	 α5	 and	 α10-containing	 nAChRs.	 The	 α9	 nAChRs	 are	 present	 in	 primary	tumours	 and	 non-malignant	 breast	 tissues	 obtained	 from	 patients;	 however,	 breast	cancer	cells	have	increased	α9	nAChR	expression	compared	with	the	surrounding	normal	tissues.	 Silencing	 the	α9	 nAChR	 expression	 in	 breast	 cancer	 cells	 reduces	 proliferation	and	tumorigenic	potential	both	in	vitro	and	in	vivo	assays	(Lee	et	al.,	2010).	A	 very	 recent	 case	 control	 study	 of	 340	 non-small	 cell	 lung	 cancer	 patients	 and	 435	controls	 has	 shown	 that	 an	 increased	 risk	 of	 developing	 lung	 cancer	 is	 also	 associated	with	two	SNPs	in	the	CHRNA9	gene:	rs56159866	and	rs6819385	(Chikova	et	al.,	2012).	Analysis	of	the	mRNAs	of	human	immortalised	bronchial	epithelial	cell	line	(BEP2D)	has	shown	the	presence	of	four	mRNA	isoforms	coding	for	the	α9	protein:	one	coding	for	the	full-length	 and	 three	 coding	 for	 truncated	proteins.	 The	 full-length	 isoform	may	have	 a	N442S	aminoacid	substitution,	which	induces,	both	in	vitro	and	in	vivo,	proliferation	and	NNK-induced	 tumorigenesis	 (Chicova	et	 al.,	 2011).	On	 the	 contrary	overexpression	of	 a	truncated	isoform	decreased	proliferation	and	suppressed	cell	transformation.		
4.3	nAChR-mediated	nicotine	effects	In	1989	Schuller	 reported	 the	 first	 evidence	 that	nAChRs	 regulate	 cancer	growth.	 Since	then,	 various	 studies	 have	 described	 nAChRs	 as	 key	 molecules	 that	 act	 as	 central	regulators	 of	 a	 complex	 network	 governing	 growth,	 angiogenesis,	 metastasis	 and	apoptosis	during	carcinogenesis	in	response	to	the	tumour	microenvironment.		nAChRs	stimulate	in	a	cell	type–specific	manner	intracellular	signalling	pathways	and	can	proceed	via	ionic	and	non-ionic	pathways	activating	different	signalling	cascades.	
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The	major	pathways	activated	in	lung	cancer	cells	are	depicted	in	Figure	10.	
	 													Figure10.		Schematic	representation	of	the	nAChR-mediated	lung	cancer	signalling	pathways.	Nicotine	by	binding	nAChRs	induces	the	entry	of	ions,	which	activate	different	intracellular	cascade	leading	to	cancer	proliferation,	survival,	migration	and	angiogenesis	(Modified	from	Mucchietto	et	al.,	2016)		
4.3.1.	Proliferation		In	 SCLC	 and	 NSCLC	 lung	 cancers,	 nicotine	 induces	 cell	 proliferation	 through	 nAChR-associated	 downstream	 signal	 transduction	 pathways	 such	 as	 the	 MAP	 kinase	 (MAPK)	cascade.	 Different	 studies	 showed	 that	 α7 is	 the	 most	 nAChR	 subtype	 involved	 in	 the	stimulation	 of	 proliferation	 and	 is	 suppressed	 by	 the	 α−Bgtx	 and	 α−cobratoxin	antagonists	(Carlisle	et	al.,	2007).	In	SCLC	nicotine	induces,	 in	a	dose-dependent	manner,	MAPK	kinase	activation	and	this	effect	 is	 blocked	 by	 the	 non	 specific	 antagonist	 mecamylamine	 (Cattaneo	 et	 al.,	 1997),	whereas	 NNK	 induced-DNA	 synthesis	 and	 RAF-1	 activation	 in	 SCLC	 cells	 or	neuroendocrine	 cells	 is	 blocked	 by	 inhibitors	 of	 the	 protein	 kinase	 C	 (PKC)	 or	 by	 the	
α7 antagonist	α-Bgtx	(Jull	et	al.,	2001).	Nicotine	binding	activates	the	extracellular-signal	regulated	kinase	2	isoform	(ERK2)	and	the	PKC. However,	nicotine-induced	PKC	pathway	activation	 is	 independent	of	 the	RAS-RAF-MEK-ERK	pathway,	and	acts	upstream	of	RAF-1	in	the	signalling	sequence	(Heusch	et	al.,	1998).	Dasgupta	et	al.	(2006)	have	demonstrated	that	mitogenic	effects	of	nicotine	in	NSCLC	are	similar	to	that	of	growth	factors	but,	unlike	growth	factor	receptors,	nAChRs	do	not	have	any	intrinsic	kinase	activity.	By	binding	to	nAChRs,	nicotine	induces	the	recruitment	of	β-
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arrestin-1	to	the	receptor	and	this	actives	the	tyrosine-protein	kinase	Src	(SRC).	The	same	group	have	also	shown	that	ablation	of	β-arrestin-1	decreases	the	nicotine-induced	level	of	 phosphorylated	 SRC	 kinase	 and	 ERK1/2	 (Dasgupta	 et	 al.,	 2011).	 It	 appears	 that	 β-arrestin	 is	 a	 critical	 link	between	 the	mitogenic	 signals	 induced	by	nAChRs	 stimulation	and	 the	 cell	 cycle	machinery,	 and	 by	 activating	 β-arrestin–1	 nicotine	 promotes	 tumour	progression	and	metastasis.	It	has	been	found	that	NSCLC	release	both	excitatory	(noradrenaline,	NA)	and	inhibitory	(GABA)	 neurotransmitters	 and	 their	 level	 change	 after	 nicotine	 stimulation:	 nicotine	induces	an	increase	in	NA,	which	in	turn	stimulates	P-CREB	and	P-ERK1/2	to	support	cell	proliferation.	Nicotine	exposure	also	 increases	 the	activation	of	 the	 JAK/STAT	pathway	and	 its	 target	genes	 and	 in	 NSCLC	 high	 concentration	 of	 nicotine	 or	 NNK	 increases	 the	 STAT3	phosphorylation.	In	 cells	where	 the	α7	 nAChR	 has	 been	 silenced	 or	 in	 cells	 that	 do	 not	 express	α7	 (KO	mice)	nicotine	does	not	activate	the	JAK/STAT	pathway	(Arredondo	et	al.,	2006).	Studies	 in	 NNK-treated	 mice	 (West	 et	 al.,	 2003)	 showed	 that	 NNK	 activates	 the	ERK/MAPK	and	PI3K/AKT	cascades	as	well	as	STAT3	signalling.		In	addition	to	proliferation,	nicotine	can	also	induce	epithelial	mesenchymal	transition	in	NSCLC	cell	lines	and	tumours,	leading	to	up-regulation	of	mesenchymal	markers	such	as	vimentin	and	fibronectin	(Pillai	et	al.,	2015).		
4.3.2	Cell	Cycle	Regulation	Nicotine	and	nitrosamines	also	target	different	components	of	the	cell	cycle	machinery.		Many	studies	have	shown	that	the	expression	of	cyclins	and	proteins	involved	in	cell	cycle	checkpoints	 is	 influenced	 by	 nicotine	 (Baldi	 et	 al.,	 2011)	 and	 that	 nicotine	 and	nitrosamine	 repress	 negative	 regulators	 of	 cell	 cycle	 progression	 such	 as	 cyclin-dependent	kinase	(CDK)	inhibitors.	In	normal	human	 lung	epithelial	cells	nicotine	and	NNK	induce	 increase	 in	proliferation	by	 induction	of	 cyclin	D1	protein	expression	mediated	by	 the	nuclear	 factor	κB	 (NFκB)	(Ho	et	al.,	2005).	Similar	results	have	been	found	in	SCLC	and	NSCLC	cells	where	nicotine	activates	 cyclin	 D1	 and	 NF-kB	 by	 activation	 of	 the	 PI3K/AKT	 intracellular	 pathway	(Tsuratani	et	al.,	2005).		In	 addition,	 nicotine	 and	 NNK	 enable	 cell-cycle	 progression	 via	 nAChR	 and	 β−AR-mediated	induction	of	COX2	and	prostaglandin	E2	(PGE2),	with	an	associated	increase	in	cyclin	D1	and	decrease	in	CDK4/6	expression	(Shin	et	al.,	2008).		
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	In	NSCLC	cell	 lines	and	primary	 lung	 lines	 it	has	been	shown	 that	nicotine	activate	 the	transcriptional	repressor	ID1	by	acting	on	α7−nAChR	(Pillai	et	al.,	2011).	Moreover	 it	 has	 been	defined	 that	 components	 of	 tobacco	 smoke	 inhibit	 in	NSCLC	 also	regulators	 of	 cell-cycle	 progression	 (Norton,	 2000).	 These	 data	 suggest	 that	 tobacco	smoke	 is	 able	 to	 modulate	 multiple	 components	 of	 the	 cell	 cycle,	 enabling	 cell	 cycle	progression	and	spreading.	
4.3.3.	Antiapoptotic	effects	In	addition	to	the	effect	of	nicotine	on	tumor	growth,	various	epidemiological	and	clinical	studies	 have	 linked	 the	 activation	 of	 nAChRs	with	 the	 inhibition	 of	 apoptotic	 pathways	and	the	possibility	that	nicotine	may	confer	a	survival	advantage	by	promoting	cell-cycle	progression	and	by	preventing	apoptosis.	Indeed,	a	large	number	of	studies	have	shown	that	those	patients	who	smoke	have	a	poor	prognosis	with	standard	therapies.		The	 most	 important	 protein	 involved	 in	 the	 regulation	 of	 cell	 survival	 is	 the	 protein	kinase	AKT.	This	 kinase	 can	be	 activated	by	different	 factors	 such	 as	 growth	 factors	 as	well	as	by	nicotine	in	both	normal	and	malignant	cells.	Nicotine	effect	on	this	pathway	can	be	 blocked	 by	 PI3K	 inhibitors	 or	 by	 α3/α4−specific	 nAChR	 antagonists	 but	 not	 by	
α7−specific	antagonists	(Tsurutani	et	al.,	2005).	Nicotine	exposure	(1	µmol/L)	also	confers	apoptosis	resistance	 in	presence	of	cysplatin	and	taxol,	commonly	used	as	chemotherapeutics,	by	upregulating	XIAP	and	survivin	two	downstream	proteins	of	AKT	activation	(Dasgupta	et	al.,	2006).	AKT	by	phosphorylating	XIAP	inhibits	its	degradation	by	chemotherapeutic	agents.		Apoptosis	occurs	as	a	result	of	the	activation	of	an	intrinsic	or	extrinsic	pathway,	and	is	largely	 regulated	 by	 the	 Bcl-2	 family	 of	 apoptotic	 regulators.	 BAD	 and	 BAX	 are	 pro-apoptotic	members	of	the	Bcl2	family	of	proteins	(Wei	et	al.,	2001),	expressed	in	human	SCLC	and	NSLC	cells,	but	 their	phosphorylation	negatively	 regulates	 their	pro-apoptotic	activity	 (Jin	 et	 al,	 2004).	 By	 activating	 the	PI3K/AKT	pathways,	 nicotine	 and	NNK	both	increase	BAD	and	BAX	phosphorylation	and	cell	survival.	
4.3.4	Migration	and	Metastasis	One	of	the	most	harmful	features	of	tumours	is	represented	by	their	capacity	to	migrate	and	 invade	 the	 surrounding	 tissue	 and	metastasise.	 The	movement	 of	 cancer	 cells	 into	tissue	 surrounding	 the	 tumor	 and	 the	 vasculature	 is	 the	 first	 step	 in	 the	 spread	 of	metastatic	 cancers.	 Cell	 migration	 and	 metastasis	 are	 fundamental	 processes	 during	tumor	 cell	 invasion	 and	 these	 processes	 are	 the	 result	 of	 a	 complex	 interplay	 between	numerous	protein	families	critically	regulated	by	different	factors,	which	include	growth	
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factors,	 kinases,	 phosphates	 and	 extracellular	 matrix	 (ECM)	 components.	 Nicotine	increases	 EGF	 receptor	 expression	 in	 lung	 cells	 (Carlisle	 et	 al.,	 2007),	 which	modulate	different	 biological	 processes,	 including	 cell	 migration,	 by	 activating	 the	 signalling	cascade	of	MAPK,	PKC	and	PI3K/AKT.		Tumour	 invasiveness	 is	determined	by	modification	of	cell	adhesion,	chemo-factors	and	activation	of	proteins	with	proteolytic	activity	(calpains)	 in	order	to	migrate	through	he	ECM.	Calpains		are	a	conserved	family	of	cysteine	proteinases	that	catalyse	the	controlled	proteolysis	 of	 many	 specific	 substrates	 and	 have	 an	 altered	 expression	 during	tumorigenesis.	 Xu	 et	 al.	 (2006)	 have	 demonstrated	 that	 nicotine	 induces	 the	phosphorylation	 of	 both	 µ-	 and	 m-calpains	 via	 activation	 of	 protein	 kinase	 Cι,	 which	supports	 the	 cleavage	 of	 various	 substrates	 in	 the	 ECM	 and	 facilitates	 metastasis	 and	tumour	progression.	α−Bgtx	potently	blocks	both	nicotine-induced	phosphorylation	and	activation	 of	 µ-	 and	 m-calpains	 together	 with	 the	 inhibition	 of	 wound	 healing,	 cell	migration,	and	invasion.	This	indicates	that	nicotine-induced	cell	migration	and	invasion	may	 occur	 through	 activation	 of	 the	 α7	 nAChR	 signal	 transduction	 pathway	 involving	
α7 nAChR/c-Src/PKCι/calpains	in	lung	cancer	cells.		nAChR	 signalling	 modulates	 the	 motility	 of	 various	 epithelial	 cell	 types	 including	bronchial	cells.	The	proliferative	effect	of	nicotine	in	these	cells	appears	to	be	mediated	by	
α7 nAChR,	whereas	cell	migration	is	regulated	by	(α3β2)2α5 receptors. However	 the	 role	 of	α5-containing	 receptor	 in	 cell	migration	 is	 not	 clear	 and	 opposite	conclusions	derived	from	different	studies.		Krais	et	al.	(2011)	by	silencing	the	α5 subunit	in	normal	bronchial	 and	 in	NSCLC	has	 found	a	negative	 effect	 on	nicotine	 signalling.	 In	fact,	upon	nicotine	stimulation	 the	absence	of	α5-containing	receptors	 leads	 to	a	higher	migration	and	capacity	to	invade	the	surrounding	tissue	and	these	effects	are	blocked	by	
α−Bgtx.	 	 On	 the	 contrary	 silencing	 the	 α5	subunit	 in	 the	 same	 adenocarcinoma	 cells,	blocked	nicotine-stimulated	activation	and	suppressed	cell	migration	and	 invasion	 (Sun	et	al.,	2015).	 Nicotine	can	also	 induce	metastases	by	activating	matrix	metalloproteinases	a	 family	of	proteins	 that	 remodel	 the	 ECM	 and	 facilitate	 cell	 invasion.	 These	 proteins	 are	overexpressed	in	NSCLC	cells	and	in	biopsies	of	patients	with	NSCLC.		
4.3.5	Angiogenesis	Angiogenesis,	 the	 development	 of	 new	 blood	 vessels	 from	pre-existing	 vasculature	 is	 a	complex,	multi-steps	process	involving	endothelial	cells	modifications	and	differentiation.	In	normal	conditions	there	are	factors,	which	contribute	to	start	angiogenesis,	as	hypoxia	
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or	 inflammatory	 cytokines	 that	 in	 turn	 stimulate	 the	 release	 of	 pro-angiogenic	 factors	(VEGF	and	FGF).	Many	studies	have	demonstrated	that	nicotine	increases	angiogenesis	in	endothelial	cell	cultures	 as	 well	 as	 in	 tumour	 models.	 The	 endothelial	 cells	 express	 different	 nicotinic	subunits	and	when	nicotine	binds	the	α7 nAChR	induces	endothelial	tube	formation	and	migration	(Heeschen	et	al.,	2002).			
5.	Oxidative	stress	and	carcinogenesis	Deregulated	cellular	energetics	is	one	of	the	cancer	hallmarks.	Mitochondrial	dysfunction	plays	 a	 critical	 role	 in	 cancer	 progression	 and	 targeting	 mitochondrial	 alterations	 and	mitochondrial	 signalling	 might	 be	 an	 encouraging	 strategy	 for	 the	 development	 of	selective	anticancer	therapy	(Hsu	et	al.,	2016).	Oxidative	 stress-induced	 tumour	 initiation	 or	 progression	 may	 result	 from	 the	overproduction	of	 reactive	 oxygen	 species	 (ROS)	by	different	 cell	 components.	ROS	 are	intracellular	 chemical	 species	 that	 contain	 oxygen,	which	 react	 towards	 lipids,	 proteins	and	DNA.	Production	of	ROS	induces	different	biological	outcomes	depending	on	normal	or	 malignant	 cells.	 In	 normal	 cells	 they	 increase	 lipid	 oxidation,	 alteration	 in	 the	proliferation,	 genomic	 instability	 and	 at	 the	 end	 cell	 death,	 whereas	 in	malignant	 cells	elevated	ROS	levels	can	promote	tumourigenesis	(Wallace,	2005)	(Figure	11).										 	Figure	11.	ROS	balance	in	normal	and	malignant	conditions	(Modified	from	Sullivan	and	Chandel,	2014)		Particularly,	 in	 cancer	 cells	 ROS	 production	 shows	 two	 opposite	 effects:	 in	 a	 certain	concentration	 range	 ROS	 can	 increase	 cellular	 proliferation,	 metabolic	 alterations,	 and	angiogenesis	 leading	to	cancer	progression	and	spreading	while,	at	high	concentrations,	
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can	 induce	 cell	 death	 signalling,	 senescence	 and	 cell	 cycle	 arrest.	 Various	 studies	 have	shown	 that	 ROS	 elevation,	 either	 through	ROS	 producers	 or	 antioxidant	 inhibitors,	 can	selectively	kill	cancer	cells	and	suppress	tumour	growth	and	progression	 in	a	variety	of	cancer	cell	lines	(Glasauer	and	Chandel,	2014).		The	two	main	sources	of	ROS	are	mitochondria	and	the	family	of	NADPH	oxidases	(NOXs).		NOXs	 are	 a	 family	 of	 enzymes	 that	 trigger	 the	 transfer	 of	 electrons	 from	 intracellular	NADPH	across	the	cell	membrane	to	oxygen,	producing	superoxide	and	other	ROS	in	the	extracellular	space.	It	has	been	shown	that	the	over-expression	of	functional	NOX	proteins	lead	to	tissue	injury	and	DNA	damage	with	excessive	ROS	production	(Han	et	al.,	2016).	Recent	 studies	 suggest	 that	 NOXs	 activity	 is	 up	 regulated	 in	 lung	 cancer	 and	 ROS	production	by	NOX	species	 strongly	 influence	both	 tumour	growth	and	survival	of	 lung	cancer	cells	(Meitzler	et	al.,	2014).	In	these	cells	NOX4	is	the	most	up-regulated	isoform	and	provides	pro-oncogenic	signals	through	stimulation	of	ROS	production.		Moreover	both	oncogenes,	such	as	RAS,	MYC	and	AKT,	as	well	as	hypoxia	lead	to	increase	ROS	production,	in	order	to	promote	cancer	growth.		These	findings	may	lead	to	new	more	specific	targets	for	cancer	therapy	in	order	to	avoid	the	inefficacy	of	the	main	common	therapies.		
6.	Common	therapeutic	strategies		Lung	 cancer	 is	 one	 of	 the	most	 common	 cancers	 and	 depending	 on	 the	 type	 of	 cancer,	SCLC	or	NSCLC,	the	treatment	changes	considerably. For	SCLC	the	common	therapy	is	the	chemotherapy	based	on	cysplatin	and	dexorubucin.	The	 chemotherapy	 is	 frequently	 associated	with	 the	 radiotherapy	 to	 block	 the	 onset	 of	relapses.	 Instead	 for	 NSCLC	 surgery	 is	 the	 therapy	 of	 choice,	 unless	 metastases	 are	present,		and	in	this	case	radiotherapy	and	chemotherapy	follow	the	intervention.	In	 these	 years	 new	molecularly	 targeted	 therapies	 are	 emerging	 to	 treat	 these	 cancers	that,	 when	 compared	with	 standard	 chemotherapy,	 have	 superior	 outcomes.	 Biological	drugs	 as	 getfitinib	 (direct	 against	 the	 EGF	 receptor)	 and	 crizotinib	 (inhibitor	 of	 ALK	tyrosine	 kinase	 receptor)	 are	 recommended	 as	 first-line	 treatment	 for	 patients	 with	mutation	 in	 genes	 coding	 for	 these	 receptors,	 but	 unfortunately	 few	people	 have	 these	genetic	mutations.		Vachhani	 and	 Chen	 (2016)	 have	 demonstrated	 that	 pembrolizumab,	 an	 humanised	antibody,	 directed	 against	 the	 programmed	 cell	 death	 (PD-1)	 protein	 is	 efficacious	 in	
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some	 NSCLC	 patients	 and	 the	 US	 Food	 and	 Drug	 Administration	 has	 approved	 this	treatment	for	patients	with	metastatic	NSCLC.	Finally	predictors	of	 chemotherapy	efficacy	give	a	new	challenge	 to	novel	 technological	advances	 encouraging	 perspectives	 for	 performing	 analytical	 validation	 of	 some	promising	 candidates	 for	developing	novel	 types	of	predictive	biomarkers	 such	as	DNA	signatures	or	novel	therapeutic	targets	(Olaussen	and	Postel-Vinay,	2016).		
7. 	nAChRs	as	potential	therapeutic	targets		Nicotine	 and	 other	 tobacco	 compounds	 are	 able	 to	 promote	 lung	 cancer	 by	 activating	multiple	 intracellular	 cascades	mainly	 (but	 not	 always)	 as	 a	 result	 of	 nAChR-mediated	effects	 (Mucchietto	 et	 al.,	 2016).	 Unfortunately	 the	 disadvantage	 of	 generalised	 nAChR	antagonists	 is	 that	 they	bind	 to	all	nAChR	subtypes	both	 in	normal	and	malignant	cells,	and	so	they	can	alter	the	physiological	role	of	nAChRs	leading	to	negative	side	effects.	The	 most	 common	 antagonists	 that	 block	 the	 α7 nAChR	 include	 α−Bgtx,	methyllylcaconitine	(MLA),	α−cobratoxin	and	α−conotoxin	ImI.	In	vitro	experiments	have	shown	that	these	antagonists	block	the	proliferation	of	SCLC	(Jull	et	al.,	2001)	and	NSCLC	cells	(Schuller,	2007).		As	both	α−Bgtx	and	MLA	also	bind	to	α9-containing	nAChRs	with	high	affinity,	it	is	possible	that	the	in	vitro	blocking	effects	of	the	antagonists	is	due	to	the	involvement	 of	 the	 α9	 subtype.	 However	 the	 in	 vivo	 effect	 of	 these	 toxins	 is	 still	controversial.		Other	 compounds	 emerging	 in	 the	 α7 drug	 development	 are	 the	 selective	 positive	allosteric	 modulators	 such	 as	 the	 PNU-120596	 that	 targets	 α7 receptors	 in	 vivo.	 PNU-120596	seems	to	be	able	to	reverse	or	destabilise	the	desensitised	states	of	α7	receptors	and	 when	 given	 together	 with	 choline,	 an	 endogenous	 α7	 agonist,	 can	 have	 cytotoxic	effect	on	α7-expressing	tumour	cell	line	(Williams	et	al.,	2011).		Another	class	of	possible	compounds	is	made	by	natural	compounds	(such	as	curcumin,	resveratrol,	lycopene	and	quercetin),	which	have	been	found	to	block	different	pathways	altered	in	cancer	growth	(Feitelson	et	al.,	2015).	Epidemiological	studies	have	shown	that	natural	 compounds	can	be	active	 in	chemoprevention	and	 in	cancer	 treatment	 for	 their	lack	of	toxicity.		The	issue	to	find	new	compounds	able	to	bind	and	block	the	nAChRs	responsible	to	lung	cancer	development	and	proliferation	is	a	challenge	of	many	scientific	groups.	In	this	field	
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the	 resveratrol-	 or	 stilbene-derivatives	 can	 provide	 new	 possible	 treatments	 for	 lung	cancer	cells.		
7.1	Stylbene-derived	drugs	Stilbenes	are	part	of	a	vast	group	of	natural	defence	polyphenols	occurring	in	many	plant	species	such	as	Pinaceae	families,	Mirtaceae,	Fagaceae,	Liliaceae,	Moraceae,	Papilionaceae	
and	 Vitaceae.	 The	 stilbene-compounds	 are	 widely	 distributed	 in	 nature	 and	 their	biological	functions	have	aroused	great	interest	in	the	scientific	world.	Indeed,	 the	 stilbenoids	 are	 small	 molecules	 with	 a	 large	 spectrum	 of	 properties	(Jakubowska	 et	 al.,	 2014).	 Trans-resveratrol	 ((E)-3,5,4’-trihydroxystilbene)	 has	 an	antioxidant	 activity	 and	 also	 blocks	 the	 proliferation	 on	 different	 types	 of	 cancer	 (i.e.	lymphoid	 and	 myeloid	 cancers,	 breast,	 prostate,	 colon,	 pancreas	 cancers	 and	 others)	(Aggarwal	et	al.,	2004).	Another	class	of	natural	compounds	are	the	phenols,	which	comprise	combretastatin	A4.	This	molecule	is	a	potential	new	vascular	disrupting	agent	and	shows	also	a	remarkable	ability	 to	 inhibit	 gastric	 tumour	metastasis	 and	 enhanced	 antitumor	 immune	 reactivity	(Lin	et	al.,	2007).	Pterostilbene	(3,5-dimethoxy-4’-hydroxy-(E)-stilbene),	the	analogue	of	resveratrol,	exhibits	anti-oxidant	capacity	and	have	concentration-dependent	anticancer	activity	 	 with	 inhibition	 of	 growth,	 adhesion	 and	 metastatic	 growth(Remsberg	 et	 al.,	2008)	(Figure	12).		 	
	Figure	12.	Chemical	structure	of	natural	compounds	(Modified	from	Jakubowska	et	al.,	2014)		In	our	laboratory	different	stylbene-derived	drugs	have	been	synthesised	and	analysed.		We	 have	 characterised	 the	 N,N,N-triethyl-2-(4-trans-stilbenoxy)-2-ethylammonium	iodide,	called	MG624	or	F1,	 firstly	described	by	Cavallini	et	al.	 (1953)	and	subsequently	the	 others	 N,N,N-trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium	 iodide	 (F3)	 and	N,N-diethyl-2-(4-trans-stilbenoxy)-2-ethylammonium	iodide	(F6)	derivates	(Figure	13).		
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Binding	 experiments	 have	 shown	 their	 high	 affinity	 for	α7	nAChRs	 (nM	 concentration)	and	less	for	the	heteromeric	β2*	or	β4*	(Gotti	et	al.,	1998;	Gotti	et	al.,	2000).			
	Figure	13.	Chemical	structures	of	the	stylbene-derivates	F1,	F3	and	F6.		Recently	 it	 has	 been	 shown	 that	MG624	 inhibits	 the	 nicotine-induced	 proliferation	 and	angiogenesis	 of	 human	 lung	 microvascular	 endothelial	 cells	 (Brown	 et	 al.,	 2012).	Furthermore,	it	suppressed	the	in	vivo	angiogenesis	of	NCI-H69	human	SCLC	tumours.	As	 tobacco	 components	 like	 nicotine	 promote	 the	 angiogenesis	 and	metastasis	 of	 SCLC	tumours	 in	 patients	 who	 are	 active	 smokers	 or	 exposed	 to	 second	 hand	 smoke	 the	inhibition	of	α7-containing	nAChRs	by	synthetic	compounds	such	these,	may	be	a	useful	means	to	attenuate	nicotine-induced	angiogenesis	in	SCLC.		Moreover,	 it	 has	 been	 recently	 reported	 that	 derivatives	 of	 resveratrol,	 mitochondria-targeted	via	a	4-triphenylphosphoniumbutyl	(BTPI)	group	O-linked	at	either	position	-3	or	4,	 are	 cytotoxic	 in	 vitro	 and	 selectively	 induce	necrotic	death	of	 fast-growing	 cancer	cells	when	supplied	in	the	low	mM	range	(Sassi	et	al.,	2014).		In	conclusion	nicotine	contributes	to	cancer	mainly	by	promoting	growth	and	survival	of	mutated	 cell	 clones	 and	 protecting	 them	 from	 the	 chemo-	 and	 radiotherapy	 induced	apoptosis.	By	doing	 this,	nicotine	 increases	 the	 survival	 and	expansion	of	 cells	with	 the	genomic	damage	induced	by	carcinogens.	On	the	other	hand,	inactivation	of	nAChRs	can	attenuate	 nicotine-	 or	 tobacco	 nitrosamine-induced	 cell	 proliferation,	 and	 suppress	nicotine	 dependent	 chemoresistance.	 Therefore,	 nAChRs	 are	 viewed	 as	 a	 novel	 drug	target	for	prevention	and	treatment	of	various	forms	of	cancers.	
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AIM	OF	THE	PROJECT	For	decades,	 nAChRs	have	been	 considered	 a	 family	 of	 receptors	 expressed	only	 in	 the	central	 and	 peripheral	 nervous	 system	 (neuronal	 nAChRs)	 and	 at	 the	 neuromuscular	junction	 (muscle	 nAChRs).	 However,	 recent	 findings	 have	 shown	 that	 they	 and	 their	physiological	 agonist	 (ACh)	 are	 widely	 expressed	 in	 different	 mammalian	 cell	 types,	including	tumour	cells.	In	non-neuronal	tissues	they	regulate	physiological	functions	such	as	cell	proliferation	and	differentiation,	 cytoskeleton	organisation,	 cell-cell	 contacts,	 cell	locomotion	and	migration.	Lung	cancer	 is	one	of	 the	 leading	causes	of	cancer	deaths	worldwide.	Smoking	accounts	for	approximately	70%	of	non–	small	cell	lung	cancer	(NSCLC)	and	90%	of	small	cell	lung	cancer	 (SCLC)	 cases,	 although	 there	 is	 a	 subset	 of	 patients	 who	 develop	 lung	 cancer	without	a	history	of	smoking.	Tobacco	smoke	contains	many	classes	of	carcinogens	and,	although	nicotine	is	unable	to	initiate	tumorigenesis	in	humans	and	rodents,	it	promotes	tumour	growth	and	metastasis,	and	 the	 secretion	 of	 growth	 factors,	 neurotransmitters	 and	 cytokines	 that	 alter	 the	physiology	of	various	organ	systems.		Nicotine	promotes	tumour	progression	by	binding	and	activating	cell-surface	nAChRs.	Furthermore,	a	genome-wide	association	study	DNA	from	1,989	lung	cancer	patients	and	2,625	control	subjects	from	six	central	European	countries	has	found	a	locus	in	the	15q25	chromosome	region	that	is	strongly	associated	with	lung	cancer.		These	 findings	 highlight	 the	 importance	 of	molecularly	 and	 biochemically	 investigating	the	mechanisms	by	which	nAChRs	act	in	lung	cancer	cells.	The	 aim	 of	 this	 thesis	 is	 to	 increase	 our	 knowledge	 of	 the	 pathophysiological	 role	 of	nAChRs	in	lung	cancer	by:	a)	molecularly	establishing	which	nicotinic	receptor	subtypes	are	 expressed	 in	 lung	 cancer	 cell	 lines;	 b)	 investigating	 the	 molecular	 mechanisms	 by	which	nicotinic	receptors	regulate	cell	proliferation	and	intracellular	signalling,	and	if	this	signalling	are	modulated	by	nicotine;	and	c)	providing	a	framework	for	the	development	of	new	drugs	that	specifically	target	the	receptors	expressed	in	lung	tumour	cell	lines.				
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MATERIALS	AND	METHODS	
Compounds	Nicotine	and	α-bungarotoxin	(α-Bgtx)	were	purchased	from	Tocris	Bioscience	(Bristol,	UK).	All	 other	 reagents	 (PMSF,	 proteases	 inhibitors,	 chemicals)	 were	 purchased	 from	 Sigma-Aldrich.		Drugs	 F1,	 F3,	 stylbene,	 RS12	 and	 RS18	 were	 synthesised	 from	 the	 group	 of	 Professor	Marco	Pallavicini	(Department	of	Medicinal	Chemistry	PietroPratesi,	Milano);	NNN,	NNK	and	 ICH3	 were	 synthesised	 from	 the	 group	 of	 Prof	 Marco	 De	 Amici	 from	 the	 same	department;	Toxins	RgIA4	and	ArIB	[V11L;	V16D]	(called	 for	convenience	RG-I	and	AR)	are	a	generous	gift	of	Dr	JM	McIntosh	(Department	of	Psychiatry,	University	of	Utah,	Salt	Lake	City,	USA).		
1.	Antibody	production	and	characterization	For	the	detection	of	nAChR	subunits	we	used	affinity-purified,	subunit-specific,	polyclonal	antibodies	(Abs),	produced	in	rabbit	against	the	human	α7	and	α5	subunits.	For	each	of	these	 subunits	 Abs	 against	 peptides	 derived	 from	 the	 C-terminal	 (COOH)	 or	 intra-cytoplasmic	loop	(Cyt)	of	human	nAChR	subunit	sequences	were	produced	as	previously	described	 (Gotti	 et	 al.,	 2006;	 Grady	 et	 al.,	 2009).	 The	 Abs	 directed	 to	 the	 human	 α5	subunit	 were	 made	 against	 the	 COOH	 peptide	 (PVHIGNANK)	 and	 the	 Cyt	 peptide	(DRYFTQKEETESGSGPKSSRNTLEA).	 	The	Abs	against	 the	human	α7	subunit	were	made	against	 the	 C-terminal	 COOH	 (SAPNFVEAVSKDFA)	 and	 cytoplasmic	 loop	 peptide	(ACSPTHDEHLLHGGQPPEGDPDL).		The	 specificity	 of	 the	 affinity-purified	 Abs	 was	 tested	 by	 immunoprecipitation	 studies	using	the	hippocampus	of	α7	wildtype	(WT)	and	know-out	(KO)	mice;	the	same	Abs	also	were	 tested	 by	 means	 of	 Western	 blotting.	 In	 order	 to	 exclude	 any	 cross-reactivity	between	 nAChR	 subunits,	 anti-α7	 human	 subunit	 Abs	 were	 also	 tested	 by	 means	 of	immunoprecipitation	 studies	 and	 Western	 blotting	 in	 HEK	 293	 cells	 transfected	 to	express	 human	 α2β4-,	 α4β2-,	 α4β4,	 or	 α3β4-nAChR	 subtypes	 or	 in	 SH-SY5Y	 cells	transfected	 to	 express	 human	 α7-nAChR.	 The	 α5	 Abs	 was	 tested	 using	 HEK	 cells	transfected	with	the	α3β4	and	α3β4α5	subunits.						
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2.	Pharmacological	and	biochemical	analyses	
• Purification	of	α-bungarotoxin-binding	nAChR		For	our	mice	studies,	hippocampus	tissue	from	either	WT	or	subunit-null	mice	(KO)	was	pooled	 in	 every	 experiment.	 The	 tissue	 was	 homogenised	 in	 10	 ml	 of	 50	 mM	 Na	phosphate,	 pH	 7.4,	 1	 M	 NaCl,	 2	 mM	 EDTA,	 2	 mM	 EGTA	 and	 2	 mM	phenylmethylsufonylfluoride	(PMSF)	to	covalently	inactivate	serine	protease	activity	and	the	 homogenates	 were	 diluted	 and	 centrifuged	 for	 1.5	 hour	 at	 60,000g.	 The	 entire	membrane	 homogenisation,	 dilution	 and	 centrifugation	 procedure	 was	 then	 repeated,	and	 the	resulting	pellets	were	collected,	 rapidly	rinsed	with	50	mM	Tris	HCl,	pH	7,	120	mM	NaCl,	5	mM	KCl,	1	mM	MgCl2,	2.5	mM	CaCl2	and	2	mM	PMSF.	The	washed	pellets	were	then	 re-suspended	 in	 2	ml	 of	 the	 same	 buffer,	 further	 supplemented	with	 10	 µg/ml	 of	each	of	 the	 following	protease	 inhibitors:	 leupeptin,	bestatin,	pepstatin	A	and	aprotinin.	Triton	X-100	at	a	final	concentration	of	2%	was	added	to	the	washed	membranes,	which	were	 extracted	 for	 2	 h	 at	 4°C.	 The	 extracts	 were	 centrifuged	 for	 1.5	 hour	 at	 60,000g,	recovered	 and	 an	 aliquot	 of	 the	 supernatants	 was	 collected	 for	 protein	 measurement	using	 the	BCA	protein	assay	(Pierce	Biotechnology,	 Inc.,	Rockford,	 IL,	USA),	with	bovine	serum	 albumin	 used	 as	 standard.	 Extracts	 (2	 ml)	 were	 incubated	 with	 200	 µl	 of	Sepharose-α-Bgtx	(concentration	of	coupled	toxin	1	mg/ml	of	gel)	and	shaken	overnight	at	4	 °C.	The	 following	day,	 the	beads	were	 centrifuged,	 the	 supernatant	was	 recovered,	and	the	resins	were	washed	4-6	times	by	re-suspension	followed	by	centrifugation.	After	washing,	 the	 Sepharose-α-Bgtx	 beads	 with	 bound	 nAChR	 (purified	 α-Bgtx-binding	receptors)	were	incubated	with	one-two	volumes	of	Laemmli	sample	buffer	(125	mM	Tris	phosphate,	4%	SDS,	20%	glycerol,	0,02%	bromophenol	blue	and	10%	2-mercaptoethanol	pH	6.8)	and	boiled	for	2	min.	The	supernatant	was	then	recovered	by	centrifugation.		In	the	case	of	α-Bgtx	receptors	purified	from	the	A549,	H1975	and	SH-SY5Y	human	cells	the	same	procedure	as	that	used	for	mouse	tissue	was	used	starting	from	100x106	cells	for	each	cell	line.	
• Immunoprecipitation	 of	 nAChRs	 containing	 the	 α5	 and/or	 α7	
subunits			The	immunoprecipitation	of	receptors	containing	the	α5	and	α7	subunits	was	determined	on	two	human	lung	cancer	cell	 lines	(H1975	and	A549)	and	on	a	human	neuroblastoma	cell	line	(SH-SY5Y).	
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Affinity	 purified	 Abs	 against	 the	 α5	 or	 α7	 subunits	 were	 covalently	 immobilized	 on	agarose-Protein	A	beads	at	a	concentration	of	4	mg/ml	of	wet	resin.	Immunoprecipitation	was	 then	 performed	 by	 adding	 20	 µl	 of	 agarose-Protein	 A	 beads	 with	 bound,	 affinity-purified	 Abs	 or	 control	 IgG	 to	 the	 2%	 TritonX-100	 cells	 extracts.	 After	 overnight	incubation,	 immunoprecipitates	 were	 recovered	 by	 centrifugation	 and	 washed	 three	times	with	phosphate-buffered	saline	containing	0.1%	Triton	X-100	and	then	 loaded	on	SDS	gel.	
• Immunoblotting	 and	 densitometric	 quantification	 of	 western	 blot	
bands	nAChR	 subunit	 contents	 of	 tissue	 immunoprecipitated	 extracts,	 affinity	 purified	α-Bgtx	receptors	 complexes	 or	 cell	 lysates	 stimulated	 by	 nicotine	 exposure	 were	 analysed	 by	Western	blotting.	For	the	extracts	were	 loaded	10	µg	of	proteins	before	the	purification	whereas	 for	the	α-Bgtx-purified	receptors	a	constant	volume	(40	µl),	 that	depending	on	the	cell	 line,	which	represent	1/2	or	1/3	of	 the	 total	 recovered	Laemmli	sample	buffer-eluted	receptors,	was	 loaded	onto	a	9%	acrylamide	 (Biorad,	Hercules,	CA,	USA)	gel	and	subjected	 to	 sodium	 dodecyl	 sulphate-polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE).	After	 SDS-PAGE,	 proteins	 were	 electrophoretically	 transferred	 to	 nitrocellulose	membranes	with	0.45	mm	diameter	pores	(Schleicher	and	Schuell,	Dassel,	Germany).	The	blots	were	blocked	overnight	in	4%	non-fat	milk	in	Tris-buffered	saline	(TBS),	washed	in	a	buffer	containing	4%	non	fat-milk	and	0.3%	Tween	20	in	TBS,	incubated	for	two	hours	with	 the	 primary	 nAChRs	 antibody	 (1–2.5	 mg/ml),	 and	 then	 incubated	 with	 the	appropriate	 peroxidase	 conjugated	 secondary	 Abs	 (Sigma-Aldrich.	 St	 Louis,	 MO,	 USA).	After	 10	washes,	 peroxidase	was	 detected	 using	 a	 chemiluminescent	 substrate	 (Pierce,	Rockford,	IL,	USA).	In	 the	 case	of	Abs	directed	against	ERK,	P-ERK,	AKT	and	P-AKT	proteins,	we	used	 cell-signalling	 Abs.	 Blots	 after	 overnight	 in	 4%	 non-fat	 milk	 in	 Tris-buffered	 saline	 were	incubated	 with	 the	 primary	 antibody	 (used	 1:1000	 as	 the	 datasheet;	 p44/42	 MAPK	(ERK1/2)	 and	 phospho-p44/42	 MAPK	 (Thr202/Tyr	 204)	 were	 purchased	 from	 Cell	Signalling	Technology;	AKT	BD	Transduction	Laboratories,	AKT	 [pS473]	MAB	 from	Life	Technologies).		They	were	 then	 incubated	 for	 1h	with	 the	 appropriate	 secondary	 antibody	 (anti-rabbit	Ly-Cor	IRDye800RD;	anti-mouse	Ly-Cor	IRDye680RD).	After	another	series	of	washes,	the	membranes	were	dried	overnight	in	the	dark	at	RT.	The	IR	signal	was	measured	using	an	Odyssey	CLx	-Infrared	Imaging	System.	The	signal	intensity	of	the	Western	blot	bands	was	
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quantified	using	 iStudio	software.	The	optical	density	ratio	was	calculated	by	taking	the	optical	density	of	the	control	saline	as	100%.		The	 data	 are	 expressed	 as	mean	 values	 ±	 S.E.M.	 of	 at	 least	 three	 separate	 experiments	using	each	antibody.	
• Binding	 Studies	 and	determination	of	 the	Ki	 values	of	 oxystylbene	
compounds		The	 binding	 of	 [125I]-α−Bgtx	 to	 2%	 Triton	 X-100	 extracts	 of	 mouse	 tissues	 was	determined	 by	 collection	 onto	 DEAE-SepharoseTM	 Fast	 Flow	 (GE	 Healthcare,	 Uppsala,	Sweden).	 Triton	 extracts	 (250	 µl)	 from	 each	 experimental	 group	 were	 incubated	overnight	with	a	saturating	concentration	(5	nM)	of	[125I]-α−Bgtx	at	20°C	in	the	presence	of	 2	 mg/ml	 bovine	 serum	 albumin.	 Specific	 radioligand	 binding	 was	 defined	 as	 total	binding	minus	 the	 non-specific	 binding	determined	 in	 the	 presence	 of	 1	 µM	un-labeled	
α−Bgtx.	Non-specific	binding	averaged	around	the	30-40%	of	total	binding.		Binding	 to	α7-nAChR	 could	 also	 be	measured	 in	 an	 immunoprecipitation	 assay	 format:	receptor	extracts	were	 labeled	with	 [125I]-α-Bgtx	(5	nM	 in	 the	presence	or	absence	of	1	µM	unlabeled	α−Bgtx	to	define	total	and	non-specific	binding).	The	labelled	extract	could	then	be	bound	to	protein	A	beads	via	anti-α7	subunit	Abs	(Moretti	et	al.,	2014).	Similar	amounts	 of	 specific	 binding	 were	 recorded	 in	 either	 assay	 format,	 and	 non-specific	binding	was	between	10-15%	of	total	binding.	The	oxystylbene	compounds	were	tested	using	SH-SY5Y	cells	transfected	with	the	human	
α7cDNA.	 The	 inhibition	 of	 [125I]-α-Bgtx	 binding	 was	 measured	 by	 pre-incubating	membranes	 containing	 transfected	 human	α7	 receptors	with	 increasing	 concentrations	(10	pM	-	10	mM)	of	 the	drug	 for	30	min	at	RT	 followed	by	overnight	 incubation	with	a	final	concentration	of	2	nM	[125I]- α−Bgtx	at	RT.	After	the	incubation	the	membranes	were	separated	by	filtration	on	GFC	filters	hydrated	with	PEI,	and	the	radioactivity	is	counted	in	the	gamma	counter.	The	prism	software,	version	6	was	used	to	calculate	the	Ki	values	of	all	tested	compounds	obtained	from	at	least	three	independent	saturation	and	competition	binding	experiments	at	RT.						
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3.	In	vitro	cell	culture	experiments	
• Cell	culture		Human	 non-small	 cell	 lung	 adenocarcinoma	 cell	 lines	 (NSCLC)	 A549	 and	 H1975	 were	obtained	from	the	American	type	culture	collection	(ATCC).	The	neuroblastoma	cell	 line	SH-SY5Y	were	obtained	 from	European	 collection	of	 authenticated	 cell	 culture	 (ECACC)	and	Hepg2	(ATCC).	NSCLC	cells	and	the	neuroblastoma	were	grown	in	RPMI	medium	(Lanza)	supplemented	with	10%	fetal	bovine	serum	(FBS),	1%	of	penicillin-streptomycin	and	1%	of	L-glutamine,	HepG2	 in	DMEM	medium	supplemented	with	10%	FBS,	1%	penicillin-streptomycin	and	1%	of	L-glutamine.	The	cells	were	maintained	in	an	environment	of	37	°C	containing	5	%	CO2.	Microscopy	for	cells:	EVOS	XL	core		Lplan	PH2	40X/0,65		Lplan	PH2	20X/0.40	
	Figure	1.	Morphological	features	of	the	cell	lines		Each	 cell	 line	 was	 treated	 with	 different	 protocol	 in	 order	 to	 optimise	 the	 proper	condition	for	the	experiments.		
• Total	RNA	Extraction	and	Reverse	Transcription	Total	 RNA	 was	 extracted	 using	 the	 RNeasy	 Mini	 kit	 and	 accompanying	 QIAshredder	(Qiagen),	according	to	the	manufacturer’s	instructions.	Briefly,	a	maximum	of	9x106	cells	was	collected	by	centrifugation	and	the	cells	 lysed	with	600	μl	of	buffer	RLT,	previously	added	with	 β-mercaptoethanol	 (10	 μl/ml	 RLT	 buffer).	 The	 lysate	was	 homogenized	 by	means	of	QIAshredder	column	centrifuged	for	2	minutes	at	maximum	speed.	To	 avoid	 DNA	 contamination,	 samples	were	 on-column	 incubated	with	 DNAse	 I	 for	 15	minutes	and	RNA	eluted	with	50	μl	of	RNase-free	water.	The	amount	of	eluted	total	RNA	
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was	determined	by	spectrophotometer	at	260	nm	and	its	purity	was	evaluated	using	the	260/280	ratio;	1	µg	per	 sample	was	 reverse	 transcribed	using	 the	GoScriptTM	Reverse	Transcriptase	(Promega),	according	to	information	provided	by	the	company.	This	part	of	 the	work	was	done	 in	collaboration	with	Dr.	Roberta	Benfante	 (Institute	of	Neuroscience,	CNR,	Milano).	
• Quantitative	Real-Time	PCR		Gene	expression	analyses	were	performed	by	quantitative	Real-Time	PCR	assay	using	the	ABI	Prism	Thermocycler	QuantStudio	5.		The	target	sequences	were	amplified	from	50	ng	of	 cDNA	 in	 the	 presence	 of	 TaqMan®	 Gene	 expression	master	mix	 (Life	 Technologies,	Inc.).		The	 TaqMan®	 primer	 and	 probe	 assays	 used	 were	 human	 CHRNA2	 (ID	#Hs00181237_m1),	 CHRNA3	 (ID	 #Hs01088199_m1),	 CHRNA4	 (ID	 #Hs00181247_m1),	CHRNA5	 (ID	 #Hs00181248_m1),	 CHRNA6	 (ID	 #Hs00610233_m1),	 CHRNA7	 (ID	#Hs01063373_m1),	CHRFAM7A	(ID	#Hs04189909_m1),	CHRNA9	(ID	#Hs00214034_m1),	CHRNA10	 (ID	 #Hs00220710_m1),	 CHRNB2	 (ID	 #Hs00181267_m1),	 CHRNB3	 (ID	#Hs00181269_m1),	CHRNB4	(ID	#Hs00609520_m1).	GADPH	(ID	#Hs99999905_m1)	was	used	as	endogenous	control.	The	2−ΔCT	or	2−ΔΔCT	method	was	used	 to	calculate	 the	results,	as	described	in	the	figure	legends,	thus	allowing	the	normalization	of	each	sample	to	the	endogenous	control,	and	comparison	with	the	calibrator	for	each	experiment	(set	to	a	value	of	1).	
• ERK	and	AKT	pathways	activation		To	evaluate	the	activation	of	ERK	and	AKT	signalling	pathways,	the	NSCLC	cell	lines	were	seeded	 in	24-well	plates	 (80X104	cells/well)	and	starved	overnight	before	 to	be	 treated	with	different	 concentration	of	nicotine	 in	presence	or	 absence	of	 the	antagonists	or	of	the	compound	to	be	tested.	The	signal	detection	was	obtained	by	Western	blotting	analyses	with	Abs	directed	against	ERK,	P-ERK,	AKT	and	P-AKT.		
• siRNA	transfection		Sequences	of	small	interfering	RNA	(siRNA),	obtained	from	Dharmacon	(GE	Healthcare),	were	used	to	knockdown	the	endogenous	nAChR	α7,	α5	and	α9	subunits.		For	 each	 subunit	 (α7,	α5,	α9)	 four	different	 siRNAs	were	analysed	and	a	non-targeting	scrambled	siRNA	sequence	was	used	as	a	control	in	the	transfection	experiments.		
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A549	 cells	 were	 plated	 to	 70-80%	 confluence	 in	 6-well	 plate	 (4X105	 cells/well)	 and	transfected	 in	Opti-MEM	with	75	pmoli	of	 siRNA	 (scrambled	or	 subunit	 specific	 siRNA)	(GE	Healthcare,	Buckinghamshire,	UK)	using	Lipofectamine	3000	reagent	(Invitrogen)	in	RPMI	minus	penicillin/streptomycin.	Five	hours	after	transfection,	cells	were	trypsinised,	counted	 and	 plated	 in	 24-well	 plate	 (10-100	 X	 103	 cells/well)	 and	 the	 medium	 was	replaced	by	complete	medium.	The	cells	were	collected	at	different	times	(48-72	hours)	in	order	to	isolate	their	mRNA	and	determine	the	mRNA	and	protein	levels	of	the	subunits.		The	 siRNAs	 that	 were	more	 active	 in	 decreasing	 the	 expression	 of	 mRNA	 and	 subunit	proteins	 were	 used	 for	 the	 cell	 proliferation	 and	 signalling	 experiments.	 To	 study	 the	effect	 of	 nicotine,	 siRNA	 transfected	A549	were	 rendered	 quiescent	 for	 72	 hours	 using	serum-free	RPMI.	Subsequently,	 they	were	 treated	with	nicotine	(100	nM)	 for	48	hours	and	then	were	counted	to	assess	their	proliferative	ratio.	To	 evaluate	 the	 activation	of	 ERK	and	AKT	 signalling	pathways,	A549	 cells,	 transfected	with	 siRNAs,	 were	 starved	 for	 24	 hours	 and	 then	 treated	 with	 nicotine	 (100	 nM)	 for	different	times	(from	five	minutes	to	one	hour).	The	cells	were	then	examined	by	means	of	Western	blotting.	
• Proliferation	assay	The	different	cell	lines	were	seeded	in	24-well	plates	and	rendered	quiescent	by	72	hours	of	serum	deprivation.	After	this	time,	cells	were	treated	with	nicotine	or	the	other	drugs	for	48	hours.	The	capacity	of	antagonists	to	block	the	effect	of	nicotine	was	assessed	by		pre-incubating	 the	 cells	 for	 30	 minutes	 with	 specific	 antagonists	 at	 the	 appropriate	concentration	before	adding	nicotine.	At	 the	 end	 of	 the	 treatment,	 the	 cells	 were	 washed	 once	 with	 PBS	 1X,	 trypsinised,	suspended	 in	500	µl	of	medium,	and	manually	counted	using	a	hemocytometer	(Burker	camera)	at	the	optical	microscope.		
• Viability	assay	Cell	viability	was	assessed	using	the	CellTiter	96®	AQueous	One	Solution	Cell	Proliferation	Assay	(Promega).	The	assay	is	based	on	the	reduction	of	MTS	tetrazolium	compound	[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]	by	viable	cells	to	generate	a	colour	formazan	product	that	 is	soluble	 in	cell	culture	 media.	 This	 conversion	 is	 carried	 out	 by	 NAD(P)H-dependent	 dehydrogenase	enzymes	 in	 metabolically	 active	 cells.	 The	 formazan	 dye	 produced	 is	 quantified	 by	measuring	 the	 absorbance	 at	 490	 and	 is	 directly	 proportional	 to	 the	 number	 of	 living	cultured	cells.	
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				 Figure	2.	Structure	of	MTS	tetrazolium	converted	to	its	soluble	product	as	a	result	of	cell	metabolism		Cells	 were	 plated	 in	 24-well	 plates	 at	 different	 densities	 depending	 on	 the	 metabolic	activity	of	each	cell	line	(i.e.	8X103	A549cells/well,	15X103	SHSY5Y	and	H1975	cells/well)	and	were	treated	with	nicotine,	nicotinic	antagonists	or	other	compounds	synthesised	by	the	groups	of	Prof.	Pallavicini	and	Prof	De	Amici	(University	of	Milan)	for	48	or	72	hours	in	complete	medium	(RPMI	or	DMEM).		At	 the	 end	 of	 the	 treatment,	 the	 cells	 were	 washed	 and	 50	 µl/well	 MTS	 solution	 was	added	 to	each	well.	The	plates	were	 incubated	 for	 two	hours	and	absorbance	was	 read	using	spectrophotometer	at	a	wavelength	of	490	nm.	Optical	density	(OD)	of	each	plate	was	measured	 in	triplicate,	and	normalised	by	taking	the	OD	of	untreated	cells	as	100%.	
• Wound-healing	assay	Wound-healing	assay	was	used	to	assess	cell	migration.		Cells	were	grown	to	a	confluence	of	90%	and	the	monolayer	was	wounded	by	scratching	the	 surface	 of	 the	 24-well	 plate	 as	 uniformly	 as	 possible	 using	 a	 P200	 pipette	 tip.	 The	wells	 were	 rinsed	 twice	 with	 phosphate	 buffered	 saline	 (PBS)	 and	 fresh	 medium	containing	 100	 nM	 nicotine,	 with	 or	 without	 nicotinic	 antagonist,	 was	 added.	 The	antagonists	 were	 added	 30	 minutes	 before	 nicotine.	 Cells	 were	 incubated	 at	 37°C	 for	different	times.		The	initial	wounding	and	movement	of	the	cells	in	the	scratched	area	were	photographed	using	 an	 Olympus	 CKX41	 inverted	microscope	 equipped	with	 a	 digital	 imaging	 system	(time	 0)	 and	 subsequently	 until	 the	 wound	 closure.	 The	 healing	 wound	 width	 was	measured	at	time	0,	and	after	24	and	48	hours.	All	of	the	values	were	normalised	to	the	control	cells.			 		 	Figure	3.	Scheme	of	the	Wound	healing	protocol	
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• ROS	production	ROS	generation	 in	A549	 cells	was	 assessed	by	using	2’,7’-diclhorofluorescein	di-acetate	(DCFH-DA),	 a	 fluorogenic	 dye	 that	measures	 intracellular	 	 hydroxyl,	 peroxyl	 and	 other	ROS	 activity.	 DCFH-DA	 is	 deacetylated	 in	 cells	 by	 esterases,	 and	 becomes	 highly	fluorescent	when	oxidised	by	ROS.													 Figure	4.	DCFH-DA	conversion	in	cells	upon	ROS	stimulation	
	Briefly,	A549	cells	line	were	seeded	in	a	black	96-well	plate	(1,2X104	cells/well),	washed	with	 HBSS	 buffer,	 and	 incubated	 with	 20	 mM	 DCFH-DA	 for	 45	 min	 at	 37°C.	 After	incubation,	 DCFH-DA	 was	 removed	 and	 the	 cells	 were	 treated	 with	 different	concentrations	of	oxystylbene	compounds	and	derivatives	for	24	hours.	ROS	levels	were	measured	 during	 the	 treatment	 period	 at	 emission	 wavelengths	 of	 485-535	 nm.	 The	results	were	normalised	using	the	protein	value	of	each	sample.		
4.	Electrophysiological	studies		
• Xenopus	oocytes	and	RNA	injection		These	experiments	were	done	in	collaboration	with	Dr	Michel	Mcintosh	Utah.	
Xenopus	oocytes	were	purchased	from	Ecocyte	Bioscience	US	(Austin,	TX)	and	incubated	upon	 arrival	 at	 13°C.	 The	 tips	 of	 pulled	 glass	micropipettes	were	 broken	 to	 achieve	 an	outer	diameter	of	~40	µm	(resistance	of	2-6	MΩ),	and	pipettes	were	used	to	inject	20-60	nl	containing	10	ng	of	cRNA/oocyte.		To	improve	functional	expression	of	α7*-nAChR,	Ric-3	mRNA	was	also	co-injected	(Halevi	et	al.,	2002).	A	ratio	of	1:50	Ric-3:	α7	subunit	mRNA	by	mass	was	determined	to	be	optimally	effective	in	pilot	experiments	(data	not	shown).	
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• Two-electrode	 voltage-clamp	 recording	 of	α7-	 and	α9 α10-nAChR	
function	Two-electrode	 voltage-clamp	 recordings	 were	 made	 at	 room	 temperature	 (20°C)	 in	oocyte	saline	(OR2)	solution	(containing	82.5	mM	NaCl,	2.5	mM	KCl,	5	mM	HEPES,	1.8	mM	CaCl2·2H2O,	 and	 1	 mM	 MgCl2·6H2O,	 pH	 7.4).	 Seven	 to	 fourteen	 days	 after	 injection,	
Xenopus	oocytes	expressing	concatenated	α7	or	α9- α10	-nAChRs	were	voltage	clamped	at	 −70	mV	with	 an	 Axoclamp	 900A	 amplifier	 (Molecular	 Devices,	 Sunnyvale,	 CA,	 USA).		Recordings	were	 sampled	at	10	kHz	 (low-pass	Bessel	 filter:	 40Hz;	high-pass	 filter:	DC),	and	the	resulting	traces	were	saved	to	disk	(Molecular	Devices	Clampex	v10.2).	Data	from	oocytes	with	leak	currents	(Ileak)	>	50	nA	were	excluded	from	recordings.		
• Nicotinic	receptor	pharmacology	Fresh	stock	drug	solutions	of	ACh,	methyllycaconitine	(MLA)	or	α-Bungarotoxin	(α-Bgtx),	F1	or	F3,	were	made	daily	and	diluted	as	required.	Agonists	and	antagonists	were	applied	using	 a	 sixteen	 channel,	 gravity-fed,	 perfusion	 system	 with	 automated	 valve	 control	(AutoMate	 Scientific,	 Inc.;	 Berkeley,	 CA,	 USA).	 All	 solutions	 were	 supplemented	 with	atropine	 sulphate	 (1.5	 µM)	 to	 ensure	 that	 muscarinic	 Ach	 receptor	 responses	 were	blocked	and	thus	not	recorded.	Oocytes	expressing	α7	or	α9- α10	-nAChRs	were	perfused	with	 ACh	 for	 5	 seconds	 with	 60second	 washout	 times	 between	 each	 subsequent	application.	Oocytes	were	preincubated	with	F1	or	F3	 for	2	minutes	prior	 to	 activation	with	ACh	(100	uM;	5	seconds).	All	of	the	data	of	the	F1	and	F3	inhibition	of	Ach	currents	were	normalised	 to	 those	obtained	upon	superfusion	of	 the	 same	oocytes	with	100	µM	ACh.	
5.	Statistical	analyses	All	 the	 experiments	were	 performed	 in	 triplicate	 or	 quadruplicate,	 and	 the	 results	 are	expressed	as	mean	values	±	SE.		The	data	from	the	binding,	cell	proliferation	and	western	blotting	studies	were	expressed	as	mean	values	±	SEM	and	analysed	by	means	of	Student	 t	 test	 for	 comparisons	of	 two	groups	or	one-way	ANOVA	followed	by	a	Bonferroni	post	hoc	test	(paramatric	data)	or	by	Kruskal–Wallis	test	followed	by	Dunn's	post	hoc	test	(non	parametric	data).	The	accepted	level	 of	 significance	was	p	 <	0.05.	All	 of	 the	 statistical	 analyses	were	made	using	Prism	software,	version	5	(GraphPad).		
	 55	
RESULTS	
1. Molecular	studies	
• Expression	of	nAChRs	in	NSCLC	cell	lines		We	used	RT-PCR	analysis	 to	 compare	 the	expression	of	 the	α2-α10	and	β2-β4	nAChR	subunits	 and	 CHRFAM7A	 in	 A549	 and	 H1975	 NSCLC	 cell	 lines	 with	 that	 of	 the	 same	subunits	 in	 the	 SH-SY5Y	 neuroblastoma	 cell	 line	 (Figure	 1).	 The	 two	 lung	 cancer	 cell	lines	had	a	high	level	of	transcripts	for	the	α5	subunit	and	the	CHRFAM7A	protein	and	low	level	of	α9	and	α3	subunits	whereas	the	other	subunits	were	only	found	in	one	or	the	other	NSCLC	cell	line.		The	 SH-SY5Y	 neuroblastoma	 cell	 line	 had	 higher	 levels	 of	 almost	 all	 of	 the	 subunits,	particularly	α3,	α7,	β2	and	β4.		In	 order	 to	 confirm	 the	 expression	 of	 nAChR	 subunits	 at	 protein	 level,	we	 performed	Western	blotting	analyses	and	immunoprecipitation	studies.	
• Antibody	specificity		The	 specificity	 of	 the	 antibodies	 (Abs)	 has	 been	 checked	 in	 preliminary	 experiments.	Figure	2Aa	 shows	 the	 specificity	of	anti-α7	Abs	 tested	on	α7	receptors	obtained	 from	hippocampus	of	wild	type	(WT)	(left)	and	α7	knockout	(KO)	(right)	mice.	The	same	Abs	where	 also	 tested	 on	 human	α7	 receptors	 purified	 using	α-Bgtx	 covalently	 bound	 to	Sepharose	4B	(Figure	2Ab)	in	the	absence	(left)	or	presence	(right)	of	an	excess	of	2	µM	cold	α-Bgtx.	The	α7	Abs	recognised	the	presence	of	the	α7	subunit	in	WT	mice	(Figure	
2Aa	left)	and	SH-SY5Y	cells	(Figure	2Ab	left),	but	not	in	α7	KO	mice	(Figure	2Aa	right),	or	when	the	binding	to	the	resin	was	competed	by	cold	α-Bgtx	(Figure	2Ab	right).	As	detailed	in	the	methods	we	have	raised	two	Abs	against	the	human	α7	subunit,	one	against	a	peptide	located	at	the	terminus	(COOH	Abs)	and	one	against	a	peptide	located	in	 the	 intracellular	M3-M4	 loop	 (Cyt	 Abs).	 These	α7	Abs	were	 tested	 in	 SH-SY5Y	 and	HEK	 cells	 transfected	with	 the	 human	α7	 cDNA.	 As	 shown	 in	 the	 Figure	2Ac	 the	 Abs	directed	 against	 the	 COOH	 and	 Cyt	 α7	 peptides	 recognised	 a	 peptide	 of	 identical	molecular	weight	in	transfected	HEK	and	SH-SY5Y	cells	and	this	signal	was	very	low	in	un-transfected	SH-SY5Y	cells.	No	signal	was	found	in	the	un-transfected	HEK	cells.			
	 56	
We	also	tested	the	specificity	of	an	anti	human	α5	Abs	using	HEK	cells	stably	transfected	with	 the	 α3β4	 and	 α3β4α5	 subtypes.	 As	 shown	 in	 Figure	 2B,	 the	 anti-α5	 Abs	 only	recognised	a	band	in	the	α3β4α5	subtype.			
• Western	blotting	and	Immunoprecipitation	analyses		nAChR	were	originally	described	 in	neuronal	 tissues	but	 it	has	been	recently	reported	that	other	cell	types,	including	non-small	cell	lung	cancer	(NSCLC)	cells,	express	nAChR	subunits.		After	 having	 checked	 the	 specificity	 of	 the	 Abs,	 we	 used	 them	 to	 characterise	 the	nicotinic	 subunits	 expressed	 in	 the	 NSCLC	 (A549	 and	 H1975)	 and	 SH-SHSY	neuroblastoma	cell	lines.	We	 first	 performed	 immunoprecipitation	 experiments	 on	2%	Triton	 extracts	 obtained	from	the	A549,	H1975	and	SH-SY5Y	cells,	using	anti-α5	Abs	(Figure	3Aa),	anti-α7	Abs	(Figure	 3Ab),	 and	 control	 IgG	 bound	 to	 protein	 A	 (Figure	 3Ac).	 Western	 blotting	analysis	with	anti-α5	Abs	showed	that	the	anti-α5	Abs	recognised	a	50	kDa	peptide	in	all	the	 cell	 lines	 (Figure	 3A).	 The	 peptide	 recognised	 by	 α5	 Abs	 was	 absent	 when	 the	extracts	were	immunoprecipitated	by	anti-α7	(Figure	3Ab)	or	control	IgG	(Figure	3Ac).	As	the	level	of	endogenous	α7-containing	receptors	is	very	low	in	the	SH-SY5Y	cells,	we	purified	 the	 receptors	 by	 means	 of	 affinity	 purification	 using	 the	 α-Bgtx	 coupled	 to	Sepharose	 4B.	 As	 shown	 in	 Figure	3B,	 after	 affinity	 purification	 the	Western	 blotting	with	 the	α7	 Abs	 demonstrated	 that	α-Bgtx	 receptors	 were	 highly	 enrichment	 in	α7-containing	receptor.	When	measured	by	RT-PCR	α7	mRNA	expression	was	 lower	 in	A549	cells	 than	 in	SH-SY5Y	 cells,	 and	 so	 we	 analysed	 the	 expression	 of	 the	 α7	 protein	 only	 after	 affinity	purifying	the	α7-containing	α-Bgtx	receptors	on	a	Sepharose-aBgtx	column.		Figure	3B	 shows	 a	diagram	of	 the	purification	of	α-Bgtx	 receptors	 from	A549,	H1975	and	SH-SY5Y	cells,	and	 the	Western	blotting	analyses	of	 the	α−Bgtx-purified	receptors	probed	with	anti-α7	Abs.	The	α7	Abs	recognised	a	specific	band	in	the	receptors	purified	from	A549	cells	but	not	in	those	purified	from	H1975	cells,	which	is	in	line	with	RT	-PCR	findings.		As	 the	α5	 protein	 is	 expressed	 at	 high	 level	 in	 all	 the	 three	 cell	 lines	we	 also	 probed	whether	the	α5	subunit	could	be	associated	with	the	purified	α-Bgtx	receptors.	Figure	
3B	 (left)	 shows	 the	 probing	 of	 the	 α-Bgtx	 receptors	 with	 anti-α5	 Abs.	 No	 specific	
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labelling	was	determined	in	the	α-Bgtx	receptors	whereas	the	labelling	of	the	α5	subunit	was	determined	in	the	positive	control	(HEK	α3β4α5	subtype)	run	in	the	same	gel.	These	data	suggest	 that	 the	α5	subunit	 is	expressed	 in	 the	 tumour	cell	 lines	A549	and	H1975,	 whereas	 the	 α7	 subunit	 is	 only	 expressed	 in	 A549	 cells.	 Moreover	 we	determined	that	the	α5	subunit	is	not	associated	with	α7	receptors	in	the	A549	cells.		
2.	Nicotine-induced	effects	
• Nicotine	increases	cell	viability	and	proliferation	in	NSCLC	In	order	 to	 study	 the	 role	of	nicotinic	 receptors	 in	 the	proliferation	of	NSCLC	cells	we	treated	the	A549	and	H1975	cell	 lines	with	increasing	nicotine	concentrations	(10	nM-100	mM).	As	shown	in	Figures	4A	and	4B,	48	hours	exposure	to	nicotine	increased	A549	cell	 viability	 (measured	 by	 means	 of	 an	 MTS	 assay)	 and	 proliferation	 (measured	 by	counting	 cells),	 but	 not	 the	 viability	 or	 proliferation	 of	 H1975	 cells.	 The	 nicotine	concentrations	that	increased	cell	proliferation	were	comparable	with	those	found	in	the	serum	of	habitual	tobacco	smokers	(50	-1000	nM).	As	nicotine	100	nM	gave	a	significant	result	and	falls	in	the	range	of	the	blood	nicotine	levels	of	habitual	smokers,	we	used	this	dose	for	most	of	the	follow-up	experiments.	
• Nicotine	induces	A549	cell	migration	We	evaluated	the	effects	of	nicotine	on	A549	cell	migration	using	a	wound-healing	assay.	The	level	of	wound	healing	was	measured	by	the	average	decrease	in	distance	between	the	edges	of	the	wounds	at	different	time	points	in	the	presence	or	absence	of	nicotine	stimulation	(100	nM).	The	results	indicate	that,	after	treatment	with	nicotine	for	24	and	48	hours,	 the	 cells	migrated	more	quickly	 to	 close	 the	wounds	 than	 control	 cells	 (not	treated)	(Figure	4C).		
• Nicotine	 stimulates	 activation	 of	 ERK	 and	 AKT	 intracellular	
pathways	Previous	work	by	other	groups	has	shown	that	nicotine	increases	the	cell	proliferation	of	a	number	of	tumour	cells	by	activating	the	ERK	pathway,	or	inhibits	cell	apoptosis	by	activating	the	AKT	pathway.		We	 used	 Western	 blotting	 analyses	 to	 investigate	 the	 possible	 nicotine-induced	activation	of	ERK	and	AKT	pathways	in	A549	and	H1975	lung	cancer	cells.	Nicotine	(100	nM)	by	 increasing	 the	P-AKT	and	P-ERK	 levels	 activated	both	pathways	 in	A549	cells,	but	not	in	H1975	cells	(Figure	5A-B).		
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This	 activation	 was	 time-dependent	 and	 nicotine-stimulated	 phosphorylation	 peaked	five	 and	 ten	 minutes	 after	 nicotine	 stimulation	 and	 decreased	 permanently	 after	 30	minutes.	Nicotine	did	not	affect	the	protein	levels	of	total	AKT	or	ERK.	The	lack	of	effect	of	 nicotine	 on	 H1975	 cells	 suggests	 that	 nicotine-mediated	 effects	 are	 due	 to	 specific	nAChR	subtypes,	which	are	little	or	not	expressed	in	H1975	cell	line.		
3.	Pharmacological	studies	Previous	studies	have	shown	that	α7−, α5− and α9− containing nAChRs	are	involved	in	tumour	growth	and	promote	resistance	to	apoptosis,	cancer	cell	proliferation,	migration	and	intracellular	activation	when	stimulated	by	nicotine.	As	we	have	found	that	NSCLC	cells	 express α5, α7 and α9 mRNAs,	 we	 evaluated	 the	 involvement	 of	 receptors	containing	these	subunits	in	the	proliferative	effect	of	nicotine	by	studying	the	effects	of	subtype-specific	 antagonists	 (pharmacological	 studies)	 and	 by	 using	 interfering	 RNAs	(siRNAs)	 against	 the	 CHRNA5,	 CHRNA7	 and	 CHRNA9	 genes	 to	 knock	 down	 the	expression	 of	 the	 subunits	 (silencing	 experiments).	 We	 also	 analysed	 the	 effects	 of	nAChR	antagonists	and	siRNAs	on	the	intracellular	pathways	activated	by	nicotine.		
• α−bungarotoxin	(α-Bgtx)		
α-Bgtx	 is	 a	 selective	 nAChR	 antagonist	 of	 homomeric	 and/or	 heteromeric	 receptors	containing	α7	or	α9	subunits	(Gotti	et	al.,	2006;	Olsen	et	al.,	2008)	and	was	used	to	study	the	 nicotine–induced	 proliferation	 of	 A549	 and	H1975	 cells.	 Both	 cell	 lines	were	 pre-treated	with	1	µM	α-Bgtx	for	30	minutes,	and	then	with	nicotine100	nM.	The	effect	of	α-Bgtx	on	nicotine-induced	proliferation	was	evaluated	after	48	hours.	We	 found	 that	 α-bgtx	 abrogated	 the	 nicotine–induced	 proliferation	 of	 A549	 cells	 as	measured	by	means	of	an	MTS	assay	and	counting	assay	(Figure	6A).		We	also	evaluated	the	effect	of	α-Bgtx	on	the	nicotine-induced	activation	of	P-ERK	and	P-AKT,	and	found	that	in	the	presence	of	the	antagonist,	nicotine	did	not	activate	either	in	 A549	 cells	 (Figure	 6B).	 The	 presence	 of	α-Bgtx	 had	 any	 effect	 on	 H1975	 cell	 line	(Figure	6C).		
• Methyllycaconitine	(MLA)	MLA	is	a	selective	antagonist	of	homomeric	or	heteromeric	nAChRs	containing	the	α7	or	
α9	 subunits	 (Gotti	 et	 al.,	 2006),	 and	 we	 tested	 its	 effect	 on	 the	 nicotine-induced	proliferation	of	A549	and	H1975	cells.	As	in	the	case	of	α-Bgtx,	30	minutes	of	pre-treatment	with	500	nM	MLA	followed	by	100	
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nM	 nicotine	 for	 48	 hours	 blocked	 nicotine-induced	 proliferation	 and	 cell	 viability	 as	measured	by	MTS	viability	assay	and	counting	assay	(Figure	7A).	Wound	 healing	 assay	 showed	 that	 nicotine-treated	 A549	 cells	migrated	more	 quickly	than	control	cells	and	this	effect	was	slowed	in	the	presence	of	MLA	(Figure	7B).	MLA	(500	nM)	also	blocked	the	nicotine-induced	increase	in	P-ERK	and	P-AKT	levels	in	A549	cells	(Figure	7C)	but	had	no	effect	on	H1975	cells	(Figure	7D).	
α-Bgtx	and	MLA	toxins	act	on	α7	and	α9-containing	recepors	and	both	 toxins	blocked	the	 effects	 of	 nicotine	 on	 A549	 cells,	 to	 discriminate	 the	 subtypes	 involved	 the	 same	proliferation	and	signalling	experiments	were	carried	out	using	a	toxin	selective	for	the	
α7-containing	subtype	(AR)	and	a	toxin	selective	for	the	α9-containing	subtype	(RG-I).	
• Effects	of	subtype-specific	toxins		The	inhibitory	activity	of	AR	(Whiteaker	et	al.,	2007;	Innocent	et	al.,	2008)	was	tested	by	pre-incubating	A549	cells	with	AR	1	µM	and	then	treating	the	cells	for	48	hours	with	100	nM	nicotine.	As	 shown	 in	Figure	 8A	 this	 toxin	alone	did	not	affect	 the	proliferation	of	untreated	cells	but	blocked	nicotine	induced	proliferation.	We	also	analysed	the	effect	of	AR	1	µM	in	nicotine-induced	AKT	and	ERK	signalling	and	found	 that	 it	 significantly	 decreased	 the	 nicotine-induced	 activation	 of	 P-AKT	 (Figure	
8B)	after	10	minutes	of	nicotine	stimulation	but	had	no	significant	effect	on	the	nicotine-induced	modulation	of	the	ERK	pathway.	This	suggests	that	the	inhibition	of	α7	nAChR	has	 a	 greater	 effect	 on	 the	 anti-apoptotic	 pathway	 induced	 by	 P-AKT	 than	 on	 the	proliferative	 pathway	 induced	 by	 P-ERK	 and	 that	 nicotine	 exposure	 induces	 cell	proliferation	and	signalling	activation	through	the	α7-containing	nAChRs	 in	the	NSCLC	A549	cell	line.	The	α9	nAChR	specific	toxin	RG-I	1	µM	completely	abolished	proliferation	of	A549	cells	induced	 by	 48	 hours	 treatment	 with	 nicotine	 (100	 nM)	 (Figure	 9A)	 and	 when	administrated	alone	the	toxin	had	no	effect	on	basal	cell	proliferation.		When	 tested	 for	 the	 activation	 of	 intracellular	 pathways	 we	 found	 that	 RG-I	 toxin	blocked	the	nicotine-activated	downstream	cascades	of	P-AKT	and	P-ERK	(Figure	9B).		
• Nicotine-derived	 nitrosamines	 and	 an	 α7-selective	 agonist	 (ICH3)	
induce	A549	cell	proliferation		It	 has	been	previously	 shown	 that	 two	nicotine-derived	nitrosamines	 (NNK	and	NNN)	can	induce	carcinogenesis	and	tumour	progression	by	binding	nAChRs.	For	this	reason,	
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we	tested	their	activity	on	the	A549	cell	line	using	the	MTS	assay.	The	cells	were	treated	separately	with	NNK	and	NNN	at	different	concentrations	(10	nM-100	µM)	for	48	hours.	Our	results	show	that	NNK	and	NNN	stimulate	A549	cell	viability	only	at	a	very	low	dose	(10	nM)	and	not	at	higher	doses.	This	effect	may	be	explained	by	the	fact	that	the	higher	concentration	may	lead	to	nAChR	desensitisation	(Figure	10A-B).		We	also	investigated	the	role	of	a	selective	α7	agonist	called	ICH3	previously	identified	by	our	group	(Dallanoce	et	al.,	2011b).	This	agonist	increased	cell	viability	1-1.5-fold	in	a	dose-dependent	manner	at	doses	ranging	from	100	nM	to	10	µM	(Figure	10C).		
3.1	Silencing	gene	studies		Small	(or	short)	interfering	RNA	(siRNA)	is	the	most	commonly	used	RNA	interference	(RNAi)	tool	for	inducing	short-silencing	of	protein	coding	genes.		As	α7-		and	α9-containing	nAChRs	are	associated	with	various	 types	of	 cancer	 and	 the	
α5	subunit	is	associated	with	a	high	risk	of	nicotine	dependence	and	lung	tumour	onset,	we	 investigated	whether	knocking-down	the	nAChR	containing	these	subunits	affected	their	nicotine-induced,	pro-tumorigenic	effects	in	the	A549	NSCLC	cell	line.	
• The	effect	of	siRNAs	on	α7-containing	nAChR	In	 preliminary	 experiments	 we	 screened	 among	 four	 different	 siRNAs	 (Dharmacon)	using	RT-PCR	and	Western	blotting	analysis.		In	 order	 to	 evaluate	 the	 ability	 to	 knock	 down	 the	 gene	 of	 interest,	 A549	 cells	 were	transfected	for	48	hours	with	scrambled	siRNA	(used	as	negative	control)	or	four	siRNAs	targeting	specific	CHRNA7	sequences	(Figure	11A).		RT-PCR	 analysis	 shows	 that,	 in	 comparison	 with	 control	 untreated	 cells,	 scrambled	siRNA	had	no	 significative	 effect	 on	 the	α7	mRNA	 level	 but	 three	α7	 siRNAs	 knocked	down	more	than	50%	of	CHRNA7	gene	transcript:	siRNA	II	(48	%),	siRNA	III	(58%)	and	siRNA	IV	(60%).	As	said	above	we	could	not	detect	the	endogenous	α7	protein	using	our	α7-specific	Abs	and	so,	in	order	to	investigate	the	effect	of	the	different	siRNAs	on	α7	expression,	we	co-transfected	α7	cDNA	into	A549	cells	for	48	hours.	We	measured	the	level	of	silencing	by	means	of	Western	blotting	with	the	anti-α7	Abs.	Under	these	conditions,	we	found	that	the	siRNAs	that	were	most	potent	in	silencing	the	transfected	α7	protein	were	siRNA	II	and	siRNA	IV	(Figure	11B).		We	next	analysed	the	effect	of	scrambled	siRNA,	siRNAs	II	or	IV	on	the	nicotine-induced	
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stimulation	 of	 cell	 proliferation.	 To	 this	 end	 the	 cells	 were	 first	 transfected	 with	scrambled	 or	 siRNAs	 II	 or	 IV,	 starved,	 by	means	 of	 FBS	 deprivation,	 and	 then	 treated	with	 100	 nM	 nicotine	 for	 48	 hours.	 As	 shown	 in	 Figure	 11C,	 transfection	 with	 the	scrambled	siRNA	did	not	affect	basal	proliferation	or	the	pro-proliferative	effect	of	100	nM	nicotine	and	transfection	with	siRNAs	II	and	IV	did	not	change	basal	proliferation	but	abolished	nicotine-induced	proliferation	(Figure	11C).			We	 also	 examined	 whether	 knocking	 down	 the	 α7 subunit		 affects	 the	 nicotine-activation	of	the	intracellular	ERK	and	AKT	pathways.	A549	cells	were	transfected	with	scrambled,	siRNA	II	or	siRNA	IV	for	48	hours	and	then	stimulated	with	100	nM	nicotine	for	different	 times,	 from	 five	minutes	 to	one	hour,	 and	analysed	by	means	of	Western	blots.	 Figures	 12A	 and	 B	 showed	 that	 knocking	 down	α7	 protein	with	 siRNA	 II	 and	siRNA	IV	blocked	the	nicotine	activation	of	P-AKT	at	all	times,	and	treatment	with	siRNA	IV	 and	 siRNAII	 also	 decreased	 the	 P-ERK	 activation	 induced	 by	 nicotine	 stimulation	(Figure	12B)	although	it	was	only	significant	with	siRNA	IV.	These	data	suggest	that	α7-containing	receptors	are	mainly	involved	in	AKT	pathway	activation	and	are	maybe	not	so	essential	for	mediating	the	effect	of	nicotine	on	the	ERK	pathway.	
• The	effect	of	siRNAs	on	α5-containing	nAChRs	It	 is	well	 known	 that	α5−nAChR	 subunit	 is	 involved	 in	 lung	 cancer	 susceptibility	 and	nicotine	addiction	and	genetic	studies	demonstrated	that	specific	polymorphism	in	this	gene	can	lead	to	a	higher	risk	of	developing	lung	cancer	(Amos	et	al.,	2008).	We	 therefore	assessed	whether	nAChRs	containing	 the	α5	subunit	 are	 involved	 in	 the	effects	on	A549	cells	induced	by	nicotine.	We	first	used	RT-PCR	to	analyse	the	activity	of	four	siRNAs	directed	against	α5	subunit	transcript	and	found	that	all	four	decreased	the	expression	of	the	CHRNA5	gene	by	65%	or	more	(Figure	13A).	As	the	most	effective	were	siRNA	II	and	siRNA	IV	we	tested	them	for	 their	ability	 to	decrease	 the	expression	of	 the	α5	subunit.	The	 level	of	endogenous	
α5 protein	 in	A549	cells	 is	 too	 low	to	be	correctly	detected	by	our	α5	subunit	 specific	Abs,	 and	 so	 we	 co-transfected	 the	 cells	 with	 α5 cDNA	 and	 the	 siRNAs.	 Western	 blot	analysis	showed	that	in	comparison	with	control	α5	transfected	cells,	scrambled	siRNA	had	no	effect	but	both	siRNA	II	and	siRNA	IV	reduced	the	α5 protein	expression	(Figure	
13B).	We	then	transfected	A549	cells	with	scrambled	siRNA,	siRNA	II	or	IV,	starved	them	by	means	of	FBS	deprivation,	and	then	treated	them	with	100	nM	nicotine	for	48	hours.	As	shown	in	the	Figure	13C,	 transfection	with	scrambled	siRNA	or	siRNA	IV	did	not	affect	
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the	 basal	 proliferation	 of	 the	 A549	 cells	 or	 the	 pro-proliferative	 effect	 of	 100	 nM	nicotine,	but	siRNA	IV	abolished	 the	nicotine-induced	proliferation	(Figure	 13C)	while	siRNA	 II	 did	 not	 abrogated	 the	 nicotine-induced	 proliferation	 (data	 not	 shown).	Knocking	 down	 the	 α5	 protein	 in	 A549	 cells	 with	 siRNA	 IV	 also	 completely	 blocked	nicotine-induced	P-AKT	and	P-ERK	activation	(Figure	13D).	These	 results	 indicate	 that	 α5−containing	 nAChRs	 are	 also	 involved	 in	 nicotine-mediated	effects	on	cell	proliferation.	
• The	effect	of	siRNAs	on	α9-containing	nAChR	
α9−containing nAChRs	play	an	 important	 role	 in	 the	development	of	 smoking-induced	breast	 cancer	 (Lee	 et	 al.,	 2010),	 and	human	variants	 of	 this	 receptor	 can	dramatically	affect	cell	proliferation	and	neoplastic	transformation	in	human	bronchial	cells	(Chicova	and	Grando,	2011).	For	these	reasons,	we	analysed	the	possible	role	of	these	receptors	in	nicotine-induced	effects	on	A549	cells.	Our	preliminary	RT-PCR	studies	showed	that	the	α9	subunit	is	expressed	in	A549	cells	and	so	we	analysed	the	ability	of	four	α9-directed	siRNAs	to	knowdown	the	α9	subunit.	Using	the	same	protocol	as	that	used	to	study	the	effect	of	α5	and	α7	siRNAs,	we	found	that	all	four	siRNAs	down	regulated	the	α9	mRNA	but	the	most	potent	were	siRNAs	II,	III	and	 IV	 (Figure	14A).	 Unfortunately,	 we	 could	 not	 use	Western	 blotting	 to	 assess	 the	effect	of	α9	siRNAs	on	the	overexpressed	α9	subunit	because	no	α9	subunit	specific	Abs	are	available.	We	 used	 siRNA	 II	 and	 siRNA	 IV	 to	 determine	 whether	α9-containing	 receptors	 were	involved	 in	 the	 nicotine-induced	 proliferation	 and	 intracellular	 signalling	 pathways	 of	A549	cells	(Figure	14B).	
Figure	14C	shows	that	siRNAs	II	and	IV	both	inhibited	nicotine-induced	cell	growth,	and	that	siRNA	II	reduced	the	nicotine-induced	activation	of	P-AKT	after	10	and	30	minutes	(but	not	at	the	other	times)	without	inducing	any	change	in	the	ERK	pathway.	siRNA	IV	showed	a	tendency	to	block	the	activation	of	P-AKT,	but	it	had	no	effect	on	P-ERK.	
	
4.	Oxystilbene	derivatives		In	 collaboration	 with	 the	 group	 of	 Pallavicini	 (University	 of	 Milan),	 our	 group	 have	previously	 synthesised	 and	 characterised	 4-oxystilbene	 derivatives	 as	 selective	 α7	antagonists	(Gotti	et	al.,	1998;	Gotti	et	al.,	2000)	and	found	that	two	of	these	compounds,	F1	(previously	called	MG624)	and	F3,	bind	with	high	affinity	to	the	human	α7	subtype	
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(Ki	 values	 of	 respectively	 161	 and	 100	 nM).	 At	 that	 time	 these	 compounds	were	 not	characterised	for	their	effects	on	α9-containing	receptors,	but	now,	in	collaboration	with	Dr.	McIntosh,	we	have	done	this.	Electrophysiological	experiments	were	used	to	test	the	effects	of	F1	and	F3	on	oocytes	 expressing	 the	α9-α10	 receptor	 subtype.	As	 shown	 in	Figure	15,	both	compounds	reduced	the	ACh	activation	of	the	α9-10	subtype	in	a	dose–dependent	manner	with	IC50	values	of	10.1	nM	(C.I.	5.6-18	nM)	in	the	case	of	F1	and	4.8	nM	 (C.I.	 3.1-7.3	 nM)	 in	 the	 case	 of	 F3.	 These	 values	 are	 very	 similar	 to	 the	 values	determined	 in	the	human	α7	subtype	expressed	 in	oocyte,	 tested	 in	parallel,	and	were	F1	 IC50	 value	 was	 33.5	 nM	 (C.I.	 21-53	 nM)	 and	 16.8	 nM	 for	 F3	 (C.I.	 13.8	 -19.8	 nM)	(Figure	15).		
• Inhibition	 of	 A549	 cell	 viability,	 proliferation	 and	migration	 by	 4-
oxystilbene	derivatives	We	then	characterised	the	activity	of	F1	and	F3	by	treating	A549	cells	with	 increasing	concentrations	 of	 each	 compound	 (10	 nM-	 100	 µM)	 for	 72	 hours	 and	 using	 an	 MTS	assay.	Both	compounds	blocked	the	proliferation	and	viability	of	A549	cells,	with	an	IC50	of	4.3	µM	(F1)	and	11	µM	(F3),	but	were	much	less	active	on	SH-SY5Y	and	in	HepG2	cells	(Figure	16A).	As	F1	was	more	potent	than	F3	in	A549	cells,	we	co-incubated	nicotine	(100	nM)	with	three	different	doses	of	F1	(1	µM,	5	and	10	µM)	for	48	hours,	and	then	manually	counted	the	cells.	Our	results	showed	that	 the	 lowest	concentration	of	F1	(1	µM)	was	not	toxic	but	 blocked	 nicotine-induced	 proliferation,	while	 the	 higher	 concentrations	 (5	 and	 10	
µM)	 administrated	 alone	 decreased	 the	 viability	 of	 control	 cells.	 For	 this	 reason	 the	following	 experiments	were	 conducted	 using	 F1	 at	 the	 concentration	 of	 1	µM	 (Figure	
16B).		We	 next	 investigated	 the	 anti-migratory	 activity	 of	 F1	 in	 the	A549	 cell	 line	 using	 the	wound-healing	assay.	The	cells	treated	with	nicotine	(100	nM)	quickly	closed	the	scratch	(as	 previously	 shown),	whereas	 those	 treated	with	 nicotine	 and	F1	had	 increased	 the	time	to	wound	closure.	This	suggests	that	F1	inhibits	the	A549	cell	migration	induced	by	nicotine	(Figure	16C).	We	 analysed	 the	 effect	 of	 F1	 on	 intracellular	 ERK	 and	 AKT	 signalling	 by	 treating	 the	A549	cells	with	nicotine	 (100	nM)	 for	different	 times	 (from	 five	minutes	 to	one	hour)	alone	 or	 in	 combination	 with	 F1	 (1	 µM).	 Western	 blotting	 analyses	 showed	 that	 F1	
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significantly	abrogated	the	nicotine-induced	activation	of	AKT	and	ERK	after	five	and	ten	minutes	of	nicotine	stimulation	(Figure	17A).	
• F1	activates	ROS	production	It	 is	 becoming	 gradually	 clear	 that	 ROS	 play	 an	 important	 role	 in	 the	 biology	 of	tumourigenesis	(Sullivan	and	Chandel,	2014). As	cancer	cells	have	increased	ROS	levels,	they	may	be	selectively	sensitive	to	the	damaging	effects	of	further	increasing	ROS.		We	examined	the	possible	role	of	F1	in	mediating	ROS	production.		A549	 cells	 were	 treated	 with	 increasing	 concentrations	 of	 F1	 (10	 nM-10	 µM)	 for	 24	hours.	ROS	production	was	measured	using	the	DCF-DA	probe,	and	the	results	showed	that	F1	increases	ROS	production	at	concentrations	of	50,	100,	250	and	500	nM	(Figure	
17B).		However,	we	still	do	not	know	whether	this	mechanism	is	mediated	by	nAChRs	or	is	an	intrinsic	feature	of	the	drug,	passing	through	the	cell	membrane.		
4.1	New	oxystilbene	derivatives		It	has	recently	been	reported	that	derivatives	of	resveratrol,	mitochondria-targeted	via	a	4-triphenylphosphoniumbutyl	 iodide	 (BTPI)	 group	 O-linked	 at	 position	 3-	 or	 4′-,	 are	cytotoxic	 in	 vitro	 and	 selectively	 induce	 mainly	 the	 necrotic	 death	 of	 fast-growing	tumour	 cells	 when	 administrated	 in	 the	 low	 μM	 range.	 It	 has	 also	 been	 shown	 that	“capping”	 the	 resveratrol's	 free	 hydroxyls	with	 acetyl	 or	methyl	 groups	 increases	 the	cytotoxicity	 of	 such	derivatives	 and	 their	 effectiveness	 as	 respiratory	 chain	 inhibitors,	and	promotes	ROS	generation	(Sassi	et	al.,	2014).		As	 our	 4-oxystylbene	 derivatives	 F1	 and	 F3	 share	 the	 stylbene	 scaffold	 and	 a	 para	positioned	 ω-onium	 alkyloxy	 group	 with	 the	 BTPI	 derivatives	 of	 3,5-dimethyl	resveratrol,	 we	 decided	 to	 synthesise,	 a	 the	 3,5-dimethyl	 resveratrol-analogue	 of	 F1	(RS12),	 and	 a	 derivative	 (RS18)	 that	 was	 further	 modified	 by	 replacing	trialkylammonium	with	a	triphenylphosphonium	head	(Figure	18A).	We	determined	the	α7affinity	and	the	effect	on	cell	viability	of	the	new	compounds	RS12	and	RS18	and	found	that	the	former	has	similar	affinity	(Ki	186	nM)	but	lower	potency	(IC50	of	12	µM)	to	those	of	F1,	whereas	the	latter	has	lower	affinity	than	F1	(Ki	1.52	µM)	but	slightly	higher	potency	(IC50	2.5	µM).	The	effects	of	these	compounds	are	cell	specific	because	they	had	no	effect	on	HepG2	or	SH-SH5Y	cells	(Figure	18B).	
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Figure	1:	mRNA	expression	 level	of	different	nAChRs	 subunits	 in	non-small	 cell	 lung	 cancer	 cell	 lines	A549	 (A)	and	
H1975	(B) qRT-PCR	analysis	of	the	human	adenocarcinoma	cell	lines	A549	(A)	and	H1975	(B)	and	the	neuroblastoma	cell	line	SH-SY5Y	(C)	in	 the	 presence	 of	 specific	 TaqMan®	 primers	 and	 probe	 assay	 for	 nAChR	 subunits.	 Data	 are	 shown	 as	 relative	 expression	normalised	to	endogenous	GAPDH	expression,	according	to	the	2^-ΔCt	method. 
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Figure	2:	Analysis	of	antibody	specificity 	A)	Characterisation	of	α7	Abs	tested	on	hippocampus	membrane	of	wildtype	(WT)	and	α7	knockout	(KO)	mice	(a),	and	α−Bgtx	receptors	purified	from	SH-SY5Y	cells	(b).	Anti- α7	Abs	directed	against	the	α7	COOH	peptide	and	the	Cyt	peptide	were	tested	on	untransfected	and	α7	transfected	SH-SY5Y	and	HEK	cells	(c). B)	Anti-α3,	α5	and	b4	Abs	tested	on	HEK	cells	transfected	with	the	a3b4	and	a3b4a5	subtypes. 
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Figure	3:	Analysis	of	native	nAChR	receptors	expressed	in	NSCLC	and	neuroblastoma	cells	 A)	Western	blotting	analysis	of	A549,	H1975	and	SH-SY5Y	cell	extracts	immunoprecipitated	with	anti-α5	(lane	a),	anti-
α7	(lane	b)	and	control	IgG	(lane	c)	and	probed	with	anti-α5	Abs. B)	Diagram	of	the	purification	experiment	and	Western	blot	analysis	of	the	α−Bgtx	affinity	receptors	purified	from	A549,	H1975	and	SH-SY5Y	cells	and	Western	blotting	analysis	of	 the	purified	α-Bgtx	receptors	probed	with	anti	α7	(left)	or	anti	α5	(right)	Abs. 
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Figure	4:	Effects	of	chronic	nicotine	exposure	on	cell	viability,	proliferation	and	migration	 in	NSCLC	A549	and	
H1975	cells Chronic	(72	hours)	exposure	 to	the	indicated	concentrations	of	nicotine	increased	the	viability	(A	left)	and	number	(B	left)	 of	 A549	 cells,	 but	 not	 H1975	 cells	 (A	 and	 B	 right).	 Results	 are	 the	 average	 of	 three	 experiments	 performed	 in	triplicate.	 The	analysis	was	made	using	one-way	ANOVA	followed	by	post	hoc	Bonferroni	test	for	cell	count	or	Dunn	test	for	cell	viability	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). C)	Nicotine-induced	migration	was	evaluated	using	the	wound-healing	assay.	At	time	0	wells	containing	A549	cells	were	scratched	and	not	exposed	(ctrl)	or	exposed	to	100	nM	nicotine.	The	cells	were	imaged	after	24	and	48	hours,	and	the	wound	width	of	nine	random	views	of	the	nicotine-treated	cells	was	measured	and	compared	with	that	of	the	untreated	cells. 
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Figure	5:	Analysis	of	nicotine-induced	AKT	and	ERK	pathway	activation	in	A549	and	H1975	NSCLC	cells A549	(A	and	B	left)	and	H1975	(A	and	B	right)	cells	were	treated	with	100	nM	nicotine	for	the	indicated	times	and	the	 incubation	 was	 blocked	 by	 adding	 sample	 buffer.	 Proteins	 were	 separated	 on	 9%	 acrylamide	 SDS	 gels,	transferred	 to	 nitrocellulose	 and	 probed	 with	 antibodies	 directed	 against	 AKT	 and	 P-AKT,	 ERK	 and	 P-ERK	 as	described	in	the	Methods. The	Western	blot	analysis	is	expressed	as	the	P-AKT	/AKT	and	P-ERK/	ERK	ratio	at	the	indicated	time	of	nicotine	stimulation	 (0,	 5,	 10,	 30	 and	60	minutes).	 The	 graphs	 show	 the	mean	 values	 ±	 SEM	 obtained	 in	 at	 least	 three	different	 experiments	performed	 in	duplicate	 or	 triplicate.	A	 representative	blot	 at	 the	 corresponding	 times	 is	shown	above	the	graph.	The	Western	blotting	data	were	statistically	analyzed	using	one-way	ANOVA	followed	by	Dunn's	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001,	versus	untreated	cells). 
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Figure	6:	α−Bungarotoxin	inhibits	nicotine-induced	A549	cell	proliferation	and	signalling	activation A)	Effect	of	100	nM	nicotine	treatment	for	48	hours	in	presence	or	absence	of	1uM	α-Bgtx	on	A549	cell	number	(left)	and	viability	(right).	Graphs	show	 the	mean	values	±	SEM	obtained	by	 analysis	 of	 three	different	experiments	performed	 in	triplicate.	The	analysis	was	made	using	one-way	ANOVA	followed	by	post	hoc	Bonferroni	test	for	cell	count	or	Dunn	test	for	cell	viability	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). B-C)	 Western	 blot	 analysis	 of	 AKT	 and	 ERK	 pathway	 activation	 in	 A549	 and	 H1975	 cells	 exposed	 to	 nicotine	 in	 the	presence	or	absence	of	1	µM	α−Bgtx.	Cells	were	pre-incubated	or	not	for	30	minutes	with	1	µM	α−Bgtx	and	then	treated	with	100	nM	nicotine	for	the	indicated	times.	The	graphs	show	the	mean	values	±	SEM	obtained	by	analysing	at	least	three	different	 experiments	 performed	 in	 duplicate	 or	 triplicate.	 A	 representative	 blot	 at	 the	 corresponding	 times	 is	 shown	above	each	graph.	 Western	blotting	data	were	statistically	analysed	using	one-way	ANOVA	followed	by	Dunn's	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). 
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Figure	7:	Methyllycaconitine	inhibits	nicotine-induced	A549	cell	proliferation	and	migration A)	The	effect	of	treatment	with	100	nM	nicotine	for	48	hours	in	the	presence	or	absence	of	500	nM	MLA	on	A549	cell	number	(left)	and	viability	(right)	is	shown.	The	analysis	was	made	using	one-way	ANOVA	followed	by	post	hoc	Bonferroni	test	for	cell	count	or	Dunn	test	for	cell	viability	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). B)	Nicotine-induced	migration	was	evaluated	using	wound-healing	assay.	Wells	containing	A549	cells	were	scratched	at	time	0	 and	not	 exposed	 (ctrl)	 or	 exposed	 to	100	nM	nicotine	 in	 the	presence	or	 absence	of	 500	nM	MLA.The	 graph	 shows	 the	results	 obtained	by	 imaging	 the	 cells	 24	 and	 48	hours	 after	 the	 scratch	 and	measuring	 the	wound	width	 in	nine	 random	views	compared	to	untreated	cells. C-D)	Western	blot	analysis	of	ERK	and	AKT	pathway	activation	in	A549	and	H1975	cells	by	100	nM	nicotine	in	the	presence	or	absence	of	500	nM	MLA	for	the	indicated	times.	Cells	were	then	lysed	and	loaded	onto	9%	acrylamide	SDS	gels	and	probed	with	antibodies	against	AKT,	P-AKT,	ERK	and	P-ERK.	 The	graphs	show	the	mean	values	±	SEM	obtained	by	analysing	at	least	three	different	experiments	performed	in	duplicate	or	triplicate.	 A	 representative	 blot	 at	 the	 corresponding	 times	 is	 shown	 above	 each	 graph.	 The	Western	 blotting	 data	 were	statistically	analysed	using	one-way	ANOVA	followed	by	Dunn's	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001).	 	 
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Figure	8:	The	α7	subtype-selective	toxin	AR	blocks	the	proliferative	effect	of	nicotine A)	The	effect	of	treatment	with	100	nM	nicotine	for	48	hours	in	the	presence	or	absence	of	1	µM	of	toxin	AR	on	the	number	of	A549	cells	is	shown.	The	results	are	the	average	of	three	experiments	performed	in	triplicate,	and	are	expressed	as	the	number	of	proliferative	cells	in	each	well.	The	statistical	analysis	was	made	using	one-way	ANOVA	followed	by	a	post	hoc	Bonferroni	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001) B)	Western	 blot	 analysis	ERK	and	 AKT	pathway	 activation	 in	A549	 cells	 in	 the	 presence	or	 absence	of	 1	µM	 toxin	 AR.	The	method	 is	 the	same	 as	 that	 described	 in	part	C-D	of	Figure	6	except	 for	 the	 fact	 that	1	µM	toxin	AR	was	used.	The	Western	blotting	data	were	statistically	analysed	using	one-way	ANOVA	followed	by	Dunn's	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). 
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Figure	9:	The	α9	subtype-selective	toxin	RG-I	blocks	the	proliferative	effect	of	nicotine A)	The	effect	of	treatment	with	nicotine	(100	nM)	for	48	hours	in	the	presence	or	absence	of	1	µM	RG-I	on	the	number	of	A549	cells	 is	shown.	The	results	are	the	average	of	three	experiments	performed	in	triplicate,	and	are	expressed	as	the	number	of	proliferative	cells	in	each	well.	The	statistical	analysis	was	made	using	one-way	ANOVA	followed	by	a	post	hoc	Bonferroni	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001) B)	Western	blot	analysis	ERK	and	AKT	pathway	activation	in	A549	cells	in	the	presence	or	absence	of	1	µM	RG-I.	The	method	is	the	same	as	that	described	in	part	C-D	of	Figure	6	except	for	the	fact	that	1	µM	RG-I	was	used. The	Western	blotting	data	were	statistically	analysed	using	one-way	ANOVA	followed	by	Dunn's	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). 
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Figure	10:	Chronic	treatment	with	nicotine-derived	nitrosamines	or	the	α7	agonist	(ICH3)	increases	the	number	
of	A549	cells	 A549	cells	were	chronically	treated	(48	hours)	with	increasing	concentrations	of	nitrosamines	NNN	(A)	or	NNK	(B)	or	(C)	the	α7	agonist	(ICH3).	The	two	nicotine-	derived	nitrosamines	increased	cell	proliferation	at	low	doses	(10	nM),	whereas	ICH3	increased	the	number	of	A549	cells	in	a	dose-dependent	manner. The	results	are	the	average	of	three	experiments	in	triplicate,	and	are	expressed	as	the	number	of	viable	cells	in	each	well.	The	statistical	analysis	was	performed	using	one-way	ANOVA	followed	by	post	hoc	Bonferroni	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001versus	untreated	cells). 
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Figure	11:	siRNA	knockdown	of	the	α7	subunit	in	A549	cells A)	RT-PCR	analysis	of	α7	subunit	mRNA	level	in	A549	cells	transfected	for	48	hours	with	75	pmoli	of	the	indicated	α7	siRNAs.	The	values	are	expressed	taking	the	level	of	a7	subunit	mRNA	present	in	cells	trasfected	with	scrambled	siRNA	as	100%. B)	Western	blot	analysis	of	A549	cells	transfected	with	α7	cDNA	and	or	not	the	α7	siRNA	II	and	siRNA	IV.	 C)	Effect	of	knocking	down	the	α7	subunit	on	nicotine-induced	cell	proliferation.	 A549	cells	were	transfected	with	75	pmoli	of	siRNA	II	or	siRNA	IV,	treated	for	48	hours	with100	nM	nicotine,	and	then	counted.	The	results	shown	in	the	graph	are	the	average	of	three	experiments	performed	in	triplicate,	and	are	expressed	as	the	number	of	proliferative	cells	 in	each	well.	The	statistical	analysis	was	made	using	one-way	ANOVA	followed	by	a	post	hoc	Bonferroni	 test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001).	Both	siRNA	II	and	IV	reduced	the	nicotine-induced	proliferation	of	A549	cells. 
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Figure	12:		α7	siRNA	reduces	the	nicotine-induced	activation	of	P-ERK	and	P-AKT	in	A549	cells A549	cells	were	transfected	with	scrambled	siRNA	or	α7	siRNAs	II	and	IV,	starved	one	day,	and	then	stimulated	with	nicotine	100	nM	for	the	indicated	times	and	then	lysed.	Proteins	were	separated	on	9%	acrylamide	SDS	gels,	electro-transferred	to	nitrocellulose	and	then	probed	with	the	antibodies	directed	against	AKT,	P-AKT,	ERK	and	P-ERK.	The	bar	graphs	show	the	quantifications	as	mean	values	±	S.E.M	of	at	least	three	independent	experiments.	 The	Western	blotting	data	were	statistically	analysed	using	one-way	ANOVA	followed	by	Dunn's	test	 (*P<	0.05,	**	P<	0.01	and	***P<	0.001). 
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Figure	13:	siRNA	knockdown	of	the	α5 subunit	reduces	nicotine-induced	proliferation	and	activation	of	P-ERK	and		
P-AKT	in	A549	cells A)	RT-PCR	analysis	of	α5	subunit	mRNA	level	in	A549	cells	transfected	for	48	hours	with	75	pmoli	of	the	indicated	siRNAs.	The	values	are	expressed	taking	the	scrambled	siRNA	as	100%. B)	Western	blot	analysis	of	A549	cells	transfected	with	α5	cDNA	with	or	without	α5	siRNA	II	and	siRNA	IV. C)	Effect	of	siRNA	IV	on	nicotine-induced	cell	proliferation.	A549	cells	were	transfected	with	siRNA	IV,	treated	for	48	hours	with	100	nM	nicotine,	and	then	counted.	 D)	Western	blot	analysis	of	P-ERK	and	P-AKT	pathway	activation	in	A549	cells	in	the	presence	or	absence	of	100	nM	nicotine	and	
α5	siRNA	IV.	 Nicotine-induced	 proliferation	 as	 ERK	 and	 AKT	 pathway	 activation	 in	 the	 presence	 of	 scrambled	 siRNA	 or	 α5	 siRNAs	 were	measured	 in	 at	 least	 three	 independent	 experiments	 performed	 in	 triplicate.	 The	 statistical	 analysis	was	made	using	one-way	ANOVA	followed	by	Bonferroni's	post	hoc	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001	versus	untreated	cells)	or	Dunn	test. 
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Figure	14:	siRNA	knockdown	of	the	α9	subunit	reduces	nicotine-induced	proliferation	and	activation	of	P-ERK	and		
P-AKT	in	A549	cells A)	RT-PCR	analysis	of	α9	subunit	mRNA	level	in	A549	cells	transfected	for	48	hours	with	the	indicated	α9	siRNAs	.The	values	are	expressed	taking	the	level	of	α9	subunit	mRNA	present	in	the	cells	transfected	with	scrambled	siRNA	as	100%. B)	Effect	of	knocking	down	the	α9	subunit	on	nicotine-induced	cell	proliferation.	A549	cells	transfected	with	siRNA	II	or	siRNA	IV	were	treated	for	48	hours	with100	nM	nicotine,	and	then	counted.	 C)	Western	blot	analysis	of	ERK	and	AKT	pathway	activation	in	A549	cells	in	the	presence	or	absence	of	100	nM	nicotine	with	or	without	the	α9	siRNA	II	or	siRNA	IV.	 The	statistical	analysis	of	nicotine-induced	proliferation	and	ERK	and	AKT	pathway	activation	in	the	presence	of	scrambled	siRNA	or	α9	siRNAs		were	made	in	at	least	three	independent	experiments	performed	in	triplicate	using		one-way	ANOVA	followed	by	Dunn	test	(*P<	0.05,	**	P<	0.01	and	***P<	0.001,	respectively		versus	untreated	cells	)	or	Dunn	test. 
	 79	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
h 
Figure	15.	Effects	of	F1	and	F3	on	oocyte-xpressed	α9-α10	and	α7-containing		nicotinic	receptors	 Oocytes	were	 injected	with	mRNA	encoding	 the	human	α9-α10	(left)	or	α7	(right)	subunits.	Maximal	 function	(Imax)	was	measured	in	each	group	by	means	of	perfusion	with	the	full	agonist	ACh	(100	µM). Concentration–effect	 curves	 of	 F1	 and	 F3	 inhibition	 of	 100	 µM	 ACh-induced	 ion	 currents.	 Within	 each	 group,	 all	responses	were	normalized	to	an	initial	control	stimulation	with	100	µM	ACh.	The	data	points	represent	mean	values	±	SEM.	 Drug	 potency	 and	 efficacy	 parameters	were	 calculated	 using	 non-linear	 least-squares	 curve	 fitting	 to	 the	 Hill	equation	(see	Methods).	 
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Figure	16:	F1	decreases	A549	line	cell	viability,	proliferation	and	migration A)	A549	 cells	 viability	was	 tested	using	 the	MTS	assay.	Cells	were	plated	 and	 incubated	with	F1	 (a)	or	F3	 (c)	 for	 72	hours	at	increasing	concentration.	F1	was	tested	also	in	SH-SY5Y	and	HepG2	cells	(b). The	 data	 points	 are	 the	 mean	 values	 ±	 SEM	 of	 three	 experiments	 in	 which	 each	 drug	 concentration	 was	 tested	 in	triplicate. B)	F1	(1	µM)	abolished	the	chronic	(72	hour)	nicotine-induced	increase	in	the	number	of	A549	cells.	 The	analysis	was	made	using	one-way	ANOVA	followed	Dunn	test	for	cell	viability	or	by	post	hoc	Bonferroni	test	for	cell	count	(*P<	0.05,	**	P<	0.01	and	***P<	0.001). C)	 F1	 	 (1	µM)	decreased	 nicotine-induced	migration	by	wound-healing	 assay.	 At	 time	0,	 wells	 containing	A549	 cells	were	scratched	and	not	exposed	(ctrl)	or	exposed	to	100	nM	nicotine	in	the	presence	or	absence	of	1	µM	F1.		The	cells	were	 imaged	 after	 24	 and	 48	 hours,	 and	 the	 wound	 width	 of	 nine	 random	 views	 of	 the	 nicotine-treated	 cells	 was	measured	and	compared	with	that	of	the	untreated	cells. 
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Figure	17:	F1	blocks	the	nicotine-induced	activation	of	P-ERK	and	P-AKT	and	increases	ROS	production	 A)	Western	blot	analysis	of	ERK	and	AKT	pathway	activation	upon	nicotine	stimulation	in	A549	cells	with	or	without	F1	(1	µM). B)	The	A549	cells	were	seeded	in	black	96-well	plates,	pre-treated	with	the	indicated	concentrations	of	F1	for	24	hours,	and	 then	 incubated	 with	 25	μM	 DCFH-DA	 for	 30	minutes	 at	 37°C.	 Fluorescence	 was	 measured	 at	 485	nmex/530	nmem	using	a	microplate	reader.	The	results	are	expressed	as	the	increase	in	fluorescence	units/µg	of	cell	proteins	taking	as	the	production	of	ROS	in	untreated	cells	as	100%. 
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Figure	18.	Characterisation	of	new	oxystilbene	derivatives	 The	new	componds	RS12	and	RS18	were	tested	for	their	α7	affinity		(B)	and	effect	on	A549	cell	viability	by	MTS	assay		(A). B)	 Ki	 affinities	 were	 determined	 from	 inhibition	 of	 125I α-Bgtx	 binding	 by	 inhibition	 curves	 whereas	 the	 IC50values	 were	determined	from	dose-response	curves	with	the	MTS	assay.	 
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DISCUSSION	 	Many	 literature	 data	 indicate	 that	 in	 lung	 tumours	 nAChRs	 are	 central	 regulatory	elements,	which	mediate	 nicotine	 and	 nicotine	 derivates	 cellular	 responses	 (Schall	 and	Chellapan,	2014;	Grando,	2014).		Delineating	the	biological	and	pharmacological	effects	of	nicotine	on	lung	cancer	cells	at	receptor	subtype	level	represents	a	big	challenge	for	cancer	prevention	and	treatment.	As	in	the	case	of	the	nAChRs	express	in	the	CNS,	the	function,	ligand-binding	affinity	and	pharmacological	profile	of	 lung	 tumoural	nAChRs	depend	on	 their	 subunit	 composition.	For	this	reason	we	used	RT-PCR	to	analyse	the	nAChR	subunit	gene	expression	levels	in	order	to	make	a	quantitative	comparison	between	the	A549	and	H1975	NSCLC	cell	lines.		The	H1975	cell	line	was	established	in	July	1988,	while	the	A549	cell	line	was	developed	in	1972	by	D.J.	Giard,	et	al.	through	cultures	of	explants	of	lung	carcinoma	tissue	of	a	58-year-old	 Caucasian	 male.	 In	 nature	 A549	 cells	 are	 responsible	 for	 the	 diffusion	 of	substances,	 such	 as	 water	 and	 electrolytes,	 across	 the	 alveoli	 of	 lungs.	 They	 grow	adherently,	and	form	confluent	monolayers	in	vitro.			Many	scientific	papers	have	reported	that	this	cell	line	expresses	the	mRNAs	for	different	nAChR	 subunits,	 but	 the	 native	 subtypes	 are	 not	 yet	 well	 identified.	 It	 has	 also	 been	reported	that	nicotinic	drugs	can	influence	the	proliferation	of	these	cells	and	that	A549	luciferase-labelled	cells,	commercially	available,	can	be	used	for	 in	vivo	bioluminescence	imaging	 to	 study	 the	 effects	 of	 nicotinic	 toxins	 or	 compounds	 in	 NOD/SCID	 mice	xenografted	 with	 A549	 cells.	 The	 properties	 of	 A549	 cell	 line	 to	 be	 very	 manageable,	resistant	 and	 little	 subject	 to	 contamination	 or	 cell	 death	make	 them	 the	most	 suitable	scientific	model	for	our	in	vitro	experimental	analyses.		We	demonstrated	that	both	cell	lines	showed	a	high	level	of	transcripts	for	the	α5	subunit	and	the	α7	dup	protein;	the	other	subunits	were	only	found	in	one	or	the	other	cell	line.	In	particular	H1975	cells	did	not	express	α7 mRNA	and	the	expression	of	α9 mRNA	was	very	low.	Treatment	 of	 A549	 and	H1975	 cells	with	 nicotine	 concentrations	 in	 the	 range	 of	 those	detected	 in	 serum	 of	 smokers	 (10-8	–	 10-7	M)	 induced	 proliferation	 in	 A549	 but	 not	 in	H1975	cells.	Nicotine	 induced	a	dose-dependent	 increase	 in	S-phase	entry	of	A549	cells	that	 was	 greatest	 at	 a	 nicotine	 concentration	 of	 100	 nM	 -	 1µM	 thus	 suggesting	 the	
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involvement	 of	 cell-specific	 nAChRs	 in	 nicotine-mediated	 effects	 expressed	 in	 this	 cell	line.	 We	 found	 that	 the	 proliferation	 of	 A549	 cells	 was	 also	 induced	 by	 a	 low	concentration	 (10	 nM)	 of	 the	 nitrosamines	 NNN	 and	 NNK,	 the	 most	 harmful	 tobacco	components,	because	they	directly	bind	the	DNA,	form	DNA	adducts	and	cause	mutations.		In	order	to	identify	the	subtypes	involved	in	this	proliferative	effect	we	used	two	nAChR	antagonists	 (α−Bgtx	 and	 MLA)	 that	 act	 on	 α7	 and	 α9	 receptors,	 and	 found	 that	 both	blocked	 the	 nicotine-induced	 proliferation	 in	 A549	 cells.	 In	 order	 to	 discriminate	 the	activity	of	the	two	subtypes,	we	performed	separate	proliferation	assays	in	the	presence	of	α7	(AR)	and	α9	(RG-I)	selective	toxins,	and	found	that	both	blocked	nicotine–induced	proliferation.	 	The	 involvement	of	 the	α7	subtype	 in	nicotine-induced	proliferation	was	also	 confirmed	 by	 the	 fact	 that	 a	 very	 low	 concentration	 of	 the	 subtype	 selective	 α7	agonist	ICH3	also	increased	cell	proliferation.		It	 has	 been	 widely	 reported	 that	 cigarette	 smoking	 not	 only	 induces	 cancer	 cell	proliferation	but	might	also	promote	their	metastatic	spread	(Murin	et	al.,	2004).	Xu	et	al.	(2006)	 have	 demonstrated	 that	 invasion	 and	 metastasis	 are	 parts	 of	 a	 sophisticated	process	 that	 involves	 alterations	 in	 cell	 adhesion	 molecules	 and	 changes	 in	 cadherin	composition.		We	 found	 that	 A549	 cells	 increased	 their	migratory	 activity	 upon	 nicotine	 stimulation,	and	 that	MLA	blocked	 this	 increase.	Our	 findings	 are	 in	 agreement	with	 those	 of	 other	studies	showing	the	importance	of	the	α7-receptor	in	nicotine-induced	cell	proliferation	and	migration.	However	the	role	of	α7	receptors	in	A549	cell	proliferation	is	debated	because	one	study,	originally	 found	 that	 the	 proliferation	 of	 transplanted	 A549	 cells	 in	 nude	 mice	 can	 be	inhibited	by	α-cobratoxin,	an	α7	receptor	antagonist	(Paleari	et	al.,	2009),	but	the	authors	subsequently	retracted	some	of	their	findings	and	later	studies	of	in	vivo	tumour	growth	in	orthotopic	mice	treated	with	the	same	dose	of	a-cobratoxin	did	not	find	any	significant	reduction	in	tumour	growth	or	survival	(Alama	et	al.,	2011).	However,	our	data	indicating	that	 in	 vitro	 MLA	 abrogated	 the	 pro-invasive	 effects	 induced	 by	 nicotine	 suggests	 that	blocking	nAChRss	 containing	 the	α9	and/or	α7	subunit	 can	 reduce	 specific	 lung	cancer	invasiveness.			
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Although	nAChRs	are	ion	channels	mediating	the	influx	of	Na+	and	Ca2+	and	the	efflux	of	K+,	 their	 activation	 by	 a	 ligand,	 such	 as	 nicotine,	 may	 elicit	 both	 ionic	 and	 non-ionic	signalling	 events	 regulating	 the	 phosphorylation	 and	 dephosphorylation	 of	 target	proteins.	 We	 therefore	 analysed	 which	 intracellular	 pathways	 are	 involved	 in	 the	nicotine-induced	proliferation	and	migration	of	A549	cells.		Nicotine	stimulation	of	nAChRs	triggered	several	protein	kinase-signalling	cascades,	thus	simultaneously	 altering	 gene	 expression	 and	 inducing	 cellular	 changes.	 We	 confirmed	that	nicotine	increased	P-ERK/ERK	and	P-AKT/AKT	ratios	after	very	short	exposure	(five	–ten	minutes),	and	 that	 the	α7/α9	toxins	(MLA	and	α−Bgtx)	as	well	as	 the	α9-selective	toxin	 (RG-I),	and	 α7-selective	 toxin	 (AR)	 abrogated	 these	 intracellular	 signalling	activations.	We	 chose	 these	 pathways	 because	 many	 studies	 have	 shown	 that	 the	 ERK	 pathway	modulates	 cell	 proliferation	 and	 survival.	 It	 is	 thought	 that	 ERK	 activation	 triggers	 cell	cycle	 progression	 and	 inhibits	 cell	 death	 by	 inactivating	 pro-apoptotic	 factors	 and/or	overexpressing	 and	 activating	 anti-apoptotic	 factors	 such	 as	Bcl2	 (Balmanno	 and	Cook,	2009)	 and	 AKT,	 is	 a	 critical	 pathway	 for	 survival	 signals	 in	 cancer	 cells	 (Sheng	 et	 al.,	2009).	 The	 overexpression	 of	 serine	 473-phosphorylated	 AKT	 has	 been	 observed	 in	 a	wide	 range	 of	 human	 cancers,	 including	 colorectal	 and	 lung	 cancer	 (Roy	 et	 al.,	 2002).	Moreover,	AKT	activation	 seems	 to	be	 correlated	with	 advanced	disease	 and/or	 a	poor	prognosis	(Bellacosa	et	al.,	2005).			The	use	of	nAChR-subunit	antibodies,	has	shown	that	nAChR	subunits	are	also	expressed	on	the	mitochondrial	outer	membrane	of	lung	cells	(mt-nAChRs)	(Kalashnyk	et	al.,	2012;	
Gergalova et al., 2011)	 and	 that	 these	 receptors	 non-covalently	 connect	 to	 voltage-dependent	anion	channels	and	control	cytcrome	C	release	by	inhibiting	the	mitochondrial	permeability	 transition	pore	opening	(Saxena	et	al.,	2011;	Yu	et	al.,	2011).	Although	the	specificity	of	many	antibodies	against	nAChRs	has	been	questioned	and	 the	presence	of	mt-nAChR	 is	 still	 an	open	question,	 the	 fact	 that	nicotine-induced	 cell	 proliferation	and	intracellular	 signalling	 in	 A549	 cells	 was	 blocked	 by	 peptide	 toxins,	 that	 are	 not	 cell	permeable	and	can	only	act	at	the	plasma	membrane,	indicate	that	the	effects	of	nicotine	are	due	to	the	activation	of	nAChRs	in	the	plasma	membrane.			We	also	verified	whether	the	nAChR	subunit	genes	CHRNA5	CHRNA7	and	CHRNA9,	were	involved	 in	nicotine-induced	A549	cell	growth	and	proliferation	by	silencing	 the	α5,	α7	
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and	α9	subunits.	We	found	that	subunit-specific	siRNAs	abrogated	nicotine	 induced	cell	proliferation	 and	 the	 activation	 of	 ERK	 and	 AKT	 intracellular	 signalling	 pathways.	 The	involvement	 of	α7	 in	 ERK	 and	AKT	 activation	 has	 already	 been	 demonstrated	 in	 other	cancer	cell	 lines,	but	we	demonstrated	that	also	α9-containing	receptors	play	important	role	in	the	nicotine-induced	activation	of	P-AKT	and	P-ERK.	This	is	significant	because	α9-	containing	receptors	have	so	far	been	primarily	associated	with	breast	cancer	(Lee	CH	et	al.,	 2010).	 Various	 groups	 have	 shown	 that	 the	 specific	 inhibition	 of	 α9	 nAChRs	concomitantly	 inhibit	breast	cancer	cell	growth,	soft-agar	colony	formation,	and	tumour growth	 in	 SCID	 mice	 (Chen	 et	 al.,	 2011),	 whereas our	 pharmacological	 and	 silencing	studies	demonstrate that	they	are	involved	in	the	development	of	lung	cancer,	suggesting	a	potential	therapeutic	target	in	NSCLCs,	expressing	this	subunit.	RT-PCR	analysis	showed	that	the	α5	subunit	mRNA	is	highly	expressed	in	A549	cells,	and	that	 silencing	 this	 accessory	 subunit	 decreases	 nicotine-induced	 cell	 proliferation	 and	abrogates	 nicotine-induced	 P-AKT	 activation.	 	 Our	 results	 are	 in	 agreement	with	 those	reported	by	Ma	X.	 et	 al.	 (2014).	He	 found	 that	 silencing	α5-containing	nAChRs	 in	A549	cells	 significantly	 inhibited	 nicotine-induced	 cell	 proliferation	 and	 attenuated	 nicotine-induced	 up-regulation	 of	 HIF-1α	 and	 VEGF.	 However	 these	 results	 are	 different	 from	those	reported	by	Krais	et	al.	(2011),	who	demonstrated	that	silencing	the	CHRNA5	gene	or	 inhibiting	 α5-containing	 receptors	 nAChRs	 in	 non-transformed	 bronchial	 cells	 and	lung	cancer	cell	 lines	 increased	cell	motility	and	 invasiveness,	 thus	 indicating	that	 these	receptors	are	negative	regulators	of	nicotine-induced	cell	migration.	These	 different	 results	 may	 be	 explained	 by	 the	 fact	 that	 the	 silencing	 effect	 was	quantitatively	different	 in	 the	different	studies	and/or	that	different	sub-clones	of	A549	cells	were	used.		
α5	is	an	accessory	subunit	and	can	only	exert	 its	effect	when	it	 is	associated	with	other	nicotinic	 subunits,	 and	 so	 we	 tried	 to	 identify	 the	 possible	 subtype(s)	 containing	 this	subunit.	Previous	studies	in	normal	bronchial	cells	have	shown	that	(α3β2)2α5 receptors	are	 expressed	 during	 wound	 healing	 in	 normal	 mucosa	 and	 that	 this	 expression	 is	particularly	high	at	the	edges	of	wounds	(Tournier	et	al.,	2006).	We	used	subunit-specific	anti-α5	Abs	to	immunoprecipitate	α5	subunits	from	A549	cell	extracts	and	probed	them	with	Abs	directed	against	other	nAChR	subunits.	The	fact	that	there	was	no	anti- α3,	anti-
β2	and	anti- β4	subunit	antibody	labeling	excluded	the	presence	of	the	α3α5β2 or	α3α5β4	subtypes	in	A549	or	H1975	cells.	
	 87	
It	has	been	reported	that	a	possible	α7α5	subtype	 is	present	 in	cancer	cells.	 In	order	to	verify	 this	 we	 purified	 the	 nAChRs	 from	 A549	 cells	 using	α−Bgtx	 covalently	 bound	 to	Sepharose	4B.	Western	blot	analysis	of	 the	affinity	purified	α−Bgtx	receptors	shows	the	presence	of	the	α7	subunit	but	not	the	α5	subunit	(Figure	3B).		Although	other	findings	suggest	 that	α5-containing	 nAChRs	 contributes	 to	 cancer	 cell	 growth	 and	 progression,	further	 studies	 are	 needed	 to	 identify	 the	 subunit	 composition	 of	 the	 subtype	 that	mediates	this	effect	in	A549	cells.			Stimulated	by	recent	data	(Brown	et	al.,	2012)	showing	that	an	old	molecule	MG624	(also	called	F1)	previously	characterized	by	our	group,	potently	suppresses	the	proliferation	of	primary	 human	micro	 vascular	 endothelial	 cells	 of	 the	 lung	 (HMEC-Ls)	 and	 suppresses	the	in	vivo	angiogenesis	of	NCi-H69	SCLC	tumours	in	the	chorioallantonic	membrane	and	nude	mice	model,	we	decided	to	characterise	its	anti-proliferative	effects	on	A549	cells.	We	 have	 previously	 reported	 that	 F1	 is	 highly	 selective	 on	 α7	 nAChRs	 expressed	 in	chicken,	 rat,	monkey	and	human	brain	membranes	 (Maggi	et	al.,	1999;	Tanibuchi	et	al.,	2010)	and,	 in	collaboration	with	Dr	McIntosh	(USA)	we	have	recently	 found	that	 it	also	binds	 the	oocyte-expressed	α9−α10	 subtype	and	blocks	 its	Ach-induced	current	at	very	low	concentration	(nM	range).	We	 found	 that	 F1	 binds	 both	 α7-	and	α9-	 containing	 nAChRs,	 potently	 abrogates	 the	viability	and	proliferation	of	A549	cell	line	after	nicotine	stimulation,	but	has	no	effect	on	control	 cell	 lines	 (HepG2	and	SH-SY5Y).	As	nicotine	 stimulates	NSCLC	 cell	 invasion	and	the	 epithelial	 to	mesenchymal	 transition	 (EMT)	preferentially	 via	α7	nAChRs	 (Zhang	et	al.,	2016),	we	assessed	whether	F1	abrogates	nicotine-induced	cell	migration	in	the	A549	cell	line	and	found	that	a	low	concentration	inhibits	cell	invasion	and	decreases	nicotine-induced	activation	of	the	P-ERK	and	P-AKT	pathways.		In	addition	F1	display	a	stylbene	structure	very	similar	to	that	of	resveratrol	and	ptero-stylbene,	so	we	investigated	whether	F1	exerts	some	of	its	effects	by	simply	passing	the	membrane	and/o	increasing	ROS	production.	ROS	 play	 contradictory	 roles	 in	 tumorigenesis:	 they	 play	 a	 causal	 role	 in	 tumor	development	 and	 progression	 by	 inducing	 DNA	 mutations,	 genomic	 instability,	 and	aberrant	 pro-tumorigenic	 signalling,	 while	 very	 high	 levels	 might	 induce	 cell	 death	 in	cancer	 cells.	 There	 is	 published	 evidence	 of	 a	 correlation	 between	 increased	 oxidative	stress	 and	 apoptosis,	 and	 Luo	 et	 al.	 (2010)	 have	 shown	 that	 the	 isoflavanone,	 cajanol	induces	 apoptosis	 via	 a	 ROS-mediated	mitochondria-dependent	 pathway.	We	 therefore	
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tested	 F1	 and	 found	 that	 it	 stimulates	 ROS	 production	 at	 relatively	 low	 concentrations	(100-250	nM).	Given	this	 finding	it	 is	 important	to	clarify	the	molecular	mechanisms	by	which	F1	and	its	derivatives	can	increase	cancer	cell	apoptosis.			Starting	from	the	F1	structure	we	have	synthesised	and	pharmacologically	characterised	the	new	compounds	RS12	and	RS18.	Both	compounds	seem	to	have	a	cytotoxic	effect,	but	more	studies	are	necessary	to	define	their	possible	cytotoxic	effect	on	A549	cells.																													
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CONCLUSIONS	
The	findings	of	this	study	show	that	nAChRs	are	selectively	expressed	in	different	NSCLC	cell	 lines.	 We	 present	 substantial	 evidence	 of	 the	 expression	 of	 three	 major	 nAChR	subtypes	containing	the	α5, α7 and α9 subunits  in	NSCLC.	The	activation	of	α7-	and	α9-containing	 nAChRs	 stimulates	 nicotine-induced	 cancer	 cell	 growth	 and	 migration,	 and	inhibition	of	nAChR	subunit	 levels	 can	significantly	attenuate	nicotine	cell	proliferation,	invasion	and	the	activation	of	two	important	intracellular	signalling	pathways.		However,	 there	 is	 no	 currently	 a	 non-peptidic	 specific	 antagonist	 that	 could	 definitely	target	these	nAChR	subtypes	 in	vivo.	The	development	of	nAChR-specific	antagonists	for	clinical	purposes	is	crucial	and	will	help	to	increase	our	understanding	of	the	carcinogenic	role	of	nAChRs.			Our	findings	suggest	that	stylbene-derived	compounds	may	provide	a	molecular	means	of	investigating	lung	cancer	cell	growth	inhibition	and	death	and	become	a	lead	structure	for	the	development	of	new	therapeutic	agents	for	human	lung	cancer.		We	 believe	 that	 this	 study	 is	 important	 because	 concerns	 about	 the	 safety	 of	 nicotine-containing	products	make	it	urgent	to	discover	the	molecular	mechanisms	underlying	the	effects	of	nicotine	on	tissues	subject	to	the	development	of	tobacco-related	malignancies.											
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